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ABSTRACT 
 




P/Q-type voltage-gated calcium channels (CaV2.1) are expressed in both central 
and peripheral nervous systems, where they play a critical role in neurotransmitter 
release. Mutations in the pore-forming 1 subunit of CaV2.1 can cause neurological 
disorders such as episodic ataxia type 2, familial hemiplegic migraine type 1 and 
spinocerebellar ataxia type 6. Interestingly, a 190-kDa fragment of CaV2.1 was found 
in mouse brain tissue and cultured mouse cortical neurons, but not in heterologous 
systems expressing full-length CaV2.1. In the brain, the 190-kDa species is the 
predominant form of CaV2.1, while in cultured cortical neurons the amount of the 
190-kDa species is comparable to that of the full-length channel. The 190-kDa 
fragment contains part of the II-III loop, repeat III, repeat IV and the C-terminal tail. 
A putative complementary fragment of 80-90 kDa was found along with the 190-kDa 
form. Moreover, preliminary data show that the abundance of the 190-kDa species 
and the 80-90-kDa species relative to the full-length channel is upregulated by 
increased intracellular Ca2+ concentration. 
Truncation mutations in the P/Q-type calcium channel have been found to cause 
the neurological disease episodic ataxia type 2. Some of the disease-causing 
truncations resemble the 190-kDa truncated channel that we found. Three pairs of 
truncated versions of CaV2.1 were engineered to resemble putative products of 
proteolytic cleavage in the three intracellular loops. Electrophysiological properties of 
these truncated channels were studied. The truncated channel corresponding to the 
N-terminal fragment produced by cleavage in the II-III loop has a suppressive effect 
on full-length P/Q channel currents, resembling the effects of several truncation 
mutants that cause episodic ataxia type 2. The complementary pair of truncated 
channels created by a truncation site in the I-II loop forms a functional channel when 
coexpressed. These results shed light on the functional effects of proteolytic cleavage 
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Voltage-gated calcium channels (VGCCs) play important roles in lots of 
physiological processes, including muscle contraction, neurotransmitter release, 
endocrine secretion, and gene expression (1). In the brain and heart, the pore-forming 
1 subunits of VGCCs are present not only in the full-length forms, but also in a 
variety of short forms, which have important functions. C-terminal fragments of the 
L-type calcium channel CaV1.1 and CaV1.2 subunits can be produced by proteolysis 
and act as autoinhibitory domains to regulate L-type channel activity (2). A cryptic 
promoter can also produce a C-terminal fragment of CaV1.2, which serves as a 
transcription factor (3). CaV1.2 is also subject to “mid-channel proteolysis”, which 
produces two complementary fragments and serves as a negative feedback regulatory 
mechanism (4). Short forms of the P/Q-type calcium channel (CaV2.1) have also been 
found in the brain. A 95-kDa fragment of CaV2.1, with unknown origin, has an 
inhibitory effect on the full-length P/Q-type channel (5, 6). A C-terminal fragment of 
CaV2.1 can be produced by an internal ribosomal entry site and acts as a transcription 
factor (7). Numerous other short forms of CaV2.1 found in immunoblot analyses have 
not been studied (5, 8-12).  
CaV2.1 is crucial for neurotransmitter release in both central and peripheral 
nervous systems (13). Mutations in CaV2.1 can cause as least three types of autosomal 
dominant neurological disorders: episodic ataxia type 2 (EA2), familial hemiplegic 
migraine type 1 (FHM1) and spinocerebellar ataxia type 6 (SCA6) (14). EA2 can be 
caused by several types of mutations, including truncation mutations, i.e., mutations 
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that introduce premature stop codons into the gene of CaV2.1 and lead to short forms 
of CaV2.1 (15). Interestingly, as stated above, a variety of short forms of CaV2.1 are 
also present in healthy brains. Why do these short forms of CaV2.1 not cause any 
problems like the EA2 truncation mutants? Why and how do cells produce these short 
forms of CaV2.1? 
To begin to address these questions, I studied CaV2.1 in the mouse brain using 
biochemistry methods. The experiments showed that one of the major forms of 
CaV2.1 in the mouse brain is a 190-kDa N-terminally truncated CaV2.1. Then I 
explored the origin and function of 190-kDa truncated CaV2.1 using methods 
including biochemistry, molecular biology and electrophysiology. 
 
1.1 Overview of VGCCs 
Voltage-gated calcium channels (VGCCs) are important mediators of calcium 
influx. The calcium ion is an important intracellular messenger with many different 
signaling functions (16). Upon membrane depolarization, VGCCs open and allow 
Ca2+ to enter the cell, converting the electrical signal on the plasma membrane to an 
intracellular Ca2+ transient (1). Different types of VGCCs have different molecular 
compositions and different physiological, pharmacological, and regulatory properties. 
Activities of VGCCs are elaborately regulated by a variety of signals. Moreover, 
several types of VGCCs have been found to exist in truncated forms, which have 
different properties from the full-length channels and also influence the functions of 
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the full-length channels. 
 
1.2 Physiological and pharmacological properties (current types/subtypes) of 
VGCCs 
According to the level of membrane potential at which the channels are activated, 
VGCCs are divided into two main groups, high-voltaged-activated (HVA) and 
low-voltage-activated (LVA) calcium channels (17). HVA channels include L-, N-, 
P/Q- and R-type calcium channels, while the T-type calcium channels are designated 
as LVA channel. L-type calcium channels are distinguished by their high voltage of 
activation, large single channel conductance, slow voltage-dependent inactivation and 
sensitivity to dihydropyridines (18-21). In contrast to the L-type calcium channels, the 
T-type calcium channels are activated by weak depolarization, are inactivated quickly, 
and have tiny single channel conductance (22). The N-type calcium channels have 
varied voltage dependence and kinetics depending on the cell type (17), and are 
distinguished by the specific inhibition by -conotoxin GVIA (22).  
P- and Q-type calcium currents were originally discovered separately in different 
cell types . The two distinct types of calcium currents were later found to be from the 
same type of CaV1 subunit (see 1.3), and their differences probably result from 
alternative splicing and assembly with different auxiliary subunits (23, 24). P-type 
calcium currents, first recorded in cerebellar Purkinje neurons (25), are distinguished 
by their slow inactivation and specific inhibition by -agatoxin IVA with high 
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sensitivity (26). Q-type calcium currents, first recorded in cerebellar granule neurons, 
inactivate more quickly and are inhibited by -agatoxin IVA with a lower sensitivity 
(26). Both P- and Q-type calcium currents are potently inhibited by -conotoxin 
MVIIC (26). R-type calcium channels are resistant to all the aforementioned 
inhibitors (26). SNX-482 was found to inhibit R-type calcium channels at a much 
higher selectivity than on other types of voltage-gated calcium channels (27). 
However, SNX-482 was later found to also inhibit A-type potassium channels, 
especially KV4.3, which was even more sensitive to SNX-482 than R-type calcium 
channels are (28). 
 
1.3 Molecular properties of VGCCs 
  1.3.1 Molecular Composition and Structure of VGCCs 
A VGCC is a heteromultimeric protein complex comprised of several subunits. 
The 1 subunit is the pore-forming subunit, through which calcium ions flow when 
the channel is activated (1). Mammalian 1 subunits are encoded by 10 CACNA1x 
genes (29). The four subtypes of L-type calcium channels, CaV1.1-CaV1.4, have 1 
subunits named 1S, 1C, 1D and 1F, respectively, and these 1 subunits are 
encoded by CACNA1S, -C, -D and -F, respectively. The 1 subunits of P/Q-, N- and 
R-type calcium channels (CaV2.1-CaV2.3) are encoded by CACNA1A, -B, and -E, and 
are named 1A, 1B and 1E, respectively. The 1 subunits of T-type calcium 
channels (CaV3.1-CaV3.3) are encoded by CACNA1G, -H, and -I, and are named 1G, 
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1H and 1I, respectively. 
The 1 subunit consists of 1800-2500 amino acid residues and contains four 
homologous repeats (repeats I-IV), each comprised of six transmembrane segments 
(S1-S6). The S1-S4 segments in each repeat form the voltage-sensing domain (VSD), 
and the S5-S6 segments from all four repeats constitute the pore domain (30). A 
“re-entrant” loop, known as the pore loop or P loop, between S5 and S6 was predicted 
to form part of the pore lining of the channel (13, 17). However, the structure of the 
rabbit CaV1.1 complex recently determined by cryo–electron microscopy (cryo-EM) 
shows that the re-entrant segment between S5 and S6 is organized into two pore 
helices (P1 and P2) and a selectivity filter in between (30). 
The  subunit is an intracellular subunit (30, 31) of ~60 kDa. There are four 
subfamilies of  subunits (1-4), encoded by four genes (CACNB1-4) (29, 31), and 
each subfamily includes splice variants (31). The  subunit has five distinct regions, 
the N-terminus, the SH3 domain, the HOOK region, the GK domain and the 
C-terminus (31). The middle SH3-HOOK-GK module is called the core, which is 
critical for many key functions of the  subunit. The GK domain is able to bind with 
high affinity to the -interaction domain (AID) in the cytoplasmic loop connecting 
repeats I and II (I-II loop) of the 1 subunit. Cryo-EM structure of the CaV1.1 
complex shows that the  subunit is located adjacent to the voltage-sensing domain of 
repeat II (VSDII) of 1 (30).  
The 2 subunit has four subfamilies, 2-1 through -4, encoded by 
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CACNA2D1-4, and can form splice variants (29). The N-terminus of 2 has a signal 
sequence directing the precursor of 2 into the lumen of the ER, so that 2 
eventually becomes extracellular after being trafficked to the plasma membrane (29). 
The precursor of 2, containing about 1100 amino acid residues, is subjected to 
posttranslational proteolysis, which cleaves the protein into 2 and , which are 
linked by a disulfide bond (32). Both 2 and  have been shown to be glycosylated 
(30, 33). Several domains have been identified in 2, including a Von Willebrand 
Factor-A (VWA) domain and two Cache domains (29, 30). Through these domains, 
2 interacts with the extracellular loops of repeats I-III of 1 (30). 
The  subunit is a glycoprotein of about 30 kDa (17, 34). There are eight 
subfamilies of  subunits (1-8), encoded by CACNG1-8 (34). Several splice variants 
have been found. Hydrophobicity plots predict the  subunit to have four 
transmembrane helices (TMs) and intracellular N- and C-termini (34). This predicted 
topology of the  subunit was confirmed using immunocytochemistry (35) and in the 
Cryo-EM structure of the CaV1.1 complex, which also shows that the  subunit 
interacts with VSDIV of  via TM2 and TM3 (30). In addition, studies show that  







  1.3.2 Functions of VGCC subunits 
As a fundamental component of VGCCs, the 1 subunit contains the voltage 
sensor and the ion-conducting pore. The main voltage sensor is the S4 transmembrane 
segment (36, 37). The S4 segment of each repeat contains positively charged arginine 
and lysine residues, and thus can move outward and rotate upon membrane 
depolarization, inducing a conformational change that opens the pore. The S5-S6 
segments from the four repeats of 1 forms the pore domain, in which there is a 
selectivity filter constituted by the side chains of four conservative glutamate residues 
in the four repeats and the carbonyl oxygen atoms of the two preceding residues in 
each repeat (30). The four conservative glutamate residues are critical for the high 
calcium selectivity of the pore (38). 
Although 1 alone is able to produce currents, coexpression of 2 and 
especially  enhances the expression level of 1, promotes trafficking of 1 to the 
plasma membrane, and allows for more conventional gating properties (17, 31, 39). 
Coexpression of the  subunit has much smaller functional effects. Most  subunits 
cause a small reduction of currents by causing a hyperpolarizing shift of the 
inactivation curve (34, 40). Some  subunits have also been shown to regulate the 
trafficking, localization, and biophysical properties of AMPA receptors (31).  
 
1.4 Localization and function of VGCCs 
The L-type channel family includes one skeletal muscle-specific isoform (CaV1.1) 
9 
 
and three neuronal isoforms, (CaV1.2, CaV1.3 and CaV1.4). CaV1.1 is responsible for 
excitation-contraction coupling in skeletal muscle (1). CaV1.2 is widely distributed in 
the brain, heart, smooth muscle, and adrenal medulla (1, 13). CaV1.2 is responsible for 
excitation-contraction coupling in cardiac and smooth muscle, and contributes to 
intracellular Ca2+ transients, endocrine secretion, as well as regulation of transcription 
(1, 13). CaV1.3 is expressed in the brain, adrenal medulla, as well as cochlear hair 
cells, and contributes to intracellular Ca2+ transients, endocrine secretion, pacemaking, 
and auditory transduction (1, 13). CaV1.4 is expressed in the retina and plays an 
essential role in visual transduction (1, 13, 17). 
The P/Q-, N- and R-type channels ,(CaV2.1, CaV2.2 and CaV2.3), are widely 
distributed in the central and peripheral nervous systems, and are mainly responsible 
for neurotransmitter release as well as dendritic Ca2+ transients (1, 13). CaV2.1 is 
expressed throughout the entire brain, with particularly high levels in cerebellar 
Purkinje cells (41-43). In cerebellar Purkinje cells, CaV2.1 is robustly expressed in 
dendrites in the molecular layer (42, 43) axon terminals in deep cerebellar and Deiters’ 
nucleus, as well as in the soma and along the lengths of axons (42). CaV2.1 also 
contributes to nearly half of the VGCC currents in cerebellar granule cells (26). 
CaV2.1 is also expressed at neuromuscular junctions (44). CaV2.1 contributes to two 
distinct types of calcium currents, P-type and Q-type, depending on the splice variants, 
secondary modifications, and accessory subunits (23, 45). P-type currents are found 
throughout the central and peripheral nervous systems, especially in cerebellar 
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Purkinje cells (46). In cerebellar granule cells, ~76% of the CaV2.1 currents are 
Q-type, and the remaining are P-type (26). The CaV2.1 currents recorded at the 
synapse between hippocampal CA3 and CA1 neurons are also Q-type (47). 
Furthermore, CaV2.1 expressed in Xenopus oocytes also conducts Q-type currents 
(48). CaV2.2 is mostly distributed in dendritic shafts and presynaptic terminals (49). 
CaV2.2 can be found in a variety of regions in the brain (49), dorsal root ganglia, 
dorsal horn neurons, and neuroendocrine cells (50). CaV2.3 is also widely distributed 
in the central and peripheral nervous systems, especially in hippocampal CA3 neurons, 
where it contributes to 25% of the high-voltaged-activated (HVA) calcium channel 
currents (46). The T-type channels, (CaV3.1, CaV3.2 and CaV3.3), are expressed 
throughout the body in a variety of organs, and play a major role in cardiac 
pacemaking and oscillations (1, 13, 50). 
 
1.5 Regulation of VGCCs 
  1.5.1 Protein phosphorylation 
  1.5.1.1 Regulation of CaV1 by protein phosphorylation 
Both CaV1.1 and CaV1.2 are modulated by PKA-mediated phosphorylation in 
response to activation of the -adrenergic receptor pathways (2). A major 
phosphorylation site in cardiac 1C is S1928 (51), which can be phosphorylated by 
PKA (52) and PKC (53). Phosphorylation of S1928 has been shown to be responsible 
for PKA-mediated upregulation of CaV1.2 activity (54). Additional key 
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phosphorylation sites in cardiac 1C are S1700 and T1704 (55), which are conserved 
in 1S as S1575 and T1579, respectively (56). S1575/S1700 is a substrate for PKA 
and CaMKII, while T1579/T1704 is a substrate for casein kinase II (55, 56). Basal 
activity of CaV1.2 in unstimulated cells is regulated by phosphorylation of both S1700 
and T1704, whereas further upregulation of channel activity through stimulation of 
the cAMP/PKA pathway requires only the phosphorylation of S1700 (55). These two 
important phosphorylation sites will be discussed in detail in 1.6.1.1. 
Several isoforms of PKC have been shown to co-immunoprecipitate with CaV1.2 
(57). A-kinase anchoring protein (AKAP) 150, which binds to both CaV1.2 and PKC, 
helps to recruit PKC to CaV1.2 (57). The N-terminus of CaV1.2 is subject to 
alternative splicing involving two mutually exclusive exons, e1a (46 amino acids 
long), and e1b (16 amino acids long) (58, 59). PKC downregulates the activity of 
CaV1.2-e1a by phosphorylating T27 and T31 in the N-terminus (57). CaV1.2-e1b, 
which does not have the two threonine residues, does not show inhibition by PKC 
(57). An analogous inhibitory effect has been found on CaV1.3, and its activity is 
decreased when S81 at the N-terminus is phosphorylated by PKC (57). 
In arterial smooth muscle cells, PKC increases local CaV1.2 activity and thereby 
creates sites of sustained Ca2+ influx, leading to increased blood pressure (60). 
 
  1.5.1.2 Regulation of CaV2 by protein phosphorylation 
CaV2 can be regulated by PKA, PKC, and CaMKII. The effects of these kinases 
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on CaV2 activity vary depending on the cell type. PKA activation enhances N-type 
currents in rat nodose neurons (61) but reduces N-type currents in mouse dorsal root 
ganglion neurons (62) and rat neostriatal neurons (63). PKA activation enhances 
currents of the P/Q-type channel expressed in Xenopus oocytes (64, 65), but slightly 
reduced the non-L- and non-N-type currents, which are mostly P/Q-type currents, in 
rat cerebellar granule cells (26). PKC activation enhances N-type channel activity in 
most central and peripheral neurons studied (66, 67), but depresses N-type channel 
currents in acutely isolated guinea pig hippocampal neurons (68). The specific effect 
of a protein kinase on a calcium channel may depend on the splice variant of the 1 
subunit, the types of auxiliary subunits, and other cell-specific proteins. 
In Xenopus oocytes, PKA activation has been shown to potentiate the currents of 
P/Q-type channels (64, 65) and, to a lesser extent, N-type channels (65). In sea slug 
hair cells, activation of PKA not only causes potentiation of P/Q-type currents, but 
also mediates voltage-dependent facilitation of P/Q-type channels (69). In 
NGF-differentiated trk-PC12 cells, activation of PKA prevents the inhibition of N- 
and P/Q-type channels by ethanol (70). PKA activation has also been shown to 
alleviate the voltage-dependent inhibitory effect of PtdIns(4,5)P2 on the P/Q-type 
channel, probably by phosphorylation of the 1 subunit of the channel (71). The 
C-terminal tail of 1B contains a binding site for 14-3-3, a family of regulatory 
proteins (72). GST pull-down and coimmunoprecipitation analyses in tsA-201 cells 
showed that phosphorylation of S2126 ,(in the RFYS motif within the 14-3-3 binding 
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site) by PKA or CaMKII promotes the binding of 14-3-3, which counteracts the  
subunits to decelerate inactivation of the CaV2.2 (72). In most of the regulatory 
processes described above, it is unknown whether PKA phosphorylates CaV2 itself or 
other regulatory proteins. Further research is necessary to understand more details of  
how PKA regulates CaV2. 
Regulation of CaV2 by PKC is better understood than that by PKA. In most cases 
studied, PKC activation upregulates CaV2 activity. It has also been reported that PKC 
activation potentiates Q-type channel-mediated synaptic transmission at CA3-CA1 
synapses in rodent hippocampus (47). PKC modulates CaV2 function through 
phosphorylation of two regions of the 1 subunit, the I-II loop and the II-III loop. In 
the I-II loop of 1A and 1B, there are four consensus PKC phosphorylation sites, 
422T, 425S, 453S, and 456S, corresponding to positions in 1B. The first two 
consensus sites are located within one of the two G binding sites and result in 
crosstalk between G proteins and PKC (73). Early studies showed that activation of 
PKC reduces G protein-dependent inhibition of Ca2+ channels and upregulates basal 
calcium channel currents, especially N-type currents (66, 67). Further studies suggest 
that phosphorylation of T422 mediates the antagonistic effect of PKC on G protein 
modulation by disrupting the binding of G protein to the channel, whereas 
phosphorylation of either T422 or S425 is sufficient to increase N-type channel 
activity (74, 75). 
PKC also modulates CaV2 functions by phosphorylating the synaptic protein 
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interaction (synprint) site in the II-III loop. Binding of syntaxin 1A to the synprint site 
results in two effects on the N-type channel: a hyperpolarizing shift in the steady-state 
inactivation curve and a tonic inhibition of the channel by G subunits (76). 
Phosphorylation of the synprint peptide sequence of 1B with PKC or CaMKII, but 
not PKA or PKG, strongly inhibits binding of syntaxin 1A or SNAP25 (77). Moreover, 
phosphorylation of the synprint site of 1B eliminates the syntaxin 1A-mediated shift 
in the steady-state inactivation curve but does not influence the syntaxin 1A-induced 
G protein inhibition of CaV2.2 (75). Further research revealed that binding of syntaxin 
1A and SNAP25 is regulated by PKC phosphorylation at S774 and S898 and by 
CaMKII phosphorylation at S784, S896, and S898 (78). Interestingly, in tsA-201 cells 
where syntaxin 1A and CaV2.2 are coexpressed, PKC activation opposes the effect of 
syntaxin 1A on the steady-state inactivation curve without affecting the binding of 
syntaxin to CaV2.2 (78). 
CaMKII can also regulate CaV2 activity without phosphorylating the channel. 
CaMKII binds to a peptide sequence in the C-terminal tail of 1C, which is conserved 
as amino acid residues 1897-1912 in the C-terminal tail of CaV2.1 (79, 80). CaMKII 
constitutively binds to CaV2.1, decelerating voltage-dependent inactivation, causing a 
positive shift in the voltage dependence of inactivation, and enhancing 
Ca2+-dependent facilitation of CaV2.1 channels (80). These effects of CaMKII are 
reduced by a peptide that eliminates binding of CaMKII to CaV2.1. Therefore, the 
binding instead the phosphorylation is responsible for the regulatory effects (80). 
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  1.5.2 Ubiquitination 
  1.5.2.1 Ubiquitination of ion channels 
Ubiquitination plays an important role in regulating the surface density of ion 
channels.  The process of ubiquitination can occur at the exit of the endoplasmic 
reticulum (ER) (81) as well as the Golgi complex (82, 83), and labels newly 
synthesized ion channels for degradation in the proteasome (81, 84). Ion channels on 
the plasma membrane can also be ubiquitinated, which would lead to internalization 
and subsequently degradation in the proteasome and lysosome (81, 85). 
Ubiquitination is an enzyme-catalyzed process in which a ubiquitin protein is 
covalently attached to a substrate protein (86). Ubiquitination usually results in an 
isopeptide bond between the carboxyl group of the last amino acid residue (G76) of 
ubiquitin and the -amino group of a lysine residue on the substrate protein (86). This 
process requires the sequential actions of three enzymes: a ubiquitin-activating 
enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin-protein ligase (E3) 
(86). Ubiquitin itself can also be ubiquitinated, thereby forming polyubiquitin chains 
(86). Ubiquitin has several lysine residues, and polyubiquitin chains linked through 
different lysine residues affects the fate of the substrate protein in different ways (86). 
Ubiquitination has been found to regulate the activity and fate of a variety of ion 
channels (81). Several of these ion channels bear a PY motif (L/P-P-X-Y-X-X-, 
where L is a leucine, P is a proline, X is any amino acid, Y is a tyrosine, and  is a 
hydrophobic amino acid) (87, 88), which has been identified as a binding site for E3 
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ubiquitin ligases of the Nedd4/Nedd4-like family (89, 90). The Nedd4/Nedd4-like E3 
ubiquitin ligases, in turn, ubiquitylate the channels and downregulate their surface 
expression, typically by inducing internalization of the channels (81).           
Nedd4/Nedd4-like E3 ubiquitin ligases have been shown to ubiquitinate and 
downregulate a wide range of ion channels, including the epithelial sodium channel 
(ENaC) , NaV1.2, NaV1.3, NaV1.5, the ClC-5 chloride/proton exchanger (81), and the 
KCNQ1 potassium channel (KV7.1) (91). All these channels bear a PY motif in their 
C-terminal regions and are downregulated by Nedd4-2, the most studied member of 
the Nedd4/Nedd4-like family. NaV1.2, NaV1.3, ClC-5 (81), and KCNQ1 (91) have 
also been shown to be regulated by other membranes of the Nedd4/Nedd4-like family, 
such as Nedd4-1 (also called Nedd4) and WWP2. KV1.3 has also been shown to be 
ubiquitinated and downregulated by Nedd4-2, although KV1.3 does not have a PY 
motif (92, 93). A proline-rich motif (PQTPF) in the C-terminal tail of KV1.3 has been 
suggested to serve as the target for Nedd4-2 (93). The L-type calcium channel 1C 
subunit has a non-canonical PY motif (LPYVAL) at the end of the S4-S5 loop and 
beginning of S5 in repeat IV (4). Mutation of this motif has been shown to markedly 
reduce mid-channel proteolysis of CaV1.2, a recently discovered form of regulation of 
VGCCs (4). This indicates that the Nedd4/Nedd4-like family and/or ubiquitination 
may play an important role in CaV1.2 mid-channel proteolysis. More about 
ubiquitination of the L-type calcium channel is summarized in 1.5.2.2. 
Other ion channels have also been shown to be regulated by ubiquitination (81). 
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An important function of ubiquitination is “quality control” of ion channels. 
Unassembled and/or misfolded ion channels in the ER can be degraded through 
ER-associated degradation (ERAD), which involves the ubiquitin-proteasome system 
(81, 94). Ubiquitination is reversible. Ubiquitin moieties can be removed from a 
substrate protein by deubiquitinating enzymes (DUBs) (95). Deubiquitination of ion 
channels usually stabilizes the channels on the plasma membrane. Ubiquitin-specific 
protease (USP) 2-45, a member of the DUB family, has been reported to counteract 
Nedd4-2-mediated ubiquitination of ENaC (96, 97) and KCNQ1 (KV7.1) (98) which 
subsequently increase the surface expression of the channels. In the case of CaV1.2, 
however, USP2-45 deubiquitinates the channel and reduces surface expression of the 
channel (99). More about the regulation of CaV1.2 by USP2-45 is summarized in 
1.5.2.2. 
 
  1.5.2.2 Ubiquitination of the L-type calcium channel 
CaV subunits modulate the function of CaV1 and CaV2 channels in two ways. 
First, they affect the biophysical properties of the channels by increasing the opening 
probability and hyperpolarizing the voltage dependence of activation (100, 101). 
Secondly, CaV subunits increase the number of channels on the plasma membrane 
(102-104). Early studies on the P/Q-type channel suggested that the  subunit masks 
an ER retention motif in the CaV1 I-II loop, thereby promoting the trafficking of the 
1 subunit to the plasma membrane (102, 105), although no specific motif was 
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identified (105). More recently, it was suggested that the 1C I-II loop actually 
contains an acidic ER export motif (106). Studies of fusion proteins containing a CD4 
protein fused to different fragments of 1C and 1B show that both channels contain 
ER retention signals in the C-terminal tails but not in the I-II loops (84). 
 subunits markedly enhance surface expression of 1C, and this effect of the  
subunit can be mimicked by the proteasome inhibitor MG132. This indicates that the 
checkpoint controlling the surface expression of 1C is proteasomal degradation 
instead of ER retention.  subunits do not exert their function by masking the ER 
retention signal (84). Instead, they promote surface expression of 1C by protecting 
1C from ER-associated degradation (ERAD) (84). Without  subunits, 1C is 
subject to robust ubiquitination by the E3 ubiquitin ligase RFP2 and interacts with the 
ERAD complex proteins derlin-1 and p97, which mediate the transport of 1C to the 
proteasome for degradation (84).  subunits interfere with the ubiquitination of 1C 
and the interaction of the channel with the ERAD complex, thereby promoting the 
trafficking of the channel to the plasma membrane (84). 
Recently, a splice variant of the CaV1.2, named CaV1.2e21+22, was found to exert a 
dominant negative effect on WT CaV1.2 by sequestering  subunits and subsequently 
enhancing the ubiquitination of WT CaV1.2 (107). CaV1.2e21+22 contains both exons 21 
and 22, which encode S2 as well as part of the S1-S2 loop of repeat III and are usually 
mutually exclusive (107). This variant is highly expressed in neonatal rat hearts, and 
also abundant in the hearts of mice with induced cardiac hypertrophy, as well as hearts 
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of patients with dilated cardiomyopathy (107). CaV1.2e21+22 is retained intracellularly 
and does not conduct currents (107). CaV has significantly higher affinity for 
CaV1.2e21+22 than for WT CaV1.2, but does not increase the overall or surface 
expression of CaV1.2e21+22 (107). By competing with WT CaV1.2 for CaV, 
CaV1.2e21+22 enhances ubiquitination of WT CaV1.2 and subsequently proteasomal 
degradation of WT CaV1.2 (107). 
As mentioned in 1.5.2.1, the Nedd4/Nedd4-like E3 ubiquitin ligases bind to the 
PY motifs of a variety of ion channels, ubiquitinate the channels, and subsequently 
downregulate their surface expression. Nedd4-1 (also called Nedd4), a member of the 
Nedd4/Nedd4-like family, has also been shown to regulate the functional expression 
of CaV1.2 (108). Overexpression of Nedd4-1, but not Nedd4-2 or WWP2, decreases 
whole-cell CaV1.2 currents (108). Nedd4-1 also downregulates surface expression and 
overall expression of 1C, 2, and 2-1(108). Although CaV1.2 has a non-canonical 
PY motif (LPYVAL) (4), overexpression of Nedd4-1 does not increase ubiquitination 
of 1C, 2, or 2-1 (108). Nedd4-1 promotes the transport of CaV1.2 from the 
ER-Golgi network to the proteasome and lysosome for degradation, without 
ubiquitinating the channel (108). The transport of CaV1.2 to the lysosome relies on 
clathrin-coated vesicles (108). The regulatory effect of Nedd4-1 relies on the  
subunit and does not involve the internalization of surface CaV1.2 (108). The SH3 
domains of all four subfamilies of  subunits contain a YDVV motif (YXX motif), 
which is a signal for selection into clathrin-coated vesicles (108). Mutation of this 
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motif eliminates the Nedd4-1-induced lysosomal degradation of CaV1.2 and partially 
reversed the effect of Nedd4-1 on Cav1.2 currents, indicating that Nedd4-1 may target 
CaV-interacting proteins (108). Note that these findings point out a dual role of CaV: 
increasing and decreasing the functional expression of Cav1.2 (102-104). The authors 
did not point out that the non-canonical PY motif of 1C also encompasses a YXX 
motif (YVAL). Thus, it would be interesting to study whether this motif also 
contributes to the regulatory effect of Nedd4-1 on CaV1.2. 
While there is no evidence that any member of the Nedd4/Nedd4-like family can 
bind to the non-canonical PY motif of 1C, the motif has been found to be important 
for the mid-channel proteolysis of 1C (4). Mutation of the motif significantly 
reduces the mid-channel proteolysis of 1C (4), suggesting the participation of some 
member of the Nedd4/Nedd4-like family in this process. It has also been found that 
1C bears two PEST sequences, PEST1 and PEST3, in the I-II loop and the II-III 
loop, respectively (109). PEST sequences have been shown to serve as signals for 
rapid degradation of proteins by calpain and the ubiquitin-proteasome system (110). 
The mid-channel proteolysis of 1C is greatly reduced by the deletion of PEST3 and 
is virtually abolished by the deletion of PEST1 (4). Moreover, the mid-channel 
proteolysis of 1C can be significantly reduced by a cocktail of ubiquitin aldehyde, a 
general inhibitor of ubiquitin-recycling processes, and MG-132, a proteasome 
inhibitor (4). These findings suggest a pivotal role of the ubiquitin-proteasome system 
in the mid-channel proteolysis of 1C. Additional information about the mid-channel 
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proteolysis of 1C is summarized in 1.6.1.2. 
Deubiquitinating enzymes (DUBs) also regulate the functional expression of 
CaV1.2. Ubiquitin-specific protease (USP) 2-45, a member of the DUB family, was 
recently reported to downregulate the functional expression of CaV1.2 (99). USP2-45 
deubiquitinates both 1C and 2-1, and decreases surface expression of 1C, as 
well as the overall expression of 1C, 2, and 2-1 (99). USP2-45 interacts with 
2-1 but not 1C and 2 (99). 2-1 is necessary for the regulatory effect of 
USP2-45 on CaV1.2 (99). Note that these findings point out a dual role of the 2 
subunit: increasing (111, 112) and decreasing the functional expression of CaV1.2. The 
finding that 2-1 can be ubiquitinated and deubiquitinated indicates that part of 
2-1 is exposed to the cytosol so that E3 ubiquitin ligases and USP2-45 can have 
access to 2-1. However, the recently discovered cryo-EM structure of CaV1.1 
shows that 2-1 is an extracellular protein with no transmembrane or intracellular 
segment (30). This discrepancy is probably due to the different conditions or different 
types of channels used in the experiments. 
 
  1.5.2.3 Ubiquitination of the N-type calcium channel 
In general, the effect of ubiquitination on CaV2.2 is similar to that on CaV1.2: 
promoting proteasomal degradation and decreasing functional expression of the 
channel (85, 113, 114). The effect of  subunits on CaV2.2 also resembles that on 
CaV1.2: suppressing proteasomal degradation and increasing functional expression of 
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the channel (115, 116). However, the detailed mechanisms of these regulatory 
processes show obvious differences between CaV2.2 and CaV1.2. 
Mouse CaV2.2 has a site of alternative splicing involving a pair of mutually 
exclusive exons, e37a and e37b, which encode the proximal C-terminus (117). 
CaV2.2-e37b is the major form of CaV2.2 in the nervous system, except in some cells, 
such as the nociceptors of dorsal root ganglia, where CaV2.2-e37a is enriched (117). 
CaV2.2-e37b is subject to a higher level of ubiquitination than CaV2.2-e37a (114). 
Since CaV2.2-e37b is more sensitive to proteasomal degradation it is associated with 
lower current density than CaV2.2-e37a (114).  
CaV2.2 contains plenty of intracellular lysine residues that can potentially be 
ubiquitinated. However, the 12 lysine residues in the I-II loop are suggested to have a 
critical role in the ubiquitination and proteasomal degradation of the channel, since 
mutation of all the 12 lysine residues prevents proteasomal degradation (115). 
Palmitoylated 1B I-II loop is polyubiquitinated and degraded by the proteasome in 
the absence of  subunits (115). Mutation of all 12 lysine residues to arginines 
prevents ubiquitination and proteasomal degradation (115). However, even if 
proteasomal degradation is prevented by the lysine-to-arginine mutations or 
proteasome inhibitor MG132,  subunits are still needed for the expression of 
palmitoylated 1B I-II loop on the plasma membrane (115). Interestingly,  subunits 
do not protect palmitoylated 1B I-II loop from polyubiquitination, but can prevent 
proteasomal degradation and promote surface expression of the construct (115). In 
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accordance with these findings, full-length 1B also relies on  subunits to traffic to 
the plasma membrane, even if proteasomal degradation is prevented by mutation of 
the 12 lysine residues in the I-II loop (115) or by the proteasome inhibitor MG132 
(116). Therefore, functional expression of 1B is controlled by two distinct 
checkpoints: proteasomal degradation and a proteasome-independent checkpoint 
controlling the transport to the plasma membrane.  subunits help the channel to pass 
both checkpoints, while inhibition of ubiquitination only helps the former. 
The mechanism by which CaV promotes trafficking of 1B to the plasma 
membrane is not fully understood. Similar to 1C, 1B bears ER retention signals in 
the C-terminal tail (84), but these signals do not effectively retain the channel in the 
ER. 1B with a mutation (W391A) that prevents binding of  subunits to its AID is 
not selectively retained in the ER, but cannot traffic to the plasma membrane even 
though the overall expression level can be enhanced by the proteasome inhibitor 
MG132 (116). It has been shown that the AID of CaV1 exists as a random coil in the 
absent of CaV (118), whereas in the presence of CaV, the AID forms a continuous 
-helix along with the entire linker between S6 of repeat I and the AID (118-120). 
This conformational change induced by the binding of CaV might be crucial for the 
targeting of the channel to the plasma membrane (115). 
Ubiquitination also regulates the internalization of CaV2.2. It has been reported 
that the microtubule-associated protein 1B light chain 1 (MAP1B-LC1) interacts 
simultaneously with the C-terminal tail of 1B and the ubiquitin-conjugating enzyme 
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E2 L3 (UBE2L3) (113). This interaction occurs on the two main variants of the 
CaV2.2 channels, CaV2.2-e37a and CaV2.2-e37b (85), and presumably causes the 
ubiquitination of 1B on the plasma membrane via an unknown E3 ubiquitin ligase 
(85, 113). The ubiquitination induces dynamin-dependent endocytosis (85) and 
subsequently proteasomal degradation of CaV2.2 (113). 
 
  1.5.2.4 Summary of ubiquitination of voltage-gated calcium channels 
Ubiquitination can downregulate the functional expression of both CaV1.2 and 
CaV2.2. It has been shown that ubiquitination causes CaV1.2 to be transported from 
the ER to the proteasome for degradation, but there is no reported evidence that 
ubiquitination induces internalization of surface CaV1.2. Surface CaV2.2, however, 
can be internalized after ubiquitination mediated by MAP1B-LC1 and UBE2L3. 
CaV promotes surface expression of both CaV1.2 and CaV2.2. In the case of 
CaV1.2, CaV protects the channel from ubiquitination and ER-associated degradation 
(ERAD). In the absence of CaV, inhibition of proteasomal degradation by MG132 is 
sufficient to allow surface expression of CaV1.2. In the case of CaV2.2, however, CaV 
seems to promote surface expression of the channel without preventing ubiquitination. 
Moreover, inhibiting ubiquitination or proteasomal degradation is not enough to allow 
surface expression of CaV2.2 in the absence of CaV. The conformational change 
induced by the binding of CaV seems to be necessary for CaV2.2 to be transported to 
the plasma membrane. 
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Ubiquitination of CaV2.1has been studied to a lesser extent. MAP1B-LC1 and 
UBE2L3 have been shown to interact with not only CaV2.2 but also CaV2.1 (85), 
indicating that CaV2.1 may also be regulated by ubiquitination. However, it has been 
reported that there is little ubiquitination of CaV2.1 in the absence of CaV (84). 
Further studies are needed to reveal whether and how CaV2.1 is regulated by 
ubiquitination and the mechanism by which CaV promotes surface expression of 
CaV2.1. 
 
1.6 Proteolysis of ion channels 
  1.6.1 Proteolysis of L-type calcium channels 
  1.6.1.1 Proteolytically cleaved C-terminal fragment of L-type calcium channel 
1 subunit acting as an autoinhibitory domain 
The full-length 1S subunit of the CaV1.1 channel in rabbit skeletal muscle is 
212-kDa, as predicted from the cDNA clone (121). However, immunoblot analysis of 
membrane preparations of rabbit skeletal muscle revealed two size forms of 1S, 190 
kDa and 212 kDa, and more than 80% of the 1S subunits are in the short 190-kDa 
form (122, 123). Two size forms of 1S were also detected in cultured rat skeletal 
muscle myocytes and found to share common sites of PKA-dependent 
phosphorylation with the 1S in rabbit skeletal muscle (124). The 1C subunit of the 
CaV1.2 channel was also found to have two size forms, a short form of 190-210 kDa, 
and a long form of 210-242 kDa in rat brain (125, 126) and in rabbit heart (51, 127). 
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Immunoprecipitation and immunoblot analysis indicated that the short form is a 
truncated form of 1 missing the C-terminus (51, 122, 123, 126, 127). 
The amount of the short form of 1C was not reduced by the use of protease 
inhibitors and lower temperature during sample preparation or perfusion of rats with 
membrane-permeable protease inhibitors (126). Moreover, 1S and1C expressed in 
heterologous systems are only present in the full-length form (127-130). These results 
indicate that the short form of the channel is present in live tissue and cells, instead of 
due to proteolysis during sample preparation. 
The two size forms of CaV1 are differentially phosphorylated. While both size 
forms of 1C purified from rat brain could be phosphorylated in vitro by PKC, 
CaMKII and PKG, only the long form could be phosphorylated by PKA. Therefore, 
PKA preferentially phosphorylates sites in the distal C-terminal region that are present 
only in the long form of 1C (126, 131, 132). PKA also preferentially phosphorylates 
sites in the distal C-terminal region of 1S purified from rabbit skeletal muscle and 
cultured rabbit skeletal muscle myocytes (133, 134). Immunoprecipitation and two 
dimensional phosphopeptide mapping revealed that the major PKA phosphorylation 
sites are in the distal C-terminal region of 1S are S1854 (133) and, to a lesser extent, 
S1757 (134). Interestingly, phosphorylation of S1854 has an inhibitory effect on the 
phosphorylation of other regions of 1S (133). Similar phenomena were observed on 
rat and rabbit cardiac 1C subunits, of which only the long form could be 
phosphorylated by PKA in vitro (51, 52). Protein microsequencing and 
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phosphopeptide mapping revealed that a major phosphorylation site in cardiac 1C is 
S1928 (51), which can be phosphorylated by PKA in response to activation of the 
-adrenergic receptor pathways (52) and by PKC (53). Phosphorylation of S1928 by 
PKA has been shown to mediate, in part, CaV1.2 activation (54). 
A C-terminally truncated protein may be due to posttranslational proteolysis or 
alternative splicing. The hypothesis that the short form of L-type calcium channel 1 
subunit arises from proteolysis has been favored since the two size forms were first 
discovered in rabbit skeletal muscle (122). cDNA cloning detected only one mRNA 
for the rabbit skeletal muscle 1S (121), which accounts for the 212-kDa full-length 
form, while the 190-kDa short form is much more abundant. The C-terminal tails of 
1S and 1C were shown to be sensitive to calpain and chymotrypsin, which can 
cleave the 1 subunit in vitro into a short form of similar or identical size to the short 
form found in the animal tissue (135-137). The amount of the short form of 1 in 
comparison with the full-length form can be altered. Ca2+ influx mediated by NMDA 
receptors was shown to induce proteolytic conversion of the long form of 1C into 
the short form in rat hippocampal slices through a calpain-dependent mechanism, 
while other classes of 1 subunits were not affected (136). In rare cases, the putative 
C-terminal fragment of 20-40 kDa produced in vivo could be detected in immunoblot 
analysis. One study showed that an antibody against the C-terminal tail of 1C 
detected a 37-kDa species in E16 and adult ventricles, but no full-length channel was 
detected, probably due to the low amount (138). These results support the hypothesis 
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that the short form of L-type calcium channel 1 subunit arises from proteolysis. 
Although the putative C-terminal fragment of 20-40 kDa produced in vivo has 
rarely been detected in immunoblot analysis, numerous studies showed evidence for 
its existence and shed light on its function. The Hosey group found that in freshly 
isolated rabbit cardiac myocytes, most 1C subunits are in the 200-kDa short form 
instead of the 242-kDa full-length form, as detected by an antibody against an internal 
domain of 1C in immunoblot analysis (127). However, immunocytochemistry 
analysis revealed that the C-terminus is present and colocalizes with the main body of 
the 1C in rabbit cardiac myocytes. In addition, the amount of C-termini relative to 
the total amount of 1C subunits is similar to that of the transfected HEK cells, where 
1C is present only in the full-length form (127). This indicates that the cleaved 
C-terminal fragment may remain functionally associated with the channel. 
What effect does the cleaved C-terminal fragment have on the channel? Studies 
have shown that removal of 147-500 amino acid residues from the C-terminus of 1C 
leads to a significant increase in channel currents (137, 139, 140), suggesting that the 
C-terminus participates in inhibiting channel function. Additionally, the Hosey group 
also found that a proline-rich domain (PRD, residues 1974-2000) in the C-terminal 
tail of rabbit 1C is not only important for membrane association of the 
chymotrypsin-cleaved C-terminal fragments, but also contributes to the inhibition of 
channel currents (137). Engineered C-terminal fragments were then applied to 
different C-terminally truncated 1C subunits, which resulted in two of the 
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C-terminal fragments, CT4 (residues 1909-2171) or CT7 (residues 2030-2171), 
having inhibitory effects on the truncated 1C, with CT4 having a greater effect (140). 
Moreover, the segment between residues 1733-1905 is not only needed for the 
truncated 1C to be inhibited by the C-terminal fragments, but also able to associate 
with the C-terminal fragments, indicating that residues 1733–1905 might act to anchor 
or stabilize the inhibitory domain within the C-terminal fragments (140). One model 
suggests that the C-terminal tail of 1C is proteolytically cleaved at approximately 
residue 1900 and the distal C-terminus (DCT) binds to the DCT binding region 
between residues 1733-1900 to serve as an inhibitory domain (140). 
The exact site of proteolysis was never known until the Catterall group identified 
it as the carboxyl side of A1664 by digesting 1S protein purified from rabbit skeletal 
muscle with three proteases and analyzing the proteolytic peptides using LC/MS/MS 
(130). Proteolysis at this site in theory will result in a truncated 1S of 190 kDa, 
consistent with previous observations (122, 123). A1664 in rabbit 1S is conserved in 
rabbit and rat 1C as A1800, where a cleavage in theory will result in a truncated 1C 
of 203 kDa, consistent with previous observations (51, 125-127). 
Like the Hosey group, the Catterall group also obtained results showing that the 
C-terminal fragments of L-type calcium channel 1 subunits interact with and have an 
inhibitory effect on the channel (130, 141). Coimmunoprecipitation experiments 
showed that the C-terminal fragment of rabbit 1S can associate with the truncated 
channel in a heterologous system (130). Yeast two-hybrid assay revealed the specific 
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interaction between a proximal C-terminal interaction domain (residues 1556–1612) 
and a distal C-terminal interaction domain (residues 1802–1841) (130). Note that the 
two domains are proximal and distal to the cleavage site (A1664), respectively. 
Similar results were obtained with rabbit 1C, whose C-terminal fragment associates 
with the truncated channel in a heterologous system and serves as an autoinhibitory 
domain by decreasing the coupling between voltage sensing and channel opening and 
by shifting the voltage dependence of activation to more positive membrane potentials 
(141). Moreover, site-directed mutagenesis, coimmunoprecipitation, and structural 
modeling revealed a binding interaction between a pair of arginine residues (R1696, 
R1697) in the proximal C-terminal regulatory domain, (previously called proximal 
C-terminal interaction domain). Additionally, three negatively charged amino acid 
residues (E2103, E2106, D2110) are present in the distal C-terminal regulatory 
domain (previously called distal C-terminal interaction domain) (141). This 
interaction is critical to the autoinhibitory effect of the C-terminal fragment on CaV1.2 
channel function (141). Interestingly, the autoinhibitory effect caused by the 
non-covalent interaction between the cleaved C-terminal fragment and the truncated 
1 subunit is much more potent than when the C-terminal fragment is covalently 
associated with the proximal C-terminal domain in the full-length channel (141). 
These results indicate that the cleaved C-terminal fragment and the truncated 1 
subunit form a one-to-one autoinhibitory complex (141). 
As the molecular identity and autoinhibitory function of the L-type calcium 
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channel C-terminal fragment were being revealed, progress was also being made on 
understanding the cAMP/PKA-dependent regulation of L-type calcium channels. 
Activities of L-type calcium channels in both skeletal and cardiac muscle are 
regulated by the -adrenergic receptor pathway in the fight or flight response (2). 
Stimulation of the -adrenergic receptor pathway activates the cAMP/PKA signaling 
pathway, which then increases L-type Ca2+ currents through PKA-mediated 
phosphorylation of the L-type calcium channels and/or associated proteins (2). In both 
skeletal and cardiac muscle, PKA-dependent upregulation of L-type calcium channel 
activity requires anchoring of PKA to the CaV1 subunit via an A-kinase anchoring 
protein (AKAP), typically AKAP15 (2). AKAP15 binds to 1S and 1C via a 
modified leucine zipper interaction (142, 143). Interestingly, the AKAP15-binding site 
is distal to the proteolytic cleavage site (142, 143). This means that PKA and AKAP15 
are anchored to the C-terminal fragment cleaved off from the 1 subunit. Because 
binding of AKAP15 and PKA to the distal C-terminal domain is required for 
cAMP/PKA-dependent regulation of L-type calcium channels (2), these results offer 
another piece of evidence that cleaved C-terminal fragment can remain associated 
with the channel. 
These observations connected the proteolysis of L-type calcium channel 
C-terminal tail with cAMP/PKA-dependent upregulation of L-type Ca2+ currents and 
raise the possibility that cAMP/PKA-mediated phosphorylation of the 1 subunit does 
not inhibit the truncated 1 subunit with a bound distal C-terminal fragment. The 
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Catterall group proposed a biophysical model, in which cardiac 1C subunits are 
present in three forms, full-length, truncated, and truncated plus a non-covalent bound 
distal C-terminal fragment, in which cAMP/PKA-mediated phosphorylation of the 
C-terminal relieves the autoinhibition by the distal C-terminal fragment (141). Using 
this model, they precisely simulated the increase in Ca2+ currents rat ventricular 
myocytes (141). 
Further studies have made revealing discoveries on the molecular mechanism of 
the disinhibition of the autoinhibitory complex. The Catterall group found that 
cAMP/PKA-mediated upregulation of cardiac CaV1.2 activity in a heterologous 
system requires co-expression of a carefully titrated amount of AKAP15 (55). This 
indicates that cardiac CaV1.2 forms an autoinhibitory signaling complex comprised of 
the C-terminally truncated 1C, the C-terminal fragment, AKAP15, and PKA (55). 
With optimized expression of the different components of the autoinhibitory signaling 
complex, PKA-dependent regulation of CaV1.2 activity was able to be reconstituted in 
a heterologous system with a dynamic range similar to that in cardiac myocytes (55). 
Moreover, mass spectrometry revealed two previously unidentified sites of in vivo 
phosphorylation in rabbit skeletal muscle 1S, S1575, and T1579 (56), which are 
conserved in 1C as S1700 and T1704, respectively (55). S1575/S1700 is a substrate 
for PKA and CaMKII, while T1579/T1704 is a substrate for casein kinase II (55, 56). 
These two phosphorylation sites are “strategically” located in the proximal C-terminal 
regulatory domain and are exposed to the interface between the proximal and distal 
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C-terminal regulatory domains. At this interface, negatively charged phosphates could 
disrupt the ionic interactions between the two domains and relieve autoinhibition (55, 
56). Site-directed mutagenesis and electrophysiology revealed that basal activity of 
CaV1.2 in unstimulated cells is regulated by phosphorylation of both S1700 and 
T1704, whereas further upregulation of channel activity through stimulation of the 
cAMP/PKA pathway requires only the phosphorylation of S1700 (55). 
Transgenic mouse lines were created to test the functional role of the 1C distal 
C-terminus, S1700, and T1704 (144-146). Mice expressing only 1C without the 
distal C-terminus (DCT) have severely impaired cardiac function and die perinatally 
(144). Counterintuitively, cardiomyocytes from these mice have reduced CaV1.2 
currents, even though the autoinhibitory distal C-terminus is absent since mutant 
channels have low cell surface expression (144). The -adrenergic up-regulation of 
CaV1.2 activity is completely lost in myocytes from the DCT mice (144). In two 
other mouse lines, S1700 alone or together with T1704 was mutated to alanine. In 
both mouse lines, basal CaV1.2 activity and -adrenergic-stimulated CaV1.2 activity 
were both significantly reduced, and both mouse lines suffer impaired cardiac 
function and premature deaths (145, 146). These results indicate that the distal 
C-terminus and the two phosphorylation sites, S1700 and T1704, have crucial 
regulatory functions and are indispensible for cardiac development and function in 
vivo. Note that in the two mouse lines with mutated phosphorylation sites, 
-adrenergic upregulation of CaV1.2 activity is not completely lost, and the reduction 
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in cellular contractility is not as severe as the reduction in CaV1.2 current (145, 146). 
These findings suggest that there are other mechanisms for the -adrenergic 
upregulation of CaV1.2 activity and regulation of cardiomyocyte contractility 
independent of S1700 and T1704. 
In summary, most CaV1 subunits in skeletal and cardiac muscle are present as a 
truncated 1 subunit with a non-covalently bound C-terminal fragment, in which the 
distal C-terminal regulatory domain associates with the proximal C-terminal 
regulatory domain of the truncated 1 subunit via ionic interactions. PKA is anchored 
to the C-terminal region of the channel via AKAP, which binds to the AKAP binding 
site on the C-terminal fragment. The truncated 1 subunit, C-terminal fragment, 
AKAP, and PKA forms an autoinhibitory signaling complex, which has basal channel 
activity. In the fight or flight response, stimulation of the -adrenergic receptors 
causes cAMP/PKA-mediated phosphorylation of S1575 (in skeletal muscle 1S) or 
S1700 (in cardiac 1C). The phosphate group disrupts the ionic interactions between 
the proximal and distal C-terminal regulatory domains and relieves autoinhibition, 
causing up-regulation of channel activity. A schematic diagram of the autoinhibitory 















Figure 1. Schematic of the cardiac CaV1.2 autoinhibitory signaling complex and the 
mechanism of cAMP/PKA-mediated upregulation. The C-terminal tail of 1C is proteolytically 
cleaved on the carboxyl side of A1800. The portion between residues 1682-1740 and the portion 
between residues 2081-2124 serve as the proximal C-terminal regulatory domain (PCRD) and the 
distal C-terminal regulatory domain (DCRD), respectively. Pink dots represent the pair of arginine 
residues, R1696 and R1697. Red dots represent the group of negatively-charged residues, E2103, 
E2106, and D2110. The ionic interaction between these two groups of residues is critical to the 
autoinhibitory effect of the C-terminal fragment on the channel. The portion between residues 
1740 and 1800 enhances the binding of the distal C-terminal fragment to the proximal C-terminus, 
and thus is also necessary for the autoinhibitory effect. The proline-rich domain (PRD, 1974-2000) 
enhances the efficacy of the autoinhibition. The autoinhibitory signaling complex also includes 
AKAP15, which is anchored to the AKAP15-binding domain (ABD, residues 2063-2080) of the 
C-terminal fragment. AKAP15 anchors PKA to the C-terminal fragment. PKA is activated by 
cAMP and subsequently phosphorylates S1700 (represented by the yellow dot). The negatively 
charged phosphate group disrupts the ionic interaction between the proximal and distal C-terminal 
regulatory domains and relieves autoinhibition. (Modified from Gao et al., 2001 (140)). 
 
There are still unanswered questions about the L-type calcium channel 
autoinhibitory signaling complex. The type of enzyme that catalyzes the proteolytic 
cleavage in the C-terminal tail is still not confirmed, although both calpain and 
chymotrypsin are known to produce truncated 1 of similar size to that found in the 
animal tissue. The signal that induced the proteolysis is also unknown. Moreover, it is 
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still unclear what mechanisms cause the remaining sensitivity of cardiac CaV1.2 to the 
-adrenergic receptor pathway in mice with both S1700 and T1704 mutated to alanine. 
Are other phosphorylation sites responsible for this? What are the functions of those 
previously discovered major phosphorylation sites distal to the cleavage site, i.e., 
S1854 and S1757 in 1S, and S1928 in 1C? More research is needed to answer 
these questions and further understand the proteolysis of the L-type calcium channel 
C-terminal tail and the autoinhibitory signaling complex. 
 
  1.6.1.2 Mid-channel proteolysis of the L-type calcium channel 1 subunit 
A recent study in our lab by Michailidis and colleagues provided evidence for 
another type of regulatory proteolysis of the L-type calcium channel—mid-channel 
proteolysis (4). Mid-channel proteolysis is proteolytic cleavage of the main body of 
the  subunits, instead of the C- or N-terminal tail. A research from our group (4) 
showed that the mid-channel proteolysis of rat brain 1C is a calcium-dependent 
process, serving as negative feedback regulation of the channel. 
This research (4) utilized surface biotinylation of brain tissue and cultured 
neurons to focus on the 1C on the plasma membrane. Western blot analysis of rat 
cortical slices revealed 1C subunits of several different sizes. Two most prominent 
forms were the 240-kDa full-length channel, and a 150-kDa fragment-channel 
recognized by both an antibody against the II-III loop and an antibody against the 
C-terminal tail. The 150-kDa fragment-channel presumably contains the part of II-III 
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loop, repeats III and IV and the C-terminus, and results from mid-channel proteolysis 
in the II-III loop. A complementary fragment-channel containing the N-terminus and 
repeats I and II was detected by an antibody against the N-terminal tail. Additional 
lengths of 1C were also detected. 
To address the question whether the complementary 1C fragments remain 
associated with each other or sometimes separate, a tagged 1C construct was used 
(4). This construct at the N-terminus was tagged with GFP, and repeat III was tagged 
extracellularly with HA tag, which was later immunostained in red. Confocal imaging 
showed that in some locations of the cell surface, red signal does not colocalize with 
green signal, indicating that some complementary fragment-channels separate from 
each other on the plasma membrane. Using constructs with HA tags in different 
positions, this research (4) also showed that there may also be cleavage sites in the I-II 
loop and the III-IV loop. 
The mid-channel proteolysis was revealed to be regulated by cellular calcium 
activity. Reagents that increase intracellular [Ca2+], L-type calcium channel activity 
and/or cell excitability increase the intensity ratio of the 150-kDa fragment relative to 
the full-length channel, and also increase the separation of red and green. Reagents 
that decrease L-type calcium channel activity and/or cell excitability have the opposite 
effect. Calpain, which is responsible for proteolysis of voltage-gated sodium channels 
(1.6.2.1), was shown to contribute to the mid-channel proteolysis of 1C and the 
separation of the fragment-channels. Interestingly, the ubiquitin-proteasome system 
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was also shown to be involved in the mid-channel proteolysis. Confocal imaging 
showed that inhibitors of the ubiquitin-proteasome system, and mutations made to a 
putative ubiquitination motif (PY motif) in an intracellular loop of repeat IV, markedly 
reduced the separation of the fragment-channels on the plasma membrane. Two PEST 
sequences, PEST1 and PEST3, were found in 1C in the I-II loop and the II-III loop, 
respectively, and were shown to play important regulatory roles (109). PEST 
sequences have been shown to serve as signals for rapid degradation of proteins by 
calpain and the ubiquitin-proteasome system (110). Our group (4) showed that 
deletion of PEST1 or PEST3 greatly reduces the separation of the fragment-channels. 
Using engineered complementary fragment-channels, our group (4) showed that 
the two complementary fragments do not conduct currents individually, but together 
can form a functional channel and conduct currents with an amplitude of about 35% 
of that of the full-length channel. The channel formed by complementary 
fragment-channels also displays altered biophysical properties, with the I-V 
relationship and voltage dependence of steady-state inactivation shifted ~10 mV to the 
depolarizing direction. Incubating neurons with reagents that enhance L-type calcium 
channel activity not only increases mid-channel proteolysis, but also reduces currents 
of L-type calcium channels, corresponding to the smaller current amplitude of 
channels formed by complementary fragments. Blocking the L-type calcium channel 
has the opposite effects. Note that the decrease in current amplitude following channel 
activation may also be due to internalization of full-length channels. Nevertheless, 
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these results suggest that mid-channel proteolysis serves as a negative feedback 
regulation of the L-type calcium channel, and most likely provides protection to the 
neurons against calcium-induced cell death (147). Our group (4) examined the 
mid-channel proteolysis across the life span, and found that mid-channel proteolysis 
increases steadily with age, being ~7 times more intense in 16-month old rats than in 
10-day old rats. This phenomenon was seen in additional studies (148). The increase 
in mid-channel proteolysis associated with aging is probably a compensatory response 
to the aging-associated increase in L-type calcium channel currents (149-151). 
Both the Western blot analyses and imaging experiments (4) provided us with 
evidence that mid-channel proteolysis happens at several locations in 1C. Three 
pairs of complementary fragment-channels, (A1 & A2; B1 & B2; C1 & C2), were 
constructed to mimick the products of mid-channel proteolysis in loop I-II, II-III, and 
III-IV, respectively. None of the fragment-channel conducts currents on its own, but 
all of them can conduct currents when paired with a complementary fragment. Our 
group (4) also investigated the influence of these fragment-channels on the full-length 
CaV1.2 channel. C2 is the only fragment that has a dominant negative effect on the 
currents of the full-length channel. Neither B1 nor B2 has a significant effect on the 
biophysical properties of the full-length channel. A1, A2, and C1 all can alter the I-V 
relationship and voltage dependence of steady-state inactivation of the full-length 
channel. 
This research from our group (4) uncovered a novel form of negative feedback 
40 
 
regulation of the L-type calcium channel but also raised new questions. Where are the 
precise cleavage sites? Does mid-channel proteolysis take place on the plasma 
membrane or in the cytoplasm? What pulls the complementary fragments apart? What 
is the fate of the fragment-channels after they separate? Do the fragment-channels 
undergo conformational changes in response to membrane depolarization, like a 
95-kDa truncated 1A (152), and convey information into the cell? Does mid-channel 
proteolysis also happen to other types of VGCCs, such as P/Q- and N-type calcium 
channels? As a novel and intriguing regulatory process, mid-channel proteolysis needs 
to be further investigated.  
 
  1.6.2 Proteolysis of voltage-gated sodium channels 
Voltage-gated sodium channels (VGSCs or NaChs) are essential proteins in 
neurophysiology. VGSCs initiate action potentials (APs) in excitable tissues, and thus 
are critical for the regulation of the excitability of neurons and myocytes (153). The 
pore-forming subunit of a VGSC is the  subunit, which consists of four homologous 
domains, each containing six transmembrane helices (153), resembling VGCCs. The 
four homologous domains of a VGSC are joined by intracellular linkers, and the N- 
and C-termini are also located intracellularly (153). 
VGSCs are regulated through proteolysis under normal (154) and stress 
conditions (155). Pharmacological activation of VGSCs leads to downregulation of 
surface VGSCs by endocytosis followed by proteolysis of the  subunit, which 
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produces a 90-kDa fragment, as detected using a radioactive VGSC agonist (154). 
Axon stretch injury causes proteolysis of the III-IV loop and probably other regions of 
the VGSC  subunit, resulting in a 55-kDa fragment that can be detected by an 
antibody against the I-II loop (155). Proteolysis of VGSCs can also be induced by 
anoxia or ischemia (156). 
Calpain has been shown to be an important protease underlying the proteolysis of 
VGSCs (157). Activation of calpain leads to proteolysis of NaV1.2 in rat brain lysate 
and cultured rat cortical neurons (158). The proteolysis causes the loss of the 260-kDa 
full-length NaV1.2  subunit and produces several fragments, including a 160-kDa 
and 110-kDa band recognized by an antibody against the III-IV loop and a 150-kDa, 
100-kDa and 80-kDa band recognized by an antibody against the I-II loop (158). It is 
therefore inferred that the NaV1.2  subunit is cleaved at two sites (158). A cleavage 
in the I-II loop produces a 100-kDa N-terminal fragment and a 160-kDa C-terminal 
fragment, and a cleavage in the II-III loop produces a 150-kDa N-terminal fragment 
and a 110-kDa C-terminal fragment (158). The 80-kDa band recognized by the I-II 
loop antibody is most likely due to a cleavage in the N-terminal tail (158). 
Interestingly, most of the channel fragments remain on the plasma membrane 6 hours 
after calpain activation (158). These fragments may interact with each other to form 
channels with modified biophysical properties, like the fragments of the L-type 
calcium channel (4). 
An in vitro model of traumatic brain injury shows that stretch injury to cortical 
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neurons can cause activation of calpain and subsequently lead to proteolysis of 
VGSCs, producing the 160- and 110-kDa fragments recognized by the III-IV loop 
antibody (158, 159). Chronic inhibition of NMDA receptors (NMDARs) and VGSCs, 
but not L-type calcium channels, significantly inhibits calpain activation and VGSC 
proteolysis following stretch injury (159). Moreover, an early transient inhibition of 
NMDARs also significantly reduces VGSC proteolysis following injury (159). These 
results indicate that calcium influx through NMDARs is critical for the proteolysis of 
VGSCs by calpain. 
It has been shown that proteolysis of the VGSC  subunit prevents normal 
inactivation of the VGSC and thus leads to persistent influx of Na+ (160-162), which 
may subsequently lead to Ca2+ influx and cause further pathological changes (155). 
Spinal cord injury in rats has been shown to cause calpain-dependent cleavage of 
VGSCs associated with an upregulation of persistent sodium current (INaP) in 
motoneurons (163). INaP is an important contributing factor to spasticity following 
spinal cord injury (164, 165). Intraperitoneal injection of calpain inhibitor MDL28170 
not only reduces production of the 120-kDa product of VGSC protealysis (recognized 
by antibody against the II-III loop), but also reduces INaP in motoneurons and 
spasticity (163). These results reveal the important role of VGSC proteolysis in 
promoting the complications from spinal cord injury and offer a potential therapeutic 
tool for recovery. 
Inhibition of calpain is a promising therapeutic approach for neuropathy and 
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nerve injury. Overexpression of the calpain inhibitor calpastatin in transgenic mice 
significantly reduces hippocampal cell death following excitotoxic insult (166). 
Following traumatic brain injury, transgenic mice overexpressing calpastatin showed 
less proteolysis of VGSCs and several other calpain substrates. In addition, the 
transgenic mice have lower levels of behavioral deficits compared with wild-type 
mice, although there is no attenuation of the tissue damage (167, 168). Inhibition of 
calpain by MDL28170 has also been shown to attenuate biochemical, functional, and 
behavioral deficits in a model of diabetic neuropathy (169). 
Other proteases have also been found to catalyze VGSC proteolysis. It has been 
shown that in heart disease, aminopeptidases catalyze the excision of the N-terminal 
methionine of NaV1.5, followed by acetylation of the resulting N-terminal alanine 
(170). Truncations in NaV1.7 due to nonsense mutations have been shown to cause 
loss of function of the channel and subsequently lead to congenital insensitivity to 
pain (171). Interestingly, a missense mutation (R907Q) neighboring one of the 
nonsense mutations (R908X) in the S5-S6 extracellular loop of repeat II also causes 
the disorder (172). Further research has shown that R907Q renders the Y908-H909 
bond more sensitive to matrix metalloproteinase 9 (MMP-9), indicating that 
aberrantly increased proteolysis may cause the loss of function of NaV1.7-R907Q and 





1.7 Splice variants and truncated VGCCs 
  1.7.1 A C-terminal fragment of 1C acting as a transcription factor 
As discussed in 1.6.1.1, 1C and 1S can be proteolytically cleaved to produce a 
C-terminal fragment of 20-40 kDa, which has an autoinhibitory effect on the 
full-length L-type calcium channel and is involved in the upregulation of channel 
activity in the fight or flight response. Interestingly, C-terminal fragments of 1C 
have also been found to serve as transcription factors. 
L-type calcium channels, especially CaV1.2 and CaV1.3, have been known to 
regulate gene expression through Ca2+ influx (13). A decade ago, a new mechanism 
through which L-type calcium channels regulate gene expression was reported. A 
distal C-terminal fragment of 1C was found to act as a transcription factor (148). 
This 75-kDa C-terminal fragment, termed calcium channel associated transcription 
regulator (CCAT), is enriched in the nuclei of both HEK 293T cells transfected with 
CaV1.2 and rat cortical neurons, especially inhibitory neurons that produce 
-aminobutyric acid (GABA) (148). CCAT transfected into neurons, cardiac myocytes, 
and HEK 293T cells form distinct nuclear punctae, as revealed by confocal imaging 
(148). However, the exact N-terminal residue of the CCAT is unknown, and judging 
from the molecular weight, it comprises virtually the whole C-terminal tail. 
The CCAT contains three critical domains: an N-terminal transcription activation 
domain (residues 1642-1811), nuclear localization domain (residues 1814-1864), and 
C-terminal transcription activation domain (residues 2011-2143) (GenBank accession 
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number AAA18905) (148). The N-terminal transcription activation domain modulates 
transcriptional activation, while the C-terminal transcription activation domain is 
essential for transcriptional activation (148). The nuclear localization of the CCAT is 
developmentally regulated. The level of nuclear CCAT increases substantially with 
age, starting at embryonic day 18 through adulthood (148). The nuclear localization of 
the CCAT is also regulated by changes in intracellular calcium. Activation of L-type 
calcium channels or glutamate receptors leads to a decrease in nuclear CCAT, while 
chelating Ca2+ or inhibiting L-type calcium channels or NMDARs leads to an 
increase in nuclear CCAT (148). Microarray experiments revealed that 16 mRNAs 
were significantly upregulated, and 31 genes were significantly downregulated by 
CCAT expressed in Neuro2A cells (148). One of the main upregulated targets of 
CCAT is gap-junction protein Cx31.1 (148). Chromatin immunoprecipitation (ChIP) 
analysis revealed that CCAT associates with the promoter of Cx31.1 (148). 
Upregulation of Cx31.1 by CCAT also takes place in cultured rat cortical neurons and 
thalamic neurons, and can be reduced by depolarization of the plasma membrane, in 
accordance with the finding that increased intracellular [Ca2+] decreases nuclear 
CCAT (148). 
Connexins play a critical role in forming electrical synapses and facilitating 
intercellular communication in developing and mature nervous tissues (174). 
Upregulation of Cx31.1 by CCAT suggests an important role of CCAT in electrical 
tissues. Moreover, CCAT was also shown to significantly increase the length and 
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number of neurites of cerebellar granule neurons (148). Taken together, these results 
suggest that the C-terminal fragment of 1C, as a transcription factor/regulator, plays 
an important role in the development and function of excitable tissues. 
C-terminal fragments of 1C, as transcription factors/regulators, also have been 
found to downregulate the expression of CACNA1C (138). One study reported that 
immunoblot analysis of mouse ventricular myocytes with an antibody against the 1C 
C-terminal tail detected only a 37-kDa band, while the same analysis of tsA-201 cells 
expressing CaV1.2 revealed only the 240-kDa full-length 1C (138). These results are 
consistent with the previous findings that 1C is present in two size forms in animal 
tissues but in only one size form in heterologous systems (see 1.6.1.1), suggesting that 
the 37-kDa C-terminal fragment (CTF) might be produced by proteolysis. In mouse 
ventricular myocytes, the CTF (residues 1821-2171) translocates to the nuclei (138). 
Chromatin immunoprecipitation (ChIP) analysis revealed that the CTF interacts with 
3 of the 5 putative promoter elements in the CaV1.2 promoter (138). Overexpression 
of the CTF led to a 34% decrease of CaV1.2 promoter activity, as revealed by a 
luciferase reporter assay (138). Interestingly, an N-terminally truncated CTF (residues 
1906-2171) is more enriched in the nuclei, has stronger interaction with the CaV1.2 
promoter, and, when overexpressed, causes an 80% decrease of CaV1.2 promoter 
activity (138). 
The CTF in mouse ventricular myocytes also antagonizes cellular hypertrophy 
through transcriptional regulation. Serum, a known inducer of cardiac myocyte 
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cellular hypertrophy in vitro, leads to an increase in the nuclear localization of the 
CTF, which then facilitates the suppression of CaV1.2 promoter activity, mRNA level, 
protein level, and currents (138). Moreover, CTF overexpression attenuates 
serum-induced cellular hypertrophy and, by suppressing atrial natriuretic factor (ANF) 
promoter activity, attenuates serum-induced ANF expression. 
This 37-kDa CTF has a molecular weight similar to the autoinhibitory CTF in 
cardiac myocytes mentioned in 1.6.1.1. It is unclear whether the two CTFs are related 
or are even the same fragment. It is possible that a single proteolytically produced 
CTF of 1C serves both as an autoinhibitory domain by interacting with CaV1.2, and 
as a transcription repressor of CaV1.2 by translocating into the nucleus and interacting 
with the promoter of CACNA1C. The suppressive effects of the CTF(s) on CaV1.2 
expression and currents suggest a negative feedback loop, in which elevated CaV1.2 
protein or current level leads to increased suppressive effects of the CTF. Further 
studies will be needed to confirm this negative feedback mechanism. 
A C-terminal fragment (CTF) of CaV1.2 has also been shown to be present in 
non-excitable cells and play an important role in cellular differentiation. In Western 
blot analysis of rat dental pulp stem cells (rDPSCs), an antibody against a middle 
segment of the 1C recognized a 190-kDa band, while an antibody against the 
C-terminal tail recognized a 75-kDa band (175). Interestingly, unlike many other 
calcium channel CTFs, the 75-kDa CTF in rDPSCs was not observed in the nucleus 
but only in the cytoplasm (175). Knockdown of 1C abolished the potential of 
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rDPSCs to differentiate into neural cells, and expression of the CTF is sufficient to 
rescue the differentiation (175). The apparent absence of the CTF in the nuclei 
suggests that the CTF may regulate cellular differentiation through an indirect way 
instead of acting as a transcription factor. However, it cannot be excluded that the 
CTF acts as a transcription factor, yet its amount in the nucleus is too low to be 
detected using the imaging method in the study. 
It has long been thought that CTFs of L-type calcium channels are products of 
proteolysis. Several years ago, it was found that a cryptic promoter in exon 46 of 
CACNA1C drives the expression of a CTF that acts as a transcription factor (3). 
Western blot analysis revealed that 1C expressed in Neuro2A cells is present in two 
sizes, a 250-kDa full-length form and a 40-kDa CTF, as detected by an antibody 
against the C-terminal tail (3). A luciferase reporter assay reveals that this CTF has 
transcriptional activity (3). A nonsense mutation proximal to the CTF does not abolish 
the production or transcriptional activity of the CTF, indicating that the CTF is not a 
proteolytically cleaved fragment of full-length 1C (3). Mutation of residue M2011 to 
an isoleucine causes an 8-kDa decrease in the size of the CTF, indicating that the CTF 
is the product of an independent translation event that starts at M2011 (3). Deletion of 
the promoter upstream of the CACNA1C gene abolishes the production of full-length 
1C but not the CTF (3), indicating that there is a cryptic promoter in the CACNA1C 
gene upstream of the region encoding the CTF. Northern blot analysis of Neuro2A 
cells expressing CaV1.2 revealed two transcripts of 1C, one of 7.5 kb corresponding 
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to the full-length channel, the other of 1.4 kb presumably corresponding to the CTF 
(3). Similar results were obtained from Northern blot analysis of rat cerebral cortex, 
diencephalon, and cerebellum, and further revealed that the two transcripts are 
regulated reciprocally during development (3). Moreover, single-cell quantitative PCR 
revealed that in all cells from rat forebrain, mRNAs containing exon 47 are 
approximately 80-fold more abundant than mRNAs containing exons 2, 8, and 44, and 
some cells express even only exon 47 (3). Taken together, these results offer 
convincing evidence that the CTF results from an independent transcript produced by 
a cryptic promoter in the CACNA1C gene. Luciferase reporter assays revealed that the 
238-bp region upstream of M2011 (start site of the CTF) in exon 46 is sufficient to 
drive the transcription. Exon 46 and exon 47 together offer an even stronger promoter 
activity, but exon 47 itself has no promoter activity (3). 
Mutating M2011 (start site of the CTF) to an isoleucine forces the translation to 
start from M2073, resulting in a shorter CTF that does not have transcriptional 
activity (3). Scrutiny of the peptide sequence between M2011 and M2073 revealed an 
evolutionarily conserved leucine zipper composed of the residues IFIL (3). Mutation 
of IL to AA reduced transcription by 75% while mutation of all four residues 
eliminated transcription completely, indicating the leucine zipper is necessary for the 
transcriptional activity (3). 
Rapid amplification of cDNA 5’ ends (5’ RACE) was used to identify 
transcription start sites (TSSs) in CACNA1C, and revealed multiple TSSs, which will 
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produce proteins of 240-kDa, 110-kDa, and 15-kDa, respectively (3). The presence of 
these proteins was confirmed by Western blot analysis of mouse brain (3). Conditional 
transgenic mice lacking exons 14 and 15 of CACNA1C do not produce full-length 
1C but still generate a 115-kDa and 15-kDa protein, in accordance with the TSSs 
identified (3). 
This first report of an exonic promoter that drives the transcription of part of the 
same gene, has greatly expanded our understanding of the L-type calcium channel and 
the origins and functions of fragment-channels. On the other hand, it also raises more 
questions. The authors did not explain the discrepancy in the different sizes of the 
C-terminal fragments that they observed in CaV1.2-expressing Neuro2A cells (40-kDa) 
and predicted according to the TSS (15-kDa, consistent with the protein observed in 
the mouse brain). Is the discrepancy caused by anomalous migration or are there two 
different CTFs both produced by the cryptic promoter? Are all the other previous 
reported CTFs of 1C generated by cryptic promoters too or are some of them 
produced by proteolysis? A few years before the cryptic promoter in exon 46 was 
reported, the same group of researchers reported a 75-kDa CTF of 1C that acts as a 
transcription factor (148), as discussed at the beginning of 1.7.1. There is a big 
difference between the sizes of the 75-kDa CTF and the CTF due to the cryptic 
promoter (15 kDa), and the two CTFs also have different distributions in the brain and 
are regulated differently during development (3, 148). Therefore they may be different 
fragments of 1C and have different origins. Moreover, in cardiac myocytes, the CTF 
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of 1C is present in a 1:1 ratio with the complementary part of the channel and is also 
associated with the channel (127); this is more in accordance with proteolysis instead 
of a cryptic promoter. Therefore, although there is convincing evidence that a cryptic 
promoter is present in CACNA1A and can generate a CTF of 1C, proteolysis may be 
the origin of many other CTFs. 
 
  1.7.2 Splice variants and truncated forms of the P/Q-type calcium channel 
  1.7.2.1 A variety of fragments of 1A 
The P/Q-type calcium channel 1A subunits from brain tissues of different 
animals have been analyzed using immunoblotting by many labs. Every result showed 
more than one band (5, 8-12). The sizes of the bands reported in these studies vary in 
the range of 60-250 kDa. Although these studies used tissues from different animals 
(mice, rats, rabbits, and humans), there are some similarities between the results. 
Antibodies against the peptide CNA1 (PSSPERAPGREGPYGRE) or CNA3 
(SEPQQREHAPPREHV) in the II-III loop always detected two to three bands of 
160-250 kDa, and the major band was always in the range of 180-210 kDa, in which 
no more than two bands were detected (8-10). Antibodies against epitopes near the 
end of the C-terminus of 1A always detected three bands: 220-250 kDa, 160-170 
kDa, and 60-85 kDa (11, 12). Other detection methods or immunoblotting with other 
antibodies showed bands in different patterns. An antibody against the N-terminal tail 
and an antibody against a long segment of the II-III loop (including both CNA1 and 
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CNA3) detected four and five bands, respectively, in the range of 95-220 kDa (5, 8). 
Moreover, an analysis using a radioactive antagonist of 1A detected four bands 
ranging between 140 and 220 kDa (176). 
In most of these results, the molecular weight of the longest 1A band is 220 
kDa, lower than the theoretical molecular weight of full-length 1A, which is 250 
kDa in rat (UniProtKB - P54282), 270 kDa in mouse and rabbit (P97445 and P27884), 
and 280 kDa in human (O00555). One of the studies reported that human 1A had a 
band of 250 kDa, which is smaller than the theoretical molecular weight of 280kDa 
(12). This discrepancy is probably due to anomalous migration, or an extremely low 
amount of full-length 1A in the tissue. 
Where do the other bands originate from? Are they present in the brains of live 
animals or produced in vitro? We cannot exclude the possibility that some of those 
bands are due to protein degradation during sample preparation or non-specific 
staining by the antibodies. However, plenty of evidence is in favor of the presence of 
shorter forms of 1A in the brains of live animals. Some of the studies reported that 
the banding pattern is highly reproducible in different preparations (5, 176). Inclusion 
of high concentrations of several protease inhibitors and handling of samples at 0°C 
did not alter the relative quantities of the bands (5, 8, 9). In one of the studies, 1A 
was detected as multiple bands, while 1B in the same preparation was not (5). These 
results all argue against in vitro degradation. Moreover, immunoprecipitation analysis 
showed that a 190-kDa band, the major band in rat brain, can be recognized by 
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multiple antibodies against different parts of 1A (8, 9). A 60-kDa band recognized by 
an antibody against the 1A C-terminal region was shown to contain the histidine 
tract (11), an evolutionarily conserved sequence in the 1A C-terminal tail. A 95-kDa 
1A fragment is present in preparations from wild-type rabbit and mice, but not in 
CACNA1A-knockout mice (5, 6). Therefore, these bands are unlikely due to 
non-specific staining. 
As mentioned in 1.6.1.1, 1S, and1C expressed in heterologous systems are 
only present in the full-length form, but those from animal tissues are usually present 
in two size forms. Interestingly, 1A expressed in heterologous systems also exhibits 
a much simpler banding pattern than in animal tissues. Immunoblot analysis of 1A 
expressed in HEK 293, HEK 293Tm and PC12 cells with antibodies against the 
C-terminal region or tags on the C-terminus always showed only two bands, a long 
form of 220-280 kDa (presumably full-length 1A), and a short form of 75 kDa (11, 
12, 177). In one case, an extra 55-kDa band is present on the Western blot but was not 
discussed (7). Compared with 1A in animal tissues, 1A expressed in cell lines lacks 
the middle-sized form of 160-170 kDa recognized by antibodies against the 
C-terminal region. Moreover, when an 1A construct with an HA-tag on repeat IV 
was expressed in HEK 293 cells and analyzed by immunoblot with an anti-HA 
antibody, even the 75-kDa band was absent and only a 250-kDa band was detected 
(178). The 75-kDa form was revealed to be a C-terminal fragment of 1A produced 
by an internal ribosome entry site (IRES) and acts as a transcription factor with 
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important regulatory functions (see 1.7.2.3). This explains why the anti-HA antibody 
cannot detect it. These results indicate that live animal brains have certain 
mechanisms, which cell lines do not have, to produce short forms of 1A. These short 
forms of 1A may play crucial roles in the development and function of the brain. 
What mechanisms cause so many different sizes of 1A? The two potential 
mechanisms mentioned most often in the literature are post-translational proteolysis 
and alternative splicing (5, 8, 9, 176). As mentioned in 1.6.1.2, 1C was shown to 
undergo mid-channel proteolysis resulting in two complementary fragments of 90 
kDa and 150 kDa, respectively (4). A similar proteolytic cleavage may happen to 1A 
and produce a proximal fragment of ~90 kDa and a distal fragment of 160~190 kDa, 
depending on the species. Consistent with this possibility, 1A bands of these sizes 
were detected by pertinent antibodies in many of the previous studies (see above). 
Alternative splicing is another potential mechanism since a190-kDa short form of 
1A was shown to contain the N-terminal tail, C-terminal tail and the II-III loop. 
These results indicate that this short form of 1A is not a product of proteolysis, but 
may instead be a splice variant (8). In another study, a 95-kDa short form of 1A was 
found to contain the N-terminal tail, repeat I, I-II loop, repeat II and part of the II-III 
loop (5). The authors surmised that this 95-kDa species is a product of alternative 
splicing, in consideration of the presence of two transcripts in Northern blot analysis 
of rat brain 1A (179). Moreover, it has been suggested that the four-domain sodium 
and calcium channels originated during evolution through two rounds of gene 
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duplication of a single domain ancestral channel (180, 181). The expression of the 
two-domain isoforms still occurs through alternative splicing, especially during 
embryonic development (180, 182). Thus, it is tempting to speculate that the 95-kDa 
two-domain form of 1A is also has evolutionary origins due to alternative splicing. 
However, among the numerous splice variants that have been discovered, none can 
account for an isoform as small as 190 kDa (see 1.7.2.5). The possibility of 
post-translational proteolysis cannot be ruled out. Although the origin of the 95-kDa 
two-domain fragment of 1A is unknown, progress has been made on revealing its 
physiological properties, which is summarized and discussed in 1.7.2.2. 
As will be discussed 1.7.2.2 and 1.7.2.3, the physiological properties of two short 
forms of 1A have been studied. However, as shown in the above-mentioned 
immunoblot analyses, numerous other short forms of 1A are present in the brain, and 
their physiological properties are still unknown. It has been revealed that the different 
size forms of 1A are differentially phosphorylated. A 220-kDa form of 1A from the 
rat brain is phosphorylated preferentially by PKA in vitro, while PKC and PKG 
preferentially phosphorylate a 190-kDa form in vitro (8). This suggests that different 
sizes of 1A may be differentially regulated in vivo to fulfill the complex regulation 
and function of the P/Q-type calcium channels. Further research is needed to 
understand the identities, physiological properties, and functions of the different size 




  1.7.2.2 A two-domain form of 1A with inhibitory function 
Immunoblot analysis of rabbit brain membrane protein with an antibody against 
part of the II-III loop revealed five different size forms of 1A, among which the 
shortest has a molecular weight of 95 kDa (5). This 95-kDa species is enriched in the 
cerebellum and cerebral cortex, with lower expression in the hippocampus and 
thalamus (6). This short form of 1A is unlikely to result from degradation during 
sample preparation for a variety of reasons. Firstly, 1B, which shares significant 
sequence homology with 1A, is present only as a 210-kDa form in the same 
preparation. Secondly, two preparations purified using different methods exhibited 
similar banding pattern, both having the 95-kDa band as a dominant species. Thirdly, 
inclusion or omission of several protease inhibitors did not affect the relative 
quantities of the different size forms (5). A 95-kDa short form of 1A is also present 
in the mouse brain, but is absent in the brain of CACNA1A-knockout mouse, 
signifying that the 95-kDa species and full-length 1A are different products of the 
same gene (6). 
Microsequencing of the 95-kDa species yielded 13 peptide sequences, which are 
all contained in the first half of 1A up to amino acid 829 (5). The authors surmised 
that the actual C-terminal end of this 95-kDa protein is approximately residue 969, 
since the epitope of the antibody that recognized this protein corresponds to residue 
779-969. This would include the region corresponding to CNA1 and CNA3. However, 
among the several size forms of 1A recognized by antibodies against CNA1 and 
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CNA3, the 95-kDa species is not present (8-10). This finding indicates that the 
95-kDa species probably ends before CNA1, which begins at residue 887 in rabbit 
1A (UniProtKB - P27884). Therefore, the 95-kDa species includes about 1/3-1/2 of 
the synprint site in the II-III loop. 
It is tempting to speculate that the 95-kDa two-domain form of 1A is an 
evolutionary throwback due to alternative splicing, resembling the two-domain splice 
variants of 1S, 1C, and the voltage-gated sodium channel SCN8A (180, 182). 
However, among the numerous splice variants of 1A that have been discovered, 
none can account for an isoform as small as 95 kDa (see 1.7.2.5). Another possible 
origin of the 95-kDa form of 1A is post-translational proteolysis. The L-type calcium 
channel 1C subunit was shown to undergo mid-channel proteolysis in the II-III loop 
before the CNA1 sequence (4). The 95-kDa species may be one of the two fragments 
produced by proteolytic cleavage at the equivalent site in 1A. The complementary 
fragment, of 175 kDa in theory, may account for the 160-190-kDa species recognized 
by antibodies against CNA1, CNA3 and the C-terminal region in other studies (see 
1.7.2.1).  
Deglycosylation studies showed that the 95-kDa form of 1A from the rabbit 
brain is glycosylated, presumably at N283 (5). This is the first evidence that a VGCC 
1 subunit is glycosylated. Like most glycoproteins, the 95-kDa form of 1A was 
shown to be expressed on the plasma membrane (6, 152). Co-immunoprecipitation 
analysis showed that the 95-kDa form of 1A associates with the  subunit, and its 
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association with the  subunit depends on a critical amino acid residue, Y392, in the 
alpha-interaction domain (AID) (6). Trafficking of the 95-kDa form to the plasma 
membrane relies on the association with the  subunit (6). The 95-kDa form of 1A 
does not conduct currents, but it can generate a high density of gating currents, upon 
membrane depolarization (152). This indicates that this short form of 1A can 
undergo conformational changes in response to membrane depolarization. Because 
the 95-kDa form of 1A contains at least part of the synprint site, the authors (6) 
surmised that it may be able to interact with the synaptic exocytotic machinery and 
couple depolarization to neurotransmitter release in a Ca2+-independent manner (183, 
184). 
Moreover, the 95-kDa form of 1A has a potent inhibitory effect on the current 
amplitude of full-length 1A, and the inhibitory effect can be abolished by mutating 
Y392 to serine in the 95-kDa form, signifying that the mechanism of inhibition is 
sequestration of free  subunits (6). Inhibition of full-length channel currents by 
truncated 1 subunits is a common phenomenon among cation channels. It has been 
found on L-type (185, 186), N-type (187-190), P/Q-type calcium channels (see 1.7.2.4) 
as well as potassium channel KvLQT1 (191). Note that many of the truncated 1 
subunits studied are not naturally present in normal wild-type animals. The presence 
of the inhibitory 95-kDa 1A fragment in normal brains suggests that this fragment 
may play a critical role in regulating the activity of P/Q-type calcium channels to 
ensure normal development and function of the nervous system. In order to further 
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reveal the functions and importance of the 95-kDa form of 1A, future research 
should focus on how the expression and function of the 95-kDa fragment change in 
response to different physiological conditions. Moreover, it would be interesting to 
find a way to inhibit the expression of the 95-kDa form of 1A in animals and see 
how the phenotype changes. Such studies may shed light on a critical regulatory 
mechanism of the nervous system. 
 
  1.7.2.3 A C-terminal fragment of 1A acting as a transcription factor 
As mentioned in 1.7.2.1, immunoblot analysis of mouse and human brain tissues 
with antibodies against the C-terminal region of 1A detected a 60-85-kDa short form 
of 1A (11, 12), which has also been detected as a 75-kDa species in cell lines 
expressing 1A (7, 11, 12, 177). This short form, (hereafter assigned the molecular 
weight of 75 kDa), of 1A was revealed to be a C-terminal fragment (CTF) of 1A 
produced by an internal ribosome entry site (IRES). It acts as a transcription factor 
with important regulatory functions in normal cells and mediates the 
polyglutamine-induced cellular toxicity in spinocerebellar ataxia type 6 (SCA6). 
The 75-kDa 1A CTF was originally thought to be a product of proteolysis (11, 
12, 177). It can be produced even in HEK 293T cells transfected with only the 
C-terminal tail of 1A (177). Thus it was reasonable to think that there is a proteolytic 
cleavage site in the 1A C-terminal tail. However, the latest studies have shown that 
this is not the case. 
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Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of the 
75-kDa 1A CTF produced in HEK 293 cells expressing human 1A revealed that 
the sequence of the N-terminus of 1A CTF is MIMEYYR (7). The initial methionine 
residue implies that the 1A CTF might be the direct product of a translation event, 
but the most convincing evidence that argues against proteolysis is that stop codons 
inserted upstream of the start site of 1A CTF did not abolish the expression of the 
CTF (7). Nevertheless, the expression of the 1A CTF still relies on part of the 
upstream sequence (7). To test the IRES activity of the upstream sequence, the ~1-kb 
sequence upstream of the start site of 1A CTF in the 1A cDNA was inserted into a 
bicistronic reporter vector between the two cistrons (7). As a result, the expression of 
the second cistron was drastically enhanced, while the mRNA level of neither cistron 
changed (7). In contrast, insertion of the same sequence into a promoterless reporter 
vector does not enhance gene expression (7). These results indicate that the upstream 
sequence does not contain a cryptic promoter, nor does it increase mRNA stability. 
Moreover, real-time PCR showed that the ratio of the expression levels of RNA 
upstream and downstream of the start site of 1A CTF is approximately 1:1 in 
HEK293 and PC-12 cells transfected with human 1A and in human cerebellum. 
These results argue against the presence of a cryptic promoter or alternative splicing 
(7), and offer convincing evidence that the 75-kDa 1A CTF is produced by an IRES.  
Further experiments revealed that the 75-kDa 1A CTF serves as a transcription 
factor (7). This is consistent with previous findings that the CTF is present in the 
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nuclei of mouse cerebellar cells, 1A-transfected HEK 293 cells, and probably human 
cerebellar cells (11). However, there were also contradictory results showing that the 
1A CTF is present in the nuclei in SCA6 cerebellum but not in healthy cerebellum 
(12). The 1A CTF was shown to interact with the DNA sequences and enhance the 
expression of genes such as BTG1, PMCA2, and GRN, all of which are involved in 
neural development and function (7). The 1A CTF was also shown to potentiate 
NGF-mediated neurite outgrowth in PC12 cells and partially rescue the defective 
phenotype of CACNA1A knockout mice (7). 
The 75-kDa 1A CTF not only contributes to normal neural development and 
function, but also is related to the polyglutamine-induced cellular toxicity in 
Spinocerebellar ataxia type 6 (SCA6). SCA6 is an autosomal dominant 
neurodegenerative disease characterized by cerebellar atrophy especially in the 
superior vermis, with more severe loss of Purkinje than granule cells (14). SCA6 is 
caused by an expansion of the trinucleotide CAG repeats in exon 47 of the CACNA1A 
gene, which encodes the polyglutamine (polyQ) tract near the C-terminal end of 1A 
(192). SCA6 alleles usually have 21-30 CAG repeats, as opposed to generally over 40 
in other polyQ diseases, such Huntington’s disease, while normal alleles have about 
13 repeats (192). Although some studies in heterologous expression systems reported 
that expanded polyQ can cause functional alteration of CaV2.1, two studies on 
SCA6-knockin mice found no effect of expanded polyQ on the electrophysiological 
properties of CaV2.1 (14). These findings suggest that the main pathogenic 
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mechanism of SCA6 is not due to alterations of biophysical properties or membrane 
expression of CaV2.1. 
An increasing number of studies suggest that the main pathogenic mechanism of 
SCA6 is due to cellular toxicity of the SCA6 1A CTF. Many studies showed that the 
75-kDa 1A CTF with an expanded polyQ tract is toxic to cultured cells (7, 11, 177, 
193). In addition, transgenic mice expressing SCA6 1A CTF exhibit ataxia and 
cerebellar atrophy resembling the symptoms of SCA6 in humans (7). The mechanisms 
of the cellular toxicity have been intensively studied by not yet fully understood. Two 
independent studies have shown that overexpressing the polyQ tract lacking flanking 
sequences does not cause toxicity, while overexpressing a longer fragment including 
more of the flanking regions can cause significant toxicity to cultured HEK 293T, 
HEK 293, and mouse cerebellar granule cells, regardless of the length of polyQ (4 to 
33 glutamine residues) (11, 177). These results indicate that the protein context of the 
polyQ tract contributes to the pathogenic mechanism of SCA6. One of the two 
above-mentioned studies showed that expanded polyQ tract does not add to the 
toxicity of the 1A CTF, but can make the CTF more resistant to proteolysis (177). In 
contrast, the other study showed that 1A CTF with expanded polyQ is more toxic 
than those with shorter lengths of polyQ, and showed no difference in the stabilities of 
the 1A CTFs (11). A possible reason for this discrepancy is that auxiliary subunits 
were coexpressed in the second study but not in the first one. Nevertheless, these 
results revealed that both the expanded polyQ and the flanking regions are 
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indispensable to the toxicity of SCA6 1A CTF. 
It has also been shown that expanded polyQ increases nuclear localization of the 
1A CTF in both SCA6 human cerebella and in transfected PC12 cells (12), 
indicating that nuclear localization may be important for the toxicity of SCA6 1A 
CTF. Protein sequence analysis revealed four putative nuclear localization signals 
(NLSs) upstream of the polyQ tract, and confocal imaging showed that three of them 
were shown to be critical for the nuclear localization of 1A CTF (11). Triple 
mutation of the three NLSs significantly decreased the toxicity of the 1A CTF with 
expanded polyQ. An additional artificial nuclear export signal (NEL) decreased the 
toxicity even more (11), indicating that the toxicity depends on nuclear localization of 
the CTF. However, nuclear localization is not the only reason flanking sequences are 
indispensible to the toxicity, since a polyQ tract without flanking regions also exhibits 
strong nuclear localization, but is not toxic to HEK 293 or mouse granule cells (11). 
Another possible contributing factor in the toxicity of the SCA6 1A CTF may 
be its low solubility. In SCA6 human cerebella, more cytoplasmic 1A CTFs are 
insoluble compared with normal human cerebella, but extracerebellar tissues did not 
show this difference (12). Immunocytochemistry revealed that CTFs with expanded 
polyQ form visible aggregates in the cytoplasm and nuclei of transfected PC12 cells 
(12). Similar aggregates were also observed in the cell bodies and dendrites of SCA6 
cerebellar Purkinje cells but not in normal brain tissues or extracerebellar tissue of 
SCA6 brains (12). These results suggest that SCA6 pathogenesis may be partially due 
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to the aggregate formation, which may cause cellular toxicity by sequestration of 
essential proteins. It has been shown that the whole CTF is less soluble than a more 
truncated protein with almost only the polyQ tract (177). This indicates that the low 
solubility of SCA6 1A CTF and the aggregation formation probably rely on both the 
expand polyQ tract and the flanking regions. This offers another explanation why the 
flanking regions are important for the toxicity of SCA6 1A CTF. 
The expanded polyQ in SCA6 has also been shown to cause disruption of normal 
1A CTF function. Normal 1A CTF serves as a transcription factor to enhance the 
expression of a group of genes, which are part of a Purkinje cell-specific 
developmental program (7). It has been shown that the expanded polyQ tract 
abolishes the normal function of the 75-kDa 1A CTF in regulating the expression of 
these genes and potentiating neurite growth (7). The pathogenic mechanism of SCA6 
is at least partially due to the loss of normal 1A CTF function. On the other hand, a 
gain of function may also contribute to this pathogenic mechanism. As mentioned 
above, nuclear localization of the 1A CTF is increased by the expanded polyQ (12), 
whose toxicity is in turn dependent on the nuclear localization of the CTF (11). These 
results imply a possibility that the SCA6 1A CTF may function as an aberrant 
transcription factor and cause cellular toxicity through activation of aberrant gene 
expression. Moreover, coimmunoprecipitation and pull-down analyses showed that 
1A C-termini can interact directly with myosin IIB in rat cerebellum and COS-7 
cells, and expanded polyQ can increase this interaction (193). The study also showed 
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that the expanded polyQ increases the expression of a CD4-linked 1A CTF on the 
plasma membrane. Additionally, this effect of the expanded polyQ can be reversed by 
a myosin II inhibitor (193). These results suggest that the enhanced interaction with 
myosin IIB and increase in surface expression may contribute to SCA6 pathogenesis. 
Alternatively, the pathogenesis may be caused by myosin sequestration by mutant 
1A subunits or 1A CTFs. However, the effects of expanded polyQ on the surface 
expression of 1A CTF and on the interaction with myosin II were only studied in 
COS-7 cells, and the 1A CTF used in this study not only lacks most of the region 
upstream of the polyQ tract but also is tagged with CD4 and GFP (193). However, 
further investigation is needed to determine if similar effects also happen in vivo. 
In summary, SCA6 has complex pathogenic mechanisms. The 1A CTF with 
expanded polyQ causes cellular toxicity, which relies on both the expanded polyQ and 
the flanking regions. The flanking regions contribute to the cellular toxicity by 
offering nuclear localization signals (NLSs) and by decreasing the solubility of the 
1A CTF to facilitate the formation of aggregates, which may sequestrate essential 
proteins and thus cause cell death. The expanded polyQ increases nuclear localization 
and is also necessary for the formation of aggregates. Expanded polyQ also abolishes 
the normal function of the 1A CTF as a transcription factor, and subsequently 
disrupts the normal development and function of cerebellar cells. The SCA6 1A CTF 
may also cause cellular toxicity through gain of function, e.g., aberrant gene 
activation or increased binding to regulatory proteins. More studies are necessary to 
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further understand the function of the 1A CTF and the pathogenesis of SCA6. 
 
  1.7.2.4 1A truncations causing episodic ataxia type 2 
Mutations in CACNA1A cause several autosomal dominant neurological 
disorders, including familial hemiplegic migraine type 1 (FHM1), spinocerebellar 
ataxia type 6 (SCA6) and episodic ataxia type 2 (EA2) (14). While FHM1 and SCA6 
reported so far are caused by missense mutations and expansion of the trinucleotide 
CAG repeats, respectively (14), EA2 can be caused by a variety of mutations 
including missense, nonsense, deletion, and insertion mutations (15). Most EA2 
mutations reported so far result in premature stop codons leading to the truncation of 
1A, which may arise through nonsense mutations, frameshift caused by deletion or 
insertion mutations, and aberrant splicing (15). A number of studies have investigated 
the properties of some of the EA2 truncation mutants and engineered truncation 
mutants (Figure 2). The results of these studies are summarized in Table 1. 
As shown in Table 1, the truncation mutants whose currents were measured all 
exhibited smaller currents than full-length CaV2.1 or no currents at all. Even the 
removal of a segment as small as the C-terminal tail can abolish the 
current-conducting function of the channel, as in R1824X. Most of the investigated 
truncation mutants also showed less surface expression than full-length 1A. 
Strikingly, ten of the twelve truncation mutants were shown to have a dominant 
negative effect of suppressing full-length CaV2.1 currents. Given the essential role of 
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the P/Q-type calcium channel in synaptic transmission in the central and peripheral 
nervous systems (1, 17), the dominant negative effect might be a major pathogenic 



















Figure 2. Membrane topology of 1A, showing positions of truncation mutations, including 
EA2 and non-EA2 mutations that have been studied, as well as unstudied EA2 mutations 
that resemble other mutations that have been studied. (a*) V327 aberrant splicing (194). (b**) 
330X (195). (c**) 384X (195). (d**) 402X (195). (e*) F624fs (196, 197). (f**) 612X (195). (g) 
Q681fs (196, 198, 199). (h*) S943fs (196, 200). (i*) E1004fs (196). (j**) P1219X (rabbit) (6, 
152). (k*) D1268fs (196, 201). (l**) P1217fs (rat) (188-190). (m) R1281X (178, 196, 199, 
202-205). (n) Y1446X (195, 196, 198). (o) R1549X (196, 199, 202, 203, 206). (p*) Q1564X 
(207). (q) R1669X (199, 203). (r) R1824X (196, 208, 209). Unstudied EA2 mutations are 

























Table 1. Properties of EA2 truncation mutants and engineered truncation mutants 
 
Mutation Conducting currents Less surface expression 
than full-length 1A 
Reducing full-length 
CaV2.1 current 
Altering full-length CaV2.1 activation 











A330X1,8 No (195)  No (195) No5 (195)     
Q384X1,8 No (195)  No (195) Slightly5 (195) No (195)  No (195)  
V402X1,8 No (195)  Yes (195) No5 (195) No (195)  Yes (195)  
K612X1,8 No (195)  Yes (195) Slightly5 (195) No (195)    
Q681fs  Yes (199) Yes (199)  No (199) Yes (199)   
P1219X1,6 No (152) No (6) Yes (6)    Yes (6)  
P1217fs1,7   Yes (188, 190)      
R1281X Yes2 (202); No (203, 
204) 
Yes (199) Yes (178, 199, 203); 
No3 (204) 
No (203) Yes (178); No (199) Yes (178, 199) No (178) Yes (178) 
Y1446X No (195)  Yes (195) Slightly5 (195) No (195)    
R1549X Yes2 (202); No (203) Yes (199) Yes (203) No (203)  Yes (199)   
R1669X No (203) Yes (199) Yes (203) No (203)  Yes (199)   
R1824X No (209)  Yes (209); No3 (208) No (209)     
 
 
1: Not an EA2 mutation. 2: The currents are much smaller than those conducted by full-length 
CaV2.1. 3: The short isoform of human 1A (AF004883) was used. 4: Voltage dependence and 
kinetics of activation and steady-state inactivation. 5: Lacking data for voltage dependence of 
steady-state inactivation. 6: Construct was made from rabbit X57477. The equivalent mutation in 
human AF004883 would be R1213X. 7: Rat 1A. The equivalent mutation in human AF004883 
would be P1269fs. 8: Constructs were made from rabbit X57476. Note: Residue numbers are from 
AF004884 unless otherwise indicated. 
 
Interestingly, one of the truncation mutants, 330X, which resembles an EA2 
truncation mutant caused by aberrant splicing (V327 aberrant splicing) (194), did not 
show a dominant negative effect, nor does it conduct currents. V327 aberrant splicing 
is the shortest EA2 truncation mutant reported so far. However, the loss of function of 
this mutant cannot explain why this mutant causes an autosomal dominant disorder, 
since heterozygous CACNA1A-knockout mice showed no apparent abnormality (210), 
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arguing against haploinsufficiency as the pathogenic mechanism. The V327 aberrant 
splicing mutant may cause EA2 by competing with wild-type channels for the limited 
number of presynaptic slots for P/Q-type channels (211). Alternatively, it may alter 
the voltage dependence of inactivation of full-length CaV2.1, change the way 
full-length CaV2.1 is regulated by signaling molecules, or associate with and alter the 
function of other essential proteins in the cell. 
Contradictory results were obtained as to whether the EA2 truncation mutant 
R1281X alters full-length CaV2.1 currents (Table 1). The discrepancy is probably 
partially due to the different isoforms of CaV2.1 used in the experiments. One of the 
studies used the short splice isoform of 1A (GenBank accession number AF004883), 
which lacks the last 244 amino acid residues encoded by exon 47, and revealed no 
dominant negative effect of R1281X (204). Another study used the long splice 
isoform (GenBank accession number AF004884) which included the residues encoded 
by exon 47, revealing a significant dominant negative effect of R1281X (203). 
Comparison of the long and short isoforms in parallel showed that R1281X has a 
much stronger dominant negative effect on the long isoform of 1A than on the short 
one (203). Interestingly, one group found that another EA2 truncation mutant, 
R1824X, also displayed potent dominant negative effect in one study, which involved 
the long isoform of 1A (209), but not in another study, which used the short isoform 
(208). These results suggest that the endmost segment of the C-terminal tail contains 
regulatory elements that enhance the suppressive effect of truncated 1A on the 
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full-length channel. However, the isoform difference is not the only reason for the 
contradictory results on the dominant negative effect of EA2 truncation mutants. 
While the dominant negative effect of R1281X on the short isoform of 1A could not 
be detected in Xenopus oocytes (204), another study that used HEK 293 cell as the 
expression system detected the dominant negative effect (178). It has been shown that 
R1281X, as a misfolded protein, binds to full-length 1A and induces its degradation, 
through a mechanism involving the endoplasmic reticulum (ER) retention machinery 
and the proteasome (178). It has been reported that Xenopus oocytes have a weak ER 
retention machinery for mammalian proteins (212), which may be another 
contributing factor to the lack of dominant negative effect of R1281X on the short 
isoform of 1A in oocytes. 
While contradictory results have been reported as to whether EA2 truncation 
mutants decrease the protein level of full-length 1A, all the investigated truncation 
mutants were shown to decrease surface expression of the full-length channel (Table 
1). The decrease in surface expression may be one of the main reasons for the 
decrease in full-length channel currents caused by the truncation mutants. However, it 
cannot be excluded that the some truncation mutants may also suppress full-length 
CaV2.1 currents by altering the single-channel properties of full-length CaV2.1. 
The molecular mechanisms for the suppressive effect of EA2 truncation mutants 
on full-length CaV2.1 have been intensively studied and are still not fully understood. 
It has been shown that only those 1A truncation mutants that include the 
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-interaction domain (AID) suppress full-length CaV2.1 currents (195) (Table 1), 
signifying that the mechanism of the suppressive effect may involve the  subunit. 
Coimmunoprecipitation analysis confirmed that 402X, a truncation mutant with AID, 
associates with the  subunit, while 384X, which does not have the AID, does not 
associate with  (195). Another 1A truncation mutant P1219X, which resembles the 
EA2 truncation mutants S943fs (200) and E1004fs (196), was also shown by 
coimmunoprecipitation to associate with the  subunit (6). Moreover, a single 
mutation (Y392S) in the AID of P1219X not only disrupted its interaction with , but 
also abolished its suppressive effect on the currents of full-length CaV2.1 (6). These 
results indicate that the dominant negative effects of some EA2 truncation mutants, 
including S943fs and E1004fs, may be partially due to competition with the 
full-length 1A for the  subunits. 
Some other EA2 truncation mutants, however, may exert their dominant negative 
effects through -independent mechanisms. When expressed in Xenopus oocytes, the 
EA2 truncation mutant R1281X displays a dominant negative effect, which cannot be 
reversed when the amount of cRNA coding for  and 2 subunits was increased 
(203). Coimmunoprecipitation analysis revealed that R1281X does not associate with 
 subunits (178). Instead, it associates with full-length 1A and disables the binding 
of  subunits to full-length 1A (178). Moreover, it has been shown that R1281X, like 
a lot of misfolded proteins, is retained in the ER and degraded by the proteasome 
(178), through a mechanism called endoplasmic reticulum-associated degradation 
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(ERAD) (94). Additionally, by interacting with full-length 1A, R1281X also 
promotes the ER retention and premature proteasomal degradation of the full-length 
1A, exhibiting a “destructive interaction mechanism” (DIM) (178). As expected for 
a mechanism involving ER retention, the dominant negative effects of R1281X and 
some other EA2 mutants show dependence on the experiment system and temperature. 
R1281X displayed a potent dominant negative effect on the short isoform of 1A 
(AF004883) in HEK 293 cells (178), but not in Xenopus oocytes (204), in which the 
ER retention machinery is weak (212). Moreover, the dominant negative effects of 
EA2 mutants Q681fs, R1281X ,and E1761K (a missense mutation) in HEK 293T 
cells all can be abolished by a lower culture temperature (199), which have been 
shown to overcome ER retention of misfolded proteins (212, 213). Therefore, the 
“destructive interaction mechanism” (DIM) may play an important role in the 
pathogenesis of R1281X and many other EA2 truncation mutants.  
Truncated CaV2 and CaV3 often suppress full-length CaV2 and CaV3, respectively 
(187-189). CaV2.2-Dom I-II, a truncated 1B containing the segment from the 
N-terminus up until the end of the II-III loop, displayed a dominant negative effect 
(187). CaV2.2-Dom I-II does not conduct currents, but suppresses the protein 
expression, surface expression, and currents of full-length CaV2.2, while not changing 
the I-V parameters, steady-state inactivation parameters and single-channel properties 
of full-length CaV2.2 (187). CaV2.2-Dom I, containing the segment from the 
N-terminus up until the end of the I-II loop, also showed a similar suppressive effect 
73 
 
on the expression and currents of full-length CaV2.2 (187). Similar truncated forms of 
CaV3.1 and Cav3.2 1subunits suppress the currents of full-length CaV3.1 and Cav3.2, 
respectively (188). Interestingly, there is marked cross-suppression between different 
types of channels within the CaV2 family (188). For example, CaV2.1-P1217fs, a 
truncated 1A resembling the EA2 truncation mutant D1268fs (201), suppresses not 
only currents of full-length CaV2.1, but also currents of full-length CaV2.2. In addition, 
CaV2.2-Dom I-II can also suppress currents of full-length CaV2.1 (188). However, 
there is no cross-suppression between CaV2 and CaV3 channels (188). These results 
indicate that these truncated CaV2.1 and CaV2.2 channels probably share the same 
mechanism for their dominant negative effects. 
CaV2.2-Dom I-II displays a suppressive effect on full-length CaV2.2 currents 
with or without  and 2 subunits, and transfection of a higher amount of cDNA of 
the  subunit does not reduce the dominant negative effect of CaV2.2-Dom I-II (187). 
Moreover, the 1B I-II loop itself, which was shown to interact with the  subunit by 
yeast two-hybrid analysis, does not suppress full-length CaV2.2 currents (187). These 
results suggest that the dominant negative effect of CaV2.2-Dom I-II is not due to 
sequestration of  subunits. 
Coimmunoprecipitation analysis showed that CaV2.2-Dom I-II associates with 
full-length 1B (190). Could CaV2.2-Dom I-II exert its dominant negative through a 
destructive interaction mechanism (DIM), as previously discovered on the EA2 
truncation mutant 1A R1281X (178)? In contrast to DIM, which involves the 
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proteasome, the dominant negative effect of truncated 1B does not seem to rely on 
the proteasome, since the proteasome inhibitor lactacystin has no effect on CaV2.2 
protein level in the presence of CaV2.2-Dom I (188). 
CaV2.2-Dom I not only reduces the protein expression and current amplitude of 
full-length CaV2.2 (187), but also reduces the mRNA level of full-length CaV2.2 and 
the protein level of coexpressed 2 (189). Surprisingly, CaV2.2-Dom I also reduces 
the mRNA level of a mutant inward-rectifier potassium ion channel Kir2.1-AAA in 
the presence of, but not in the absence of, full-length CaV2.2 (189). These results are 
consistent with the unfolded protein response (UPR), which is initiated when the ER 
is unable to deal with the load of newly synthesized proteins requiring folding (214). 
In the UPR, the endoplasmic reticulum resident RNA-dependent protein kinase 
(PERK) is activated and subsequently phosphorylates the ribosomal translation 
initiation factor eIF2 (214). Phosphorylation of eIF2 causes dissociation of 
ribosomes from the mRNA, leading to translation arrest (214) and mRNA 
destabilization (215). It has been shown that dominant negative PERK markedly 
reduced the suppressive effect of CaV2.2-Dom I on full-length CaV2.2 currents, while 
having no effect on full-length CaV2.2 currents in the absence of CaV2.2-Dom I (188). 
On the other hand, overexpression of wild-type PERK or treatment with the PERK 
activator thapsigargin reduces full-length CaV2.2 currents in the absence of truncated 
CaV2.2 (188). Moreover, dominant negative PERK also markedly reduced the 
suppressive effect of CaV2.1-P1217fs on full-length CaV2.1 currents, while having no 
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effect on full-length CaV2.1 currents in the absence of CaV2.1-P1217fs (188). These 
findings suggest that the UPR is also involved in the dominant negative effects of this 
truncated 1A and presumably some EA2 truncation mutants including D1268fs, 
which resembles CaV2.1-P1217fs. 
The N-terminal tails of CaV2.1 and CaV2.2 contain elements critical for the 
dominant negative effects of truncated CaV2 1 subunits. Two arginine residues in a 
RAR motif in the N-terminal tail of CaV2 1 subunits was previously shown to be 
essential for G protein-mediated inhibition of CaV2 channels (216, 217). Recently, 
they were also shown to be critical for the dominant negative effect of truncated 1A 
and 1B (189, 190). Mutation of the two arginine residues in CaV2.1-P1217fs (R57 
and R59) and CaV2.2-Dom I-II (R52 and R54) to alanine reverses their suppressive 
effects on the currents of full-length CaV2.1 and surface expression of CaV2.2, 
respectively (190). Mutating the two critical arginine residues in the full-length 
channels, however, does not weaken the suppressive effects (190).  
Surprisingly, the dominant negative effects of truncated CaV2 channels can be 
alleviated by partial N-terminal tails of the cognate 1 subunits. In one study, a partial 
CaV2.1 N-terminal tail containing residues 46-100, and a partial CaV2.2 N-terminal 
tail containing residues 43-95, were engineered to have a CAAX motif attached to 
their C-terminus, in order to promote their association with intracellular lipid bilayers 
(190). These partial N-terminal constructs, CaV2.1-(46-100)-CAAX and 
CaV2.2-(43-95)-CAAX, do not influence the currents or surface expression of 
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full-length CaV2 (190). However, CaV2.2-(43-95)-CAAX almost completely reverses 
the suppressive effect of CaV2.2-Dom I-II on CaV2.2 surface expression, and 
CaV2.1-(46-100)-CAAX partially reverses the suppressive effect CaV2.1-P1217fs on 
full-length CaV2.1 currents (190). Coimmunoprecipitation analysis showed that 
CaV2.2-(43-95)-CAAX disrupts the association between CaV2.2-Dom I-II and 
full-length CaV2.2 (190). This is most likely the main mechanism by which the partial 
N-terminal tails alleviates the suppressive effects of truncated channels. Interestingly, 
these partial N-terminal tails cannot reverse the suppressive effects of the truncated 
channels when the two critical arginine residues are mutated in the full-length channel 
CaV2.1. One reason for this observation is that these mutations cause a more robust 
interaction between the full-length channel and the truncated channel (190). A model 
has been proposed to explain the dominant negative effects of truncated CaV2 1 
subunits and how the partial N-terminal tails alleviates the dominant negative effects 
(190) (Figure 3). 
In summary, most EA2 truncation mutants of 1A display dominant negative 
effects of suppressing the surface expression and currents of full-length CaV2.1, which 
may be the main pathogenic mechanism of EA2. Different EA2 truncation mutants 
may exert their dominant negative effects through different molecular mechanisms. 
Three molecular mechanisms have been proposed. Firstly, some EA2 truncation 
mutants may suppress the expression and currents of full-length CaV2.1 by competing 
with full-length 1A for  subunits. Secondly, some EA2 truncation mutants may 
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promote the degradation of full-length 1A though a “destructive interaction 
mechanism” (DIM) involving ER-associated degradation (ERAD). By interacting 
with full-length 1A, these EA2 truncation mutants induce ER retention and 
premature proteasomal degradation of the full-length 1A. Thirdly, some EA2 
mutations may suppress the synthesis of full-length 1A by associating with the 
full-length 1A and initiating the unfolded protein response (UPR). During the UPR, 
the ER resident RNA-dependent protein kinase (PERK) is activated and subsequently 
leads to translation arrest and mRNA destabilization of full-length 1A and other 
proteins. 
As mentioned in 1.7.2.1, many 1A subunits are present in short forms in the 
brain tissues of wild-type animals and healthy human beings. One of these short forms 
of 1A, the 95-kDa two-domain form of 1A mentioned in 1.7.2.2, is one of the 
major forms of 1A in rabbit and mouse brains. It is presumably a truncated 1A 
whose peptide chain ends in the II-III loop (5, 6), resembling EA2 truncation 
mutations such as 943fs (200) and 1004fs (196). Other short forms of 1A may also 
resemble EA2 truncation mutants. Why do these short forms of 1A not cause any 
disorder like the EA2 truncation mutations do? Firstly, the short forms and full-length 
forms of 1A may belong to different isoforms of 1A, which serves different 
functions and do not interfere with each other. Secondly, the slightly different 
truncation positions may lead to substantial difference between “normal” truncated 
forms of 1A and the EA2 truncation mutants. Note that in the studies of the 
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properties of the 95-kDa two-domain form of 1A, the truncated construct P1219X 
was used (6, 152). The endogenous 95-kDa fragment, however, is presumably much 
shorter (see 1.7.2.2). Therefore, it is possible that the endogenous 95-kDa fragment 
does not have the dominant negative effect that P1219X has (6, 152). Additionally, the 
EA2 truncations in the II-III loop reported so far are all due to frameshifts, which adds 
an extra peptide sequence to the truncated 1A. It is possible that the extra peptide 
sequences contribute to the pathogenic effects of these EA2 truncations. Alternatively, 
normal and EA2 truncated forms of 1A may be regulated by signaling molecules in 
different ways, and subsequently cause different effects on the cells. Thirdly, some 
short forms of 1A may be produced by proteolysis, which produces two 
complementary fragments of 1A. While each single fragment may have a dominant 
negative effect, two complementary fragments together may abolish the dominant 
negative effects and even form a functional channel. It has been shown that two 
complementary 1B fragments, CaV2.2-Dom I-II and CaV2.2-Dom III-IV, both 
display a dominant negative effect when expressed individually(187). When 
coexpressed, however, they can form a functional channel (187). Future work on both 
non-disease and EA2 forms of truncated 1A may reveal more details of the 































Figure 3. Possible mechanisms for the dominant negative effect of truncated CaV2 1 
subunits and the rescuing effect of the partial N-terminal tails. (A) Left, cartoon of the 
full-length CaV2 1, showing the four repeats, N-terminal tail (blue line), and the two critical 
arginine residues (black dots). The N-terminal tail interacts with an intramolecular docking site 
through the two critical arginine residues. Right, full-length CaV2 1 with the two critical arginine 
residues mutated (asterisks). The intramolecular docking is reduced by the mutations. (B) 
Two-domain truncated CaV2 1. No intramolecular docking site is available. (C) The N-terminal 
tail of the truncated 1 binds to the docking site on the full-length 1 subunit, initiating the 
unfolded protein response (UPR). The binding is reduced by mutations of the two critical arginine 
residues in the truncated 1. On the other hand, when the two critical arginine residues in the 
full-length 1 are mutated, the binding is stronger because there is no competition between the 
N-terminal tails of the full-length and truncated 1 subunits. As a result, the dominant negative 
effect becomes stronger. (D) The partial N-terminal tail. (E) The partial N-terminal tail binds to 
the docking site in the full-length 1, thereby weakening the binding of the truncated 1 (left). 
When the two critical arginine residues in the full-length 1 are mutated, binding of the truncated 
1 is stronger, and makes it more difficult for the binding to be disrupted by the partial N-terminal 












  1.7.2.5 Splice variants of 1A 
Soong et al. systematically scanned the whole cDNA of human 1A using PCR 
primers (each pair spanning 1-4 exons), and discovered seven loci of alternative 
splicing (218) (Figure 4). At locus 1, inclusion of V slows inactivation, and also alters 
G-protein and PKC regulation (23). At locus 4, insertion of NP slows activation and 
inactivation, and decreases the affinity of the channel to -agatoxin IVA (45). It is 
hypothesized that the Q-type channel (low -agatoxin IVA affinity) lacks V at locus 1 
and contains NP at locus 4, while the P-type channel (high -agatoxin IVA affinity) 
contains V at locus 1 and lack NP at locus 4. However, secondary modifications and 
accessory subunits may also contribute to the functional properties of the P-type and 
Q-type channels (23, 45). At locus 5, the mutually exclusive exons e37a and e37b are 
also present in 1B and 1E (219). In the case of 1B, the two exons are associated 
with different ubiquitination levels and different sensitivities to proteasomal 
degradation (see 1.5.2.3). At locus 6, one or both of exons 43 and 44 can be deleted 
(218). The more exons are deleted at this locus, the greater the current amplitude is 
and the stronger the calcium dependence of inactivation is (218). At locus 7, exon 47 
can be included or excluded because of a frameshift (218). Additionally, there is an 
isoform with a shorter exon 47 due to a frameshift (220). Functionally, these three 
isoforms do not differ significantly when coexpressed with any of the four different 





















Figure 4. Seven loci of human 1A alternative splicing identified by transcript scanning. CI, 
Ca2+ inactivation region, containing the EF-hand and IQ domain, which is likely important for 
Ca2+ -dependent inactivation (CDI). At locus 2, deletion of exons 16 and 17 would cause a 
molecular weight loss of 7 kDa and would delete half the “P-loop” and the entire S6 of repeat II, 
probably producing a nonfunctional channel. At locus 6, deletion of exons 43 and 44 would cause 
a molecular weight loss of 6 kDa. At locus 7, deletion of exon 47 would cause a molecular weight 
loss of 16 kDa. (Adapted from Soong 2002 (218)). 
 
Rabbit and rat share two distinct isoforms of 1A that differ in the region 
encoded by exon 19: a short form termed rbA and a long form term BI (221). These 
two isoforms differ in their sub-cellular distributions and interactions with SNARE 
proteins. In cerebellar Purkinje cells, the BI isoform is preferentially localized along 
the length of dendrites, whereas the rbA isoform is preferentially localized in the soma 
(221). Presynaptic membrane proteins syntaxin and SNAP-25 both interact with the 
BI isoform of 1A, while only SNAP-25 has been found to interact with the rbA 
isoform (222). It is surmised that both BI and rbA isoforms of 1A are also present in 
humans (222), although only the BI isoform has been found in humans (223). 
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Exon 19 of 1A is also subject to another type of alternative splicing, which 
gives rise to two splice variants that lack most of the synprint site (224). mRNAs 
coding for these splice variants can be detected in most brain areas and are also found 
in two types of neuroendocrine cells: PC12 cells (a rat pheochromocytoma cell line) 
and the magnocellular neurosecretory cells (MNCs) of the hypothalamus (224). Both 
splice variants are functional, but the variant with a larger deletion in the synprint site 
displays lower current density and a marked shift in the voltage dependence of 
inactivation to the depolarizing direction (224).  
Alternative splicing loci 1 and 4 (Figure 4) have been found in both rat (23) and 
human (218). The BI and rbA isoforms are shared by rabbit, rat (221), and most likely 
in humans (222). Additionally, the mutually exclusive e37a and e37b are present in 
1A, 1B, and 1E (219). These findings suggest that most, if not all, types of 
alternative splicing of 1A is conserved across species. 
 
1.8 Thesis introduction 
The P/Q-type calcium channel plays crucial physiological roles (1, 13). 
Mutations in the pore-forming 1A subunit of the P/Q-type channel cause severe 
neurological disorders, including EA2, which can be caused by a variety of truncation 
mutations (15). Many of the EA2 truncation mutants and lots of non-disease-related 
truncated versions of 1A have been found to have dominant negative effects (see 
1.7.2.4). Interestingly, many short forms of 1A are also present in healthy brains (5, 
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8-12). These findings raised several questions about the short forms of 1A in healthy 
brains. Are they products of protein degradation or are they of physiological 
importance? What parts of the 1A protein are they? How are they produced? What 
are their functions? Why do they not cause any problems like the EA2 truncation 
mutants do? Are they related to the pathogenesis of EA2? This thesis will attempt to 
address these questions in the following chapters. 
Chapter 3 identifies a 190-kDa truncated form of 1A and investigates the origin 
of this truncated channel. In this chapter, I also explore the functional importance of 
the 190-kDa truncated channel from a biochemical perspective. Chapter 4 describes 
the attempt to visualize 1A on the plasma membrane. Chapter 5 examines the 
functions of truncated P/Q-type channels and their effects on the full-length P/Q-type 
channel. In this chapter, I also raise concern about the investigation of the dominant 
negative effects of truncated P/Q-type channels, including EA2 mutants. Chapter 6 


































2.1 Molecular biology 
The mouse 1A construct for transfection in HEK 293T cells was obtained from 
Addgene (Catalog #26573). The rat 3 (NCBI accession number NM_012828.2) 
construct used for transfection of HEK 293T and neurons is cloned in a pcDNA3.1(+) 
vector, and the one used for RNA synthesis is cloned in a pGEMHE vector. The rabbit 
2- (NCBI accession number NM_001082276.1, D87 mutated to H, S620 deleted) 
construct used for transfection of HEK 293T and neurons is in a modified pEGFP-C1 
vector without the EGFP gene, and the same 2-1 gene in pGEMHE vector was used 
for RNA synthesis. Human 1A (GenBank accession number U79666.1, Q2314 
insertion) was used for RNA synthesis and for making all the engineered 1A 
constructs. In all the tagged human 1A constructs, an 8-amino acid linker 
(GDPFALCR) was inserted between EGFP (as in pEGFP-C1) and human 1A. HA 
tags were inserted using splice-by-overlap PCR. In hPQGH1, hPQGH2, hPQGH3 and 
hPQGH4, the HA tag was inserted between residues C272-G273, G645-P647, 
G1478-P1479, and G1718-I1719, respectively. Note that in hPQGH2, T646 was 
deleted and the sequence ARHYPYDVPDYAVTFDEGTA was inserted, as previously 
reported (225). To make hPQGH4x2, one more HA tag was inserted between 
P1770-C1771 in hPQGH4. LGH3 (4) and L-SEP2-HA6 were both based on rat brain 
1C (GenBank accession number M67515.1). In L-SEP2-HA6, a super-ecliptic 
pHluorin (SEP) (GenBank accession number AAS66682.1), with an N-terminal linker 
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TRLVPRGSGG and C-terminal linker GGLVPRGSFDEMQ, was inserted between 
Q683-T684, and two HA tags were inserted between S992-A993 and G1136-P1137. 
Human 1A was truncated using PCR to make the fragment channels, A1 (M1-A444), 
A2 (D445-C2506 with M on the N-terminus), B1 (M1-N719), B2 (A720- C2506 with 
M on the N-terminus), C1 (M1-M1521), and C2 (M1522- C2506). To make the 
FLAG-tagged fragment channels, MDYKDDDDK was added to the N-terminus of A1, 
B1, and C1 by PCR. To make the HA-tagged fragment channels, MAYPYDVPDYA 
was added to the N-terminus of A2, B2, and C2 by PCR, with a 2-amino acid linker 
(ST). All the above residue numbers refer to the amino acid residues in the 
unmodified human 1A.  
 
2.2 Cell culture 
All cell cultures were kept 37°C in a humid atmosphere with 5% CO2 unless 
otherwise indicated. 
 
2.2.1 Mouse cortical neuron culture 
On postnatal day 0 (P0), C57BL/6 mouse pups were euthanized using a carbon 
dioxide chamber and then decapitated. Cerebral cortices were isolated in ice-cold 
Hanks' Balanced Salt Solution (HBSS, Life Technologies 14185052, 1X, pH 7.4) 
supplemented with 1:200 penicillin and streptomycin (Sigma-Aldrich P0781), in a 
laminar flow hood. The isolated cortices were minced and digested at 37°C for 15 min 
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in 0.25% Trypsin and 47500 U/mL of DNase I (EMD Millipore 260913) in HBSS 
supplemented with 10 mM of MgCl2 and 1 mM of CaCl2. The solution of enzymes 
were then removed and the digested cortices were triturated with a serological pipette 
in “final DMEM”, DMEM (Life Technologies 11965092) supplemented with 10% 
fetal bovine serum (Fisher Scientific SH3007002) and 10% F-12 (Life Technologies 
21700-075). The suspension with triturated cortices was centrifuged at 200 g for 30 s. 
The supernatant was collected and centrifuged at 1500 g for 3 min. The supernatant 
was aspirated and the precipitated cells were resuspended in final DMEM. 2-3×106 
cells were plated in each poly-D-lysine-coated 60-mm dish. 4-6 h after plating, cells 
were washed gently with DMEM (without supplements), and Neurobasal medium 
(Life Technologies 21103-049) supplemented with B-27 (1/50, Life Technologies 
17504-044), GlutaMAX (1/100, Life Technologies 35050-061) and 20 g/mL of 
gentamicin. Every 3-4 days, half of the culture medium was replaced with the same 
volume of Neurobasal medium supplemented with B-27, GlutaMAX, and gentamicin.  
 
2.2.2 Rat hippocampal neuron culture 
Pregnant Sprague-Dawley rats were euthanized using a carbon dioxide chamber 
and decapitated. Embryos at age E18-19 were quickly moved to ice-cold Hanks' 
Balanced Salt Solution, where the hippocampi were isolated. The hippocampi were 
digested at 37°C for 15 min in 0.125% Trypsin. The trypsin solution was then 
removed and the digested hippocampi were triturated using a syringe with a 20G 
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needle in final DMEM (see 2.2.1). 3.33×104 cells were plated on each 
poly-D-lysine-coated 12-mm glass coverslips. 16 h later and then every 3-4 days, half 
of the culture medium was replaced with the same volume of Neurobasal medium 
supplemented with B-27 and GlutaMAX.  
 
2.2.3 HEK 293T cell culture 
HEK 293T cells were maintained in DMEM supplemented with 10% fetal 
bovine serum (VWR 45001-108) and 1% penicillin and streptomycin (Sigma). When 
cells reached 85-90% confluency, they were rinsed with PBS (Life Technologies 
10010-049), dissociated using 0.05% trypsin-EDTA solution (Life Technologies 
25300-054), resuspended in DMEM supplemented with 10% fetal bovine serum and 1% 
penicillin and streptomycin, and seeded in new dishes at an appropriate density. 
 
2.3 SDS-PAGE sample preparation 
2.3.1 Preparation of tissue/cell lysate using Pierce IP Lysis Buffer 
For brain tissue lysate, a C57BL/6 mouse was euthanized using a carbon dioxide 
chamber and decapitated. The desired brain region was quickly isolated in ice-cold 
PBS (Life Technologies) containing 1/1000-1/500 Halt Protease Inhibitor Cocktail 
(Life Technologies 78430). The isolated brain tissue was homogenized using a syringe 
with a 22G needle in Pierce IP Lysis Buffer with 1/50 Halt Protease Inhibitor Cocktail. 
The homogenate was incubated at 4°C on a rotator, vortexing every 10 min, and then 
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centrifuged for 30 min at 16,100 g at 4°C. The protein concentration of the 
supernatant (lysate) was measured using the Coomassie Plus (Bradford) Assay Kit 
(Life Technologies 23236). One volume of lysate was mixed with 1/2 volume of Blue 
Loading Buffer (New England Biolabs B7703S) and 50 mM of extra dithiothreitol 
(DTT, Life Technologies 20291), and incubated at 37°C for 30 min before being 
analyzed using SDS-PAGE or frozen at -80°C for future use. 
For whole-cell lysate of cultured neurons, the neurons were first gently rinsed 
twice with prewarmed Neurobasal medium without supplements and then scraped in 
ice-cold Pierce IP lysis buffer with 1/50 Halt Protease Inhibitor Cocktail. The neurons 
were homogenized by pipetting and vortexing. The homogenate was incubated at 4°C 
on a rotator with vortexing every 10 min, and then centrifuged for 30 min at 16,100 g 
at 4°C. The supernatant (lysate) was taken and further processed in the same way as 
the brain tissue lysate. 
For whole-cell lysate of HEK 293T cells, the cells were first gently rinsed twice 
with prewarmed DMEM without supplements and then scraped in ice-cold Pierce IP 
lysis buffer with 1/50 Halt Protease Inhibitor Cocktail. The cells were homogenized 
using a syringe with a 22G needle. The homogenate was then processed in the same 






2.3.2 Preparation of tissue/cell lysate using SDS lysis buffer 
Brain tissue was isolated as described in 2.3.1 and quickly transferred to SDS 
lysis buffer (100 mM NaCl, 50 mM Tris, 10 mM EDTA, 10 mM EGTA, 2% SDS, pH 
8.0) in a glass homogenizer in a 95°C wash bath. The tissue was rapidly homogenized 
and further incubated at 95°C for 5 min. The homogenate was incubated at room 
temperature on a rotator for 30 min with vortexing every 10 min, and then centrifuged 
for 30 min at 16,100 g at room temperature. The supernatant (lysate) was taken and 
the protein concentration was measured using the Coomassie Plus (Bradford) Assay 
Kit. One volume of lysate was mixed with 1/3 volume of 30% (v/v) glycerol in PBS, 
1/6 volume of Blue Loading Buffer (New England Biolabs) as well as 50 mM of extra 
DTT (Life Technologies), and incubated at 37°C for 30 min before being analyzed 
using SDS-PAGE or frozen at -80°C for future use. 
For cultured neuron lysates, the neurons were first gently rinsed twice with 
prewarmed Neurobasal medium without supplements, and then scraped in SDS lysis 
buffer with 50 mM DTT at 95°C. Then neurons were homogenized by pipetting, and 
incubated at 95°C for 5 min. The homogenate was then processed in the same way as 
the homogenate from brain tissues. 
 
2.3.3 Purification of 1A with nickel affinity gel 
The following solutions were needed: nickel lysis buffer (300 mM NaCl, 50 mM 
NaH2PO4, 1% (v/v) Triton X-100, pH 8.0), nickel wash buffer (300 mM NaCl, 50 mM 
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NaH2PO4, 20 mM imidazole, pH 8.0) and nickel elution buffer (300 mM NaCl, 50 
mM NaH2PO4, 250 mM imidazole, pH 8.0). 
Lysate of mouse brain tissue or cultured neurons was prepared by 
homogenization and centrifugation, as described in 2.3.1, with nickel lysis buffer 
substituted for Pierce IP Lysis Buffer. 50 L of lysate was set aside as the whole-cell 
lysate sample. 
Nickel affinity gel (Ni Sepharose High Performance, GE Healthcare 17-5268-01) 
was washed with nickel lysis buffer, mixed with the lysate and 10 mM imidazole in a 
spin column (Life Technologies 69725), and incubated at 4°C on a rotator for 2 h. The 
flow-through was discarded and the nickel affinity gel was washed with nickel wash 
buffer. The protein bound to the nickel affinity gel was eluted using nickel elution 
buffer. The concentrations of the whole-cell lysate and the eluate were measured 
before they were mixed with 1/2 volume of Blue Loading Buffer (New England 
Biolabs) and 50 mM of extra DTT, and subsequently incubated at 37°C for 30 min. 
The samples were being analyzed using SDS-PAGE or frozen at -80°C for future use. 
 
2.3.4 Preparation of oocyte membrane fraction 
Xenopus oocytes were washed with oocyte lysis buffer (mM: Tris 50, EDTA 1, 
EGTA 1, pH 8.0) and then homogenized with buffer containing 1/50 Halt Protease 
Inhibitor Cocktail using a syringe with a 25G needle. The homogenate was 
centrifuged at 1,500 g for 15 min at 4°C. The supernatant was then centrifuged at 
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100,000 g for 40 min at 4°C. The surface of the pellet was washed with oocytes lysis 
buffer with 1/500 Halt Protease Inhibitor Cocktail. The pellet (membrane fraction) 
was then resuspended in Pierce IP lysis buffer with 1/50 Halt Protease Inhibitor 
Cocktail. The protein concentration was measured before the sample was mixed with 
1/2 volume of Blue Loading Buffer (New England Biolabs) and 50 mM of extra DTT, 
and incubated at 37°C for 30 min. The sample was being analyzed using SDS-PAGE 
or frozen at -80°C for future use. 
 
2.4 SDS-PAGE and Western blot 
Samples were run in 6% or 8% polyacrylamide gels or NuPAGE Novex 4-12% 
Bis-Tris Protein Gels (Life Technologies) in Tris-Gly-SDS buffer (Bio-Rad 161-0732) 
at 175 V. Spectra Multicolor High Range Protein Ladder (Life Technologies 26625) or 
Precision Plus Protein All Blue Standard (Bio-Rad 161-0373) were used. Proteins 
were transferred to PVDF membrane (Bio-Rad 162-0177) in transfer buffer (25 mM 
Tris, 192 mM glycine, 0.002% SDS) for 90 min at 90 V at 4°C. Membranes were 
blocked in blocking buffer for 3 h at room temperature. For samples from Xenopus 
oocytes, the blocking buffer is 10% newborn calf serum (NCS, Life Technologies 
26010-066), 1% fish gelatin (Sigma-Aldrich G7041) and 0.2% Tween-20 
(Sigma-Aldrich P2287) in PBS. For other samples, the blocking buffer contains 2 
volumes of Odyssey Blocking Buffer (LI-COR Biosciences 927-40000) and 1 volume 
of PBS (Life Technologies) supplemented with 0.2% Tween-20. Membranes were 
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incubated with primary antibody diluted with blocking buffer overnight at 4°C. 
Membranes were washed with PBS (Life Technologies AM9625, 1X) containing 0.2% 
Tween-20 (PBST) 4 times, 5 min each time. Then membranes were incubated with 
secondary antibody diluted with blocking buffer for 1 h at room temperature. After 
four 5-min washes with PBST, membranes were rinsed with PBS, and then the protein 
bands were visualized using enhanced chemiluminescence reagents (Life 
Technologies 34079 and 34094) on X-ray films (HyBlot and Kodak). 
The following primary antibodies were used: rabbit polyclonal anti-1A II-III 
loop (1/1000, Sigma C1353), rabbit polyclonal anti-1A N-terminus (1/1000, Abcam 
ab32642), rabbit polyclonal anti-actin (1/1500, Sigma A2066), rabbit monoclonal 
anti-Na/K-ATPase (1/10000, Abcam ab76020), mouse monoclonal anti-spectrin 
(1/1000, EMD Millipore MAB1622), rabbit polyclonal anti-PARP (1/1000, Cell 
Signaling 9542), mouse monoclonal anti-FLAG (1/500, 2 g/mL, Sigma F1804), and 
mouse monoclonal anti-HA (1/1000, BioLegend 901502). Secondary antibodies used 
are goat anti-rabbit IgG-HRP(1/2000, Santa Cruz Biotechnology sc-2004) and goat 
anti-mouse IgG-HRP (1/2000, Santa Cruz Biotechnology sc-2005). 
 
2.5 Transfection 
Cultured rat hippocampal neurons were transfected on day in vitro (DIV) 4. 6 L 
of Lipofectamine 2000 (Life Technologies 11668030) was diluted into 400 L of 
Opti-MEM (Life Technologies 31985062) and incubate at room temperature for 5 min. 
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Meanwhile, 8 g of DNA was diluted into 400 L of Opti-MEM. The diluted 
Lipofectamine 2000 was mixed with the diluted DNA and incubated at room 
temperature for 25-30 min. Meanwhile, coverslips (usually four) with neurons were 
transferred to a 60-mm Petri dish with prewarmed Neurobasal medium without 
supplements. The DNA-Lipofectamine mixture was then added to the neurons. The 
neurons were incubated in the incubator for 40 min before being electroporated using 
an electroporator (BTX Harvard Apparatus) to facilitate transfection. The neurons 
were then moved back to the original cultural medium. 16 h after transfection, half the 
culture medium was replaced with Neurobasal medium supplemented with B-27 and 
GlutaMAX. Further experiments were performed 36-48 h after transfection. 
HEK 293T cells were propagated on the day before transfection so that the cells 
will be 85~95% confluent on the day of transfection. For each 35-mm Petri dish with 
coverslips, 5 L of Lipofectamine 2000 was diluted into 125 L of Opti-MEM and 
incubated for 5 min at room temperature. Meanwhile, 4 g of DNA was diluted into 
125 L of Opti-MEM. For each 60-mm Petri dish, the amount of each reagent was 
doubled. The diluted Lipofectamine 2000 was mixed with the diluted DNA and 
incubated at room temperature for 25-30 min. The DNA-Lipofectamine mixture was 
then added to the cells. For imaging experiments with cells on coverslips, the cells 
were incubated in the incubator for 40 min, before the culture medium was replaced 
with DMEM supplemented with 10% fetal bovine serum and 1% penicillin and 
streptomycin. For biochemical experiments, the cells were incubated overnight before 
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the culture medium was replaced. Further experiments were done 24-48 h after 
transfection. 
 
2.6 RNA synthesis 
Template DNAs were linearized overnight and purified using the 
Phenol:Chloroform:Isoamyl Alcohol (25:24:1) reagent (pH 8.0, Sigma-Aldrich  
P2069) and sodium acetate/ethanol precipitation. cRNAs were synthesized using an in 
vitro transcription reaction containing the purified DNA template, 2 L T7 RNA 
polymerase (100 units, New England Biolabs M0251S), 15 L m7G(5')ppp(5')G RNA 
Cap Structure Analog (10 mM, New England Biolabs S1404S), 4 L rNTP (100 mM, 
Roche), 5 L DTT (100 mM, Life Technologies R0861), 7.2 L MgCl2 (50 mM), 4 
L RNAPol Reaction Buffer (New England Biolabs), 1.5 L ribonuclease inhibitor 
(15 units, Life Technologies 15518-012), and 10.8 L DEPC-treated water. The 
reaction mixture was incubated at 37°C for 2.5-3 h. The cRNAs were purified using 
the Phenol:Chloroform:Isoamyl Alcohol (25:24:1 reagent (pH 5.2, Fisher Scientific 
BP1753I-100) and sodium acetate/ethanol precipitation. The cRNAs were then 
dissolved in DEPC-treated water. The RNA concentration was determined by 






2.7 Oocyte preparation and cRNA injection 
Female Xenopus laevis (Xenopus I) were anesthetized in a carbon dioxide 
chamber and euthanized by decapitation followed by pithing of the spinal cord. 
Ovarian lobes were divided into small parts and treated with 0.4 mg/mL collagenase A 
(Roche 11088793001) in OR2 solution (82.4 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 5 
mM HEPES, pH 7.6) for 1.5-2.5 h under 250 rpm shaking.  The oocytes were then 
rinsed with ND96 solution (96 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 5 mM HEPES, 
1.8 mM CaCl2, 100 units/mL penicillin, 100 μg/mL streptomycin, pH 7.6). 
Defolliculated stage VI oocytes were selected. cRNAs were injected into oocytes 
(1.25 ng/oocyte for 1 or  subunits, 0.2 ng/oocyte for 2 subunit). Experiments 
were performed 3-5 d after injection. 
 
2.8 Brain slices 
21-day old C57BL/6 mice were euthanized using a carbon dioxide chamber and 
decapitated. Brain dissection was performed in a sucrose-saline solution (27 mM 
NaHCO3, 1.5 mM NaH2PO4, 2.55 mM KCl, 222 mM sucrose) bubbled with 95% O2 
and 5% CO2 at 4°C. Coronal slices of 500 μm were obtained from the cerebral cortex 
of each hemisphere using a brain slicer instrument while bubbling in ice-cold sucrose 
solution. Slices were gently transferred to artificial cerebrospinal fluid (ACF, in mM: 
NaCl 119, NaHCO3 26, NaH2PO4 1.25, KCl 2.5, glucose 15, myo-inositol 1, pyruvate 
2, N-acetyl-L-cystein 0.06) of 35-37°C, bubbled with 95% O2 and 5% CO2, to recover 
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for 60 min before any treatment. 
 
2.9 Surface biotinylation 
For surface biotinylation of brain slices, slices were rapidly moved to ice-cold 
ACF containing 1 mg/mL sulfo-NHS-SS-biotin from the Pierce Cell Surface Protein 
Isolation Kit (Life Technologies 89881), bubbled with 95% O2 and 5% CO2, and 
incubated for 45 min. Slices of the mock biotinylation control group were treated in 
parallel using the same kind of solution in which sulfo-NHS-SS-biotin was omitted. 
Quenching solution (from the kit) of 20% of the volume of the ACF was added and 
incubated for 5 min. Slices were then rapidly rinsed with phosphate-buffered saline 
(PBS, in mM: KH2PO4 1.06, NaCl 155.17, Na2HPO4 2.97, pH 7.4) with 1:250 Halt 
protease inhibitor cocktail (Life Technologies 78430). Slices were homogenized in 
lysis buffer (from the kit) with 1:50 Halt protease inhibitor cocktail using a syringe 
with a 22G needle, and incubated for 1 h at 4°C with vortexing for 40 s every 2 min. 
The homogenates were centrifuged at 10,000 g for 2 min. A small portion of each 
supernatant was set aside as the whole-cell lysate sample. The remaining supernatants 
were mixed with NeutrAvidin agarose beads in spin columns (from the kit) and 
rotated for 1 h at room temperature. The flow-through samples were collected by 
centrifugation. The beads were washed 4 times with wash buffer (from the kit) with 
1:50 Halt protease inhibitor cocktail, and then incubated with Blue Loading Buffer 
(1X, diluted with PBS, New England Biolabs B7703S) with 50 mM of extra DTT for 
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1 h at 37°C. The eluates were collected by centrifugation. 
For surface biotinylation of Xenopus oocytes, ~30 healthy oocytes from each 
group were selected 5 days after cRNA injection and washed 3 times in ice-cold OR2. 
Oocytes were incubated in 2.5 ml of 1.2 mg/ml sulfo-NHS-SS-Biotin (from the kit) in 
ice-cold OR2 for 30 min with gentle shake. 500 l quenching solution (from the kit) 
was added to each group and incubated for 5 min. Oocytes were then washed with 3 
ml of Tris Buffer Saline (from the kit) with 1:500 Halt protease inhibitor cocktail 3 
times, and homogenized using a syringe with a 22G needle in oocyte lysis buffer (mM: 
Tris 5, EDTA 1, EGTA 1, pH 8.0), 10 l per oocyte, with 1:50 Halt protease inhibitor 
cocktail. The homogenates were centrifuged at 1,000 g for 5 min at 4°C. Supernatants 
were then subjected to ultracentrifugation at 100,000 g for 40 min at 4°C. Meanwhile, 
NeutrAvidin agarose beads, 125l per group, were washed three times with Pierce IP 
lysis buffer in a spin column. After ultracentrifugation, the pellets were resuspended 
in Pierce IP lysis buffer, 5l per oocyte, with 1:50 Halt protease inhibitor cocktail, 
mixed with the NeutrAvidin agarose beads, and gently rotated at 4°C for 4 h. 
Flow-through samples were collected by centrifugation. The beads were washed 4 
times with high-salt wash buffer (300 mM NaCl and 1% (v/v) Triton X-100 in Pierce 
lysis buffer) and incubated with Blue Loading Buffer (1X, diluted with PBS, New 
England Biolabs) with 50 mM of extra DTT for 1 h at 37°C. The eluates were 




2.10 Immunocytochemistry and confocal microscopy 
2.10.1 Fixed-cell imaging 
Immunocytochemistry for fixed-cell imaging was performed at room 
temperature. Fixed-cell imaging of hippocampal neurons was performed 36-48 hours 
post-transfection. For immunocytochemistry under non-permeabilizing conditions, the 
culture medium was removed and the neurons were gently rinsed with PBS (Life 
Technologies). Neurons were fixed for 15 min in fixation solution (2% 
paraformaldehyde and 4% sucrose in PBS, pH7.4) and then washed 4 times with PBS. 
Neurons were blocked for 2 h with blocking buffer (10% goat serum in PBS, goat 
serum: Life Technologies 16210-064), and then stained with a mouse anti-HA 
antibody (1:100, Biolegend 901502) in the same kind of blocking buffer for 1 h. 
Neurons were washed 4 times with PBS before being stained with an 
Alexa594-conjugated goat anti-mouse secondary antibody (1:750, Life Technologies 
A-11005) in the same kind of blocking buffer. Neurons were finally washed 4 times 
with PBS before confocal microscopy. 
Fixed-cell imaging of HEK 293T cells was performed 24 h post-transfection. The 
protocol is the same as above except that the blocking buffer for HEK 293T is 5% 
goat serum, 1% bovine serum albumin (Jackson ImmunoResearch Laboratories 
001-000-161) and 0.5% fish gelatin (Sigma-Aldrich G7041) in PBS. 
The protocol of fixed-cell imaging under permeabilizing conditions is the same 
as the protocol of fixed-cell imaging under non-permeabilizing conditions, except that 
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the cells were permeabilized using 0.25% Triton X-100 (v/v) in PBS for 15 min 
before blocking. 
 
2.10.2 Live-cell antibody feeding 
Live-cell antibody feeding of hippocampal neurons was performed 36-48 hours 
post-transfection. Neurons were incubated in mouse anti-HA antibody (1:80, 
Biolegend 901502) diluted in conditioned medium for 45 min in the incubator. 
Neurons were washed 4 times with ice-cold PBS before being fixed with fixation 
solution (2% paraformaldehyde and 4% sucrose in PBS, pH7.4) for 40 min at room 
temperature. The following steps were all performed at room temperature. Neurons 
were washed 4 times with PBS, and then blocked for 1.5 h in 1.5 mL of blocking 
buffer (0.5% fish gelatin and 2% goat serum in PBS) supplemented with 4 drops of 
signal enhancer (Life Technologies I36933). Neurons were then stained for 1.5 h with 
the Alexa594-conjugated goat anti-mouse secondary antibody (1:500, Life 
Technologies A-11005) diluted in the same kind of blocking buffer with signal 
enhancer. Neurons were finally washed 4 times with PBS before confocal microscopy. 
 
2.11 Two-electrode voltage clamp (TEVC) 
The bath solution contained 4 mM Ba(OH)2, 96 mM NaOH, 2 mM KCl and 5 
mM HEPES (pH 7.4 with methanesulfonic acid, osmolarity 195 mmol/kg). Electrodes 
were filled with 3 mM KCl and had a resistance of 0.2-1 M. For I-V curves, currents 
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were evoked by step depolarizations to various levels from a holding potential of -100 
mV. To determine the steady-state inactivation, the oocyte was given a 20-ms 
normalization pulse to the voltage level where the peak current was, followed 
sequentially by a 5-s conditioning pulse to various levels and a 50-ms test pulse to the 
same level as the normalization pulse. The interval between sweeps is 50 s. 
 
2.12 Data analysis 
Densities of bands in Western blot were analyzed using ImageJ. TEVC data were 
analyzed using Clampfit and presented as mean ± SEM. For I-V curves, currents of 
each oocyte at different voltage levels were normalized to the peak current of that cell. 
At each voltage level, the normalized currents of all the oocytes in the same group 
were averaged. For steady-state inactivation curves, current evoked by the test pulse 
was normalized by the current evoked by the normalization pulse. At each voltage 
level, the normalized currents of all the oocytes in the same group were averaged and 



























I performed all of the experiments, except for the Western blot analysis of the 
lysate of a whole mouse brain in section 3.2 and the experiments in section 3.7, which 




The CaV1 subunits of voltage-gated calcium channels have been found to exist 
not only in full-length forms, but also in the forms of shorter lengths—fragment 
channels. A number of fragment channels of L-, P/Q- and N-type CaV1 have been 
found in Western blots (5, 8, 10-12, 49, 131, 132, 141, 176, 177, 226-230). Our lab 
found that 1C in the rat brain can be proteolytically cleaved at a site presumably in 
the II-III loop, resulting in two fragments of 90 kDa and 150 kDa, respectively (4). 
This “mid-channel” proteolysis increases significantly with calcium activity and with 
age. The mechanism involves the calcium-dependent protease calpain and the 
ubiquitin-proteasome system. 
Proteolysis has also been shown to be the mechanism for the production of other 
fragments of the L-type calcium channels (see 1.6.1.1) and sodium channels (see 
1.6.2). In contrast, the mechanisms that cause the various short forms of the P/Q-type 
calcium channel have not been thoroughly studied. A previous study reported that a 
75-kDa C-terminal fragment of 1A is generated by an internal ribosome entry site 
(IRES) (7). Another study demonstrated that a 190-kDa fragment of 1A in the rat 
brain contains both the N- and C-termini, suggesting that this fragment does not result 
from proteolysis, but from alternative splicing (8). However, known alternative 
splicing events can only reduce the molecular weight of rat 1A to about 220 kDa 
(see 1.7.2.5). 
It is noteworthy that in most of the previously reported Western blot results of 
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endogenous 1A, the apparent molecular weights of the putative full-length 1A, the 
highest band, are smaller than the theoretical molecular weights of 1A. In addition, 
they also saw shorter bands with molecular weights between 140-190 kDa (5, 8, 10-12, 
176, 177). In contrast, the apparent molecular weights of 1A expressed in 
heterologous systems were shown to be closer to the theoretical size, and there are no 
bands present between 140-190 kDa (177, 178). This indicates that native 1A 
undergoes some processing events that do not happen in heterologous systems. 
In this chapter, I report the existence of a 190-kDa fragment of 1A and 
investigate the origin of this fragment. 
 
3.2 The 190-kDa fragment of 1A in the mouse brain 
The cerebella from a wild-type (WT) male mouse and an 1A-knockout male 
mouse of postnatal day 16 (P16) were lysed in Pierce IP Lysis Buffer and the lysates 
were run on a gel for Western blot, as described in Materials and Methods. An 
anti-1A antibody (Sigma-Aldrich C1353) was used to detect 1A. This antibody is 
against the peptide CNA1, corresponding to residues 865-881 in the II-III loop of rat 
brain 1A (UniProtKB - P54282), and thus will be hereafter referred to as the “II-III 
loop antibody”. According to Sigma-Aldrich, the antibody also recognizes mouse 
1A, whose residues 865-881 (UniProtKB - P97445) have a sequence identity of 
16/17 with rat 1A. The WT sample shows a “doublet” band containing two 
similar-sized bands around 190 kDa (Figure 5A). The knockout sample does not have 
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the doublet band, indicating that the doublet band is from 1A. Surprisingly, 
full-length mouse 1A, 270 kDa in theory, is almost invisible. In some other 
experiments, the full-length band is more visible (Figure 8A). 
To investigate whether the lack of full-length 1A is an age-specific 
phenomenon, lysates of cerebella from mice of different ages were tested using 
Western blot. The result shows that the lysates of newborn, 19-day and 9-month old 
mice all have the 190-kDa doublet band as the predominant form of 1A (Figure 5B). 
To see whether the 190-kDa doublet band also exists in other regions of the 
mouse brain, lysates of the cerebellum, hippocampi and the cerebral cortex from a 
mouse were run on the same gel for Western blot. The result shows that the lysates of 
the cerebral cortex and hippocampi also have the 190-kDa doublet band (Figure 5C). 
In the lysate of a whole mouse brain, the amount of the 190-kDa doublet band is much 
higher than the full-length 1A, as detected by the II-III loop antibody (Figure 5 D 
and E). 
In some experiments, the lower-molecular-weight band of the doublet band is 
almost invisible. Thus, the 190-kDa doublet band or single band—if only one band is 


































Figure 5. Western blot analysis of the mouse brain with the II-III loop antibody reveals the 
190-kDa fragment of 1A in the mouse brain. (A) Lysates of the cerebella from a wild-type and 
an 1A-knockout P16 mouse. Probing with anti-Na,K-ATPase reveals that comparable amounts of 
protein were loaded. (B) Lysates of the cerebella from mice of different ages: 1) newborn; 2) 19 
days; 3) 9 months; 4) negative control: P14 1A-KO. (C) Lysates of different brain regions: 1) 
cerebellum; 2) hippocampus; 3) cortex. (D) Whole-brain lysate of a P10 mouse. (E) Whole-brain 
lysate of a P21 mouse. 
 
3.3 The 190-kDa fragment of 1A in cultured mouse cortical neurons 
Neurons in the brain and neurons in culture are exposed to drastically differently 
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neuron cultures, cultured cortical neurons from WT and 1A-knockout mice were 
lysed on day in vitro (DIV) 14 in Pierce IP Lysis Buffer, as describe in Materials and 
Methods. The lysates were run on a gel for Western blot. Two primary antibodies were 
used and one was the II-III antibody as in 3.2. The other was an antibody (Abcam 
ab32642) against the N-terminal tail (residues 1-100) of rat 1A, hereafter referred to 
as the “N-terminus antibody”. According to Abcam, this antibody also works with 
mouse 1A, whose N-terminus is completely the same as rat 1A. 
The II-III loop antibody detected a band with an apparent molecular weight of 
~270 kDa, the same as the theoretical molecular weight of full-length mouse 1A 
(Figure 6A). Unlike many previous reports showing a low apparent molecular weight 
of the full-length 1A (5, 8, 10-12, 176, 177), this result shows that the full-length 
1A has a normal apparent molecular weight. The II-III loop antibody also detected a 
doublet band around 190 kDa, similar to the 190-kDa fragment in mouse brain tissues. 
Like the 190-kDa fragment found in mouse brain tissues, the 190-kDa fragment in 
cultured mouse cortical neurons is detected sometimes as a doublet band, and 
sometimes as a single band (Figure 6A and 8C), and thus will be referred to simply as 
“the 190-kDa fragment” or “the 190-kDa species”. 
The N-terminus antibody also detected the full-length 1A of 270 kDa, along 
with some other bands (Figure 6B). Note that the band with an apparent molecular 
weight of ~100 kDa might be the fragment complementary to the 190-kDa fragment, 

















Figure 6. Western blot analysis of 1A in cultured mouse cortical neurons. (A) Lysates of 
1A-knockout and wild-type mouse cortical neurons probed with the II-III loop antibody. (B) 
Same samples as in (A), probed with the N-terminus antibody. 
 
3.4 1A expressed in heterologous systems shows normal molecular weight 
To find supporting evidence that the 270-kDa band in the above results is the 
full-length 1A, HEK 293T cells were transfected with mouse 1A (Addgene 26573) 
and the auxiliary subunits 3 and 2 as described in Materials and Methods.  
Another group of HEK 293T cells were transfected with only 3 and 2 as a 
negative control. The cells were lysed in Pierce IP Lysis Buffer as described in 
Materials and Methods, and the lysates were run for Western with the II-III loop 
antibody. A 270-kDa band clearly corresponds to the full-length mouse 1A and no 



































Figure 7. Western blot analysis of 1A expressed in heterologous systems. (A) Mouse 1A 
expressed in HEK 293T cells probed with the II-III loop antibody. (B) Human 1A expressed in 
Xenopus oocytes probed with the II-III loop antibody. (C) Human 1A expressed in Xenopus 
oocytes probed with the N-terminus antibody. In all three panels, the negative control and the 
sample with 1A are indicated with “-” and “+”, respectively. 
 
Besides mouse 1A, human 1A was also expressed and tested. Oocytes of the 
African clawed frog (Xenopus laevis) were injected with the cRNAs of human 1A 
and the auxiliary subunits 3 and 2 as described in Materials and Methods. A 
control group of oocytes were injected with the cRNAs of 3 and 2 only. On the 
fourth day after injection, the oocytes were lysed, and the membrane system was 
isolated and run on a gel for Western blot, as described in Materials and Methods. The 
II-III loop antibody was tried, but the result is ambiguous (Figure 7B). A thick 
non-specific band of ~300-kDa makes it hard to tell whether there is a specific band 
of ~270-kDa. No specific bands of other molecular weights were detected. Note that 
this antibody (Sigma-Aldrich C1353) is meant to be used only for mouse and rat 1A 
subunits, which have identical N-terminal tail sequences. 10% of the human 1A 
























result with human 1A is not surprising. The N-terminus antibody (Abcam 32642) 
was then tried. According to Abcam, this antibody is predicted to work also with 
human 1A, whose N-terminal tail has a sequence identity of 91/100 with rat 1A. A 
specific band at ~280 kDa was detected (Figure 7C). Additionally, there are two 
non-specific bands near 190 kDa. However, they are both of comparable intensity 
with those in the control group, and thus it is unlikely that they have covered up any 
specific bands. 
In summary, heterologously expressed mouse and human 1A did not show 
anomalous migration or bands of smaller molecular weights. 
 
3.5 Evidence that the 190-kDa fragment of 1A exists in live brains and live cells 
Could the 190-kDa fragment be a product of protein degradation during sample 
preparation, caused by a protease which does not cut 1A in live cells? Although all 
the sample preparation was carried out at 4°C or on ice with protease inhibitors, some 
residual protease activity might still exist. In order to further reduce possible protein 
degradation during sample preparation, mouse cerebellum and cultured mouse cortical 
neurons were lysed with a lysis buffer containing 2% SDS (hereafter referred to as 
SDS lysis buffer) at 95°C as described in Materials and Methods. The samples were 
run on a gel for Western blot with the II-III loop antibody in parallel with samples 
prepared using the methods described in 3.2 and 3.3. When the samples are 
homogenized with SDS at high temperature, most proteins including most proteases, 
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will be denatured rapidly, so that proteolytic degradation can be minimized. If the 
190-kDa fragment was due to proteolytic degradation during sample preparation, the 
new sample preparation method should reduce the amount of the 190-kDa fragment 
and increase the amount of full-length 1A. 
As shown in Figure 8A, the 190-kDa fragment is the dominant species in both 
samples, prepared using Pierce IP Lysis Buffer at 4°C and SDS lysis buffer at 95°C, 
respectively. A 270-kDa band, presumably the full-length 1A, is also visible in both 
samples. The ratio of the intensity of the 270-kDa band to that of the 190-kDa 
fragment is very similar between the two samples: 0.12 and 0.086, respectively. 
To confirm the specificity of the staining, the II-III loop antibody was incubated 
with a blocking peptide with the sequence of residues 865-881 of rat 1A, as in the 
immunogen of the antibody, prior to the immunoblotting. The antibody incubated with 
the blocking peptide does not recognize the 270-kDa band and the 190-kDa fragment 
anymore (Figure 8B). This indicated that both the 270-kDa band and the 190-kDa 
fragment are from mouse 1A, instead of non-specific staining. 
With cultured mouse cortical neurons, a similar result was obtained (Figure 8C). 
The sample prepared using SDS lysis buffer at 95°C even has a higher amount of the 
190-kDa fragment than the sample prepared using Pierce IP Lysis Buffer at 4°C, while 
the two samples have similar amount of full-length 1A. These results suggest that 
the 190-kDa fragment exists in the live mouse brain and neurons, and is not an artifact 




























Figure 8. Homogenization in SDS lysis buffer at 95°C does not reduce the amount of the 
190-kDa species. In all panels, lane 1 is the sample prepared using ice-cold Pierce IP lysis buffer, 
and lane 2 is the sample prepared using SDS lysis buffer at 95°C. (A) Mouse cerebellum lysates 
probed with the II-III loop antibody. The ratios of the intensity of the 270-kDa band to that of the 
190-kDa band in the two samples are 0.12 and 0.086, respectively. (B) The II-III loop antibody 
preincubated with the blocking peptide does not recognize the 270-kDa and 190-kDa species any 
more. 200 nM of blocking peptide was used for per nM of antibody. In the control group, water 
was substituted for the blocking peptide solution. (C) Lysates of cultured mouse cortical neurons 
probed with the II-III loop antibody. (D) Lysates of cultured mouse cortical neurons probed with 
the N-terminus antibody. (E) Lysates of cultured mouse cortical neurons as in C and D, probed 
with anti-Na,K-ATPase antibody, showing that sample 1 and sample 2 have comparable amounts 


















































3.6 The 190-kDa fragment of 1A contains the C-terminal tail but not the 
N-terminal tail 
Another question that we wanted to address was which part of the mouse 1A is 
included in the 190-kDa fragment. At the time, we already knew that the fragment 
included residues 865-881, since the II-III loop antibody bound to this region. Next, I 
investigated whether the 190-kDa fragment contained the C-terminal tail of the mouse 
1A. 
The C-terminal tail of the mouse 1A contains an evolutionarily conserved 
“histidine tract”, which consists of 10-11 histidine residues and, according to a 
previous study, can be recognized by an anti-penta-HIS antibody (11). We surmised 
that the histidine tract can bind to immobilized bivalent nickel ions like a 
polyhistidine-tag. Therefore, if the 190-kDa fragment contains the C-terminal tail, it 
should be able to bind to immobilized bivalent nickel ions. A WT mouse cerebellum 
was lysed in lysis buffer, and then a nickel affinity gel (Ni Sepharose High 
Performance, GE Healthcare 17-5268-01) was used to purify 1A and any 1A 
fragment that contains the histidine tract, as described in Materials and Methods. An 
1A-knockout mouse cerebellum was treated the same way as a negative control. 
As shown in Figure 9A, the eluate from the nickel affinity gel that was incubated 
with the lysate of WT mouse cerebellum contained a much higher concentration of the 
190-kDa fragment than the lysate itself. It also contained a species of a higher 
molecular weight, presumably the full-length 1A, which in this case was not 
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detected in the lysate of the cerebellum. No bands were detected in the eluate of the 
1A-knockout group. These findings suggest that the 190-kDa fragment has a high 























Figure 9. The 190-kDa fragment of 1A contains the C-terminal tail but not the N-terminal 
tail. (A) Lysates (lys) of wild-type and 1A-knockout mouse cerebella and eluates (elu) from 
nickel affinity gel that has been incubated with the lysates, probed with the II-III loop antibody. (B) 
Same samples as in (A) probed with an anti-Na,K-ATPase antibody. Volumes of the four samples 
in (A) are 23, 25, 20 and 25 L, respectively. Volumes of the four samples in (B) are 3, 7, 4, 5 L, 
respectively. (C) The II-III loop antibody recognizes the 190-kDa species. This experiment was 
done in parallel with (D). (D) The N-terminus antibody does not recognize the 190-kDa species. 
(E) Lysate of cultured mouse cortical neurons and eluate from nickel affinity gel that has been 
incubated with the lysate, probed with the II-III loop antibody. (F) Same samples as in (E), probed 
with the N-terminus antibody. 
 
To find supporting evidence that the affinity of the 190-kDa fragment to the 








































































blot with an antibody against Na/K-ATPase, a membrane protein without a histidine 
tract. The eluates of the two groups were shown to contain a much lower 
concentration of Na/K-ATPase than the cerebellum lysates (Figure 9B), indicating that 
Na/K-ATPase has very little affinity to the nickel affinity gel.  
These results suggest that the 190-kDa fragment in the mouse cerebellum 
contains the histidine tract in the C-terminal tail. The part of the channel from the 
N-terminus to the histidine track is approximately 246 kDa. Since the fragment that 
we observe is only 190-kDa, we can infer that if the 190-kDa fragment is a product of 
proteolytic processing, it is unlikely to contain the N-terminal tail. However, other 
mechanisms such as alternative splicing could produce a shorter fragment with both 
the N-terminal and C-terminal tails. Thus we also wanted to determine whether the 
190-kDa fragment contained the N-terminal tail. 
The eluate from the nickel affinity gel that was incubated with the lysate of WT 
mouse cerebellum was run on a Western blot with the II-III loop antibody and the 
N-terminus antibody respectively. The 190-kDa fragment was recognized by the II-III 
loop but not by the N-terminus antibody (Figure 9 C and D), indicating that the 
190-kDa fragment in the mouse cerebellum does not contain the N-terminal tail. Next, 
the lysate of cultured mouse cortical neurons was also purified using the nickel 
affinity gel and analyzed using Western blot with both the II-III loop antibody and the 
N-terminus antibody. The result is similar to the result obtained from the mouse 
cerebellum. The eluate from nickel affinity gel that was incubated with the lysate of 
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cultured mouse cortical neurons had a higher concentration of the full-length 1A, as 
detected by both the II-III loop antibody and the N-terminus antibody (Figure 9 E and 
F). The eluate also contained a higher concentration of the 190-kDa fragment than the 
lysate, as detected by the II-III loop antibody. The N-terminus antibody detected a 
band of 180-kDa in the lysate. We know that this band is non-specific according to the 
result in Figure 6B. In the eluate, there was only a sparse amount of this 180-kDa 
band. Judging from the intensity, apparent molecular weight, and shape of the band, it 
was unlikely for the II-III loop antibody to detect the 190-kDa fragment; instead, it 
was probably the residue of the non-specific 180-kDa band, which was not thoroughly 
washed off from the nickel affinity gel. 
These results suggest that the 190-kDa fragment of mouse 1A in both the 
mouse cerebellum and cultured mouse cortical neurons contains the histidine tract in 
the C-terminal tail but not the N-terminal tail. Therefore, the 190-kDa fragment 
appears to contain most of the II-III loop, repeat III, III-IV loop, repeat IV and the 
C-terminus. 
 
3.7 Is the 190-kDa fragment of 1A on the plasma membrane? 
The main function of voltage-gated calcium channels is to convert the electrical 
signal of the depolarization of the plasma membrane into an intracellular calcium 
signal, and this function is carried out by those channels on the plasma membrane (1). 
Therefore, we wanted to know whether the 190-kDa fragment of mouse 1A exists on 
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the plasma membrane. 
Cell surface biotinylation is an important method for isolating and analyzing cell 
surface proteins and has been widely used to study the cell surface expression of ion 
channels (4, 108, 158). Surface biotinylation was performed on mouse cortical slices 
as described in Materials and Methods. Briefly, coronal slices of mouse cerebral 
cortices were made and divided into two groups. One group of brain slices was 
subjected to biotinylation, and the other group was subjected to mock biotinylation, in 
which all treatments were the same as biotinylation except that no 
sulfo-NHS-SS-Biotin was added. The brain slices were lysed and a small portion of 
the lysate was set aside for the analysis of whole-cell 1A. NeutrAvidin Agarose was 
used to pull down the biotinylated proteins from the lysates. Both the whole-cell 
lysate and the eluate from the NeutrAvidin Agarose were analyzed using Western blot 
with the II-III loop antibody. -actin was also analyzed as both a loading control and 
an indicator of biotinylation of intracellular protein. In some experiments, the 
flow-through instead of the eluate was analyzed.  
Figure 10 shows two typical results of this experiment. The eluate from the 
biotinylation group contained a considerable amount of the 190-kDa fragment of 1A, 
while in the mock biotinylation group, the 190-kDa fragment of 1A was almost or 
completely undetectable. Surprisingly, the whole-cell lysate or flow-through in the 
biotinylation group also consistently contained a higher amount of the 190-kDa 
fragment of 1A than the mock biotinylation group. This suggests that either 
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sulfo-NHS-SS-Biotin can increase the amount of the 190-kDa fragment of 1A in the 
cells, or the biotinylated 190-kDa fragment of 1A can somehow be more easily 
detected by the II-III loop antibody. If sulfo-NHS-SS-Biotin can increase the amount 
of the 190-kDa fragment of 1A in the cells, then the difference between the amounts 
of the 190-kDa fragment in the eluates from the two groups can be explained by 
non-specific binding of the 190-kDa fragment to the NeutrAvidin Agarose. If the 
biotinylated 190-kDa fragment of 1A can be more easily detected by the II-III loop 
antibody, then the difference between the amounts of the 190-kDa fragment in the 
eluates from the two groups can be explained by biotinylation of intracellular protein 
of damaged cells. A higher amount of -actin was detected in the eluate from the 
biotinylation group than the mock biotinylation group (Figure 10 B and D); this 
indicates that some cells were indeed damaged and some intracellular protein was 
biotinylated. With the complexity of these results, it is inclusive whether the 190-kDa 


































Figure 10. Western blot analysis of 1A in mouse cortical slices after surface biotinylation. 
Results of two independent experiments are shown in panels (A and B) and panels (C and D), 
respectively. Note that 10% of the eluate was loaded on the gel, while only 1% of the whole-cell 
lysate or flow-through was loaded. (A) Western blot with the II-III loop antibody. (1) Eluate from 
the NeutrAvidin Agarose of the mock biotinylation group. (2) Lysate of cortical slices of the mock 
biotinylation group. (3) Eluate of the biotinylation group. (4) Lysate of the biotinylation group. (B) 
Same samples as in (A) probed with the anti--actin antibody. (C) Western blot with the II-III loop 
antibody. (1) Eluate of the biotinylation group. (2) Flow-through of the biotinylation group. (3) 
Eluate of the mock biotinylation group. (4) Flow-through of the mock biotinylation group. (D) 
Same samples as in (C) probed with the anti--actin antibody. 
 
3.8 Effect of calcium activity on the relative amount of the 190-kDa fragment of 
1A 
The finding that the 190-kDa fragment of mouse 1A contains the C-terminal 
tail but not the N-terminal tail (see 3.6), is consistent with the possibility that this 
fragment is caused by mid-channel proteolysis. Previous findings in our lab suggest 
that the mid-channel proteolysis of L-type calcium channel 1 subunit is upregulated 
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ubiquitin-proteasome system (4). Calpain has also been reported to mediate 
proteolysis of the voltage-gated sodium channel  subunit (158). Therefore, we 
wanted to determine whether the relative amount of the 190-kDa fragment of mouse 
1A can be altered by increased calcium activity. 
Three dishes of cultured mouse cortical neurons were prepared. The first dish 
was treated for 2 h with 65 mM of KCl and 14 M of Bay K8644, which can cause an 
increase of intracellular calcium concentration. The second dish was treated for 2 h 
with DMSO (vehicle of Bay K8644, 1/2000 diluted in culture medium). The third dish 
was not treated since it acted as a control. Then the dishes of neurons were lysed in 
SDS lysis buffer at 95°C and the lysates were analyzed using Western blot. 
Western blot stained with an anti--spectrin antibody (EMD Millipore, 
MAB1622) showed that the neurons treated with KCl and Bay K8644 had a decreased 
amount of full-length (180-kDa) -spectrin and an increased amount of a 150-kDa 
species (Figure 11A), a known calpain/caspase 3-mediated proteolytic product (158). 
Poly ADP ribose polymerase (PARP) was also analyazed. Proteolytic cleavage of the 
113-kDa full-length PARP into an 89-kDa fragment has been reported to be indicative 
of apoptosis (231-233). As shown in Figure 11B, the anti-PARP antibody (Cell 
Signaling 9542) recognized two bands of ~120 kDa and ~100 kDa, respectively, in 
each sample. The intensity ratio of the 100-kDa band relative to the 120-kDa band in 
the group treated with KCl and Bay K8644 is about twice as high as that in the other 


























Figure 11. Effects of calcium activity on the proteolysis of -spectrin, PARP and 1A in 
cultured mouse cortical neurons. The three groups of neurons were treated with KCl and Bay 
K8644 (1), DMSO (2) or nothing (3). (A) Western blot with the anti--spectrin antibody. (B) 
Western blot with the anti-PARP antibody. (C) Western blot with the II-III loop antibody. (D) 
Western blot with the N-terminus antibody. 
 
Interestingly, staining with the II-III loop antibody shows that the intensity ratio 
of the 190-kDa fragment relative to the full-length 1A is lower in the DMSO treated 
neurons than in both the other two groups (Figure 11C). This result signifies that 
increased calcium activity can increase the ratio of the amount of the 190-kDa 
fragment to that of the full-length 1A, while DMSO has an effect of decreasing that 
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of full-length 1A in the DMSO treated group than in the other two groups (Figure 
11D). However, the difference is not as dramatic as in the Western blot stained with 
the II-III loop antibody. Because of time constraints, this experiment was performed 
only once, so the effect of calcium activity on the relative amount of the 190-kDa 
fragment is not completely conclusive. 
 
3.9 Possible alternative splicing of mouse 1A 
Numerous splice variants of 1A have been discovered, but none can account for 
an isoform as small as 190-kDa (see 1.7.2.5). Nevertheless, it cannot be ruled out that 
190-kDa species is due to an undiscovered type of alternative splicing. Given that the 
190-kDa species cannot be recognized by the antibody against the N-terminal tail, the 
190-kDa species either is missing the whole N-terminal tail or has only part of it, 
which is too small to be recognized by the antibody. The N-terminal tail of 1A is 
almost entirely encoded by exon 1 of CACNA1A (See NCBI Reference Sequence 
NM_007578.3 and UniProt P97445). Therefore, if the 190-kDa species is a splice 
variant, the splice donor site (5’ splice site) should be in exon 1, either upstream of or 
shortly downstream of the start codon. In addition, the acceptor site (3’ splice site) 
should be upstream of exon 17, 18 or 19, which encodes the proximal part of the II-III 
loop. We know that acceptor sites are present in the above-mentioned areas, since the 
splicing of the full-length 1A mRNA relies on them. However, it is unknown 
whether there are splice donor sites within exon 1. 
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To identify potential splice donor sites in exon 1 of CACNA1A, the nucleotide 
sequence of exon 1 was analyzed using the method of Shapiro and Senapathy (234, 
235). A sequence of 9 nucleotides (9-mer) with a GT at fourth and fifth positions is 
highly conserved at the splice donor site. A consensus value (CV) score is calculated 
for every 9-mer in exon 1 of CACNA1A with a GT at fourth and fifth positions based 
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In this formula, i = -3, -2, -1, +1, +2, +3, +4, +5 and +6 (positions in the 9-mer); 
fi,min is the frequency (in 126,480 known human splice donor sites, similarly 
hereinafter) of the rarest nucleotide (among A, T, G and C) at position i. Additionally, 
fi,max is the frequency of the most common nucleotide at position i, and fi,n is the 
frequency of the nucleotide at position i in the 9-mer starting from nucleotide n in 
exon 1 of CACNA1A. The maximum CV score that a 9-mer can have is 1. 
The CV scores of 24 9-mers with a GT at fourth and fifth positions are displayed 
in Figure 12. All the 9-mers downstream of the start codon have CV scores under 0.6. 
Two 9-mers upstream of the start codon have CV scores higher than 0.6 (0.68 and 
0.66, respectively). Exon 1 of CACNA1A was also analyzed using the MaxEntScan 
method of Yeo and Burge (236). The two 9-mers with the highest CV scores also have 
the highest MaxEnt scores (Figure 12). Therefore, these two 9-mers are the best 













Figure 12. CV and MaxEnt scores of potential splice donor sites in exon 1 of CACNA1A. The 
brown regions of each bar indicate where MaxEnt and CV overlap. 
 
The distribution of the CV scores of the 126,480 known human splice donor sites 
is shown in Figure 13. As can be seen in the figure, only a small percentage of the 
total 126,480 donor sites have CV scores below 0.7. Among all the 126,480 donor 
sites, only 1,444 (1%) have a CV score of 0.70. Therefore, we can infer that the 
















Figure 13. Distribution of the CV scores of 126,480 known human splice donor sites. The 







  3.10.1 The presence of the 190-kDa species in live brains and cultured neurons 
We detected a 190-kDa form of 1A in mouse brain and cultured mouse cortical 
neurons. The 190-kDa species is recognized by the antibody against a 17-amino acid 
segment (CNA1) in the II-III loop of 1A, and was shown to contain the C-terminal 
tail but not the N-terminal tail. Similar short forms of 1A in animal brains have been 
reported. Westenbroek et al. reported a result very similar to ours: an anti-CNA1 
antibody recognized a very faint 250-kDa band and a 190-kDa major band in rat brain 
membrane glycoprotein preparation (9). Leenders et al. reported a 210-kDa band 
(major form) and a 190-kDa band recognized by an anti-CNA1 antibody mouse 
forebrain synaptosome lysate (10). The apparent molecular weights of proteins in 
SDS-PAGE are often inaccurate because of anomalous migration of the protein 
samples and/or markers. Thus the two bands reported by Leenders et al. might be the 
same species as the 190-kDa doublet band that we found.  
Scott et al. used an antibody against a long epitope that has 191 amino acid 
residues and includes CNA1 and flanking regions, and detected two major bands of 
95 kDa and 190 kDa, respectively (5). They identified the 95-kDa species as a 
two-domain truncated form of 1A including repeat I, repeat II and part of the II-III 
loop (5). The 190-kDa species, which was less discussed by the authors, may be the 
complementary fragment containing repeat III and repeat IV, i.e., the same fragment 
as the 190-kDa fragment found in our experiments.  
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Similar short forms of 1A have also been reported to be recognized by 
antibodies against the C-terminal tail of 1A, in accordance with our finding that the 
190-kDa species contains the C-terminal tail. Kordasiewicz et al. reported a 220-kDa 
band and a 170-kDa band of similar intensities from the mouse cerebellum recognized 
by an antibody against part of the C-terminal tail of 1A (11). Using a similar 
antibody, Ishiguro et al. found a 160-kDa strong band in the human cerebellum, along 
with additional bands including a 250-kDa faint band, which may be the full-length 
1A (12). 
Several groups tried to address the question whether the short forms of 1A are 
present in live brains or arise from proteolytic degradation during sample preparation. 
Scott et al. reported that the banding pattern (with two major bands of 95-kDa and 
190-kDa, respectively) is highly reproducible in different preparations (5). As stated 
above and in 1.7.2.1, short forms of 1A of 190 kDa or similar sizes recognized by 
antibodies against the II-III loop or the C-terminal tail were observed by many groups 
using different preparations from brains of different animals. These observations 
support the likelihood that the 190-kDa species is present in live brains. It is unlikely 
that so many conditions of sample preparation all happen to activate the same 
mechanism of proteolytic degradation or different mechanisms that produce fragments 
of similar sizes. Other lines of evidence against the likelihood of proteolytic 
degradation during sample preparation have also been reported. Scott et al. reported 
that 1A was detected as multiple bands, while 1B, which has 65% sequence 
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homology to 1A in the same preparation, was not (5). Two independent studies 
reported that inclusion of high concentrations of several protease inhibitors and 
handling of samples at 0°C did not alter the relative quantities of the bands, including 
a 190-kDa band (5, 9). 
In our experiments, sample preparation (except sample preparation with SDS 
lysis buffer at high temperature) was always performed on ice or at 4°C in a lysis 
buffer containing high concentrations of protease inhibitors, including inhibitors of 
serine proteases, cysteine proteases, aminopeptidases, and aspartyl peptidases. To 
further decrease possible proteolytic degradation during sample preparation, 
homogenization with SDS lysis buffer at 95°C was performed. Hot SDS buffer has 
been shown to effectively minimize protein degradation during sample preparation 
(237). In addition, Nucleolin, an extremely labile protein, has been shown to undergo 
autocatalyzed proteolytic degradation in nondividing T cells (237). When T cell 
samples were prepared in Triton X-100 buffer on ice, the degradation was so 
pronounced that the 105-kDa full-length nucleolin was almost completely invisible 
and short fragments of nucleolin were the most intense (237). However, when the 
samples were prepared in 1% SDS buffer at 100°C, the 105-kDa full-length nucleolin 
had the most intense band while the short forms had less intense bands (237). These 
results signify that the degradation of nucleolin continues during sample preparation 
in Triton X-100 buffer, while hot SDS buffer can better preserve the in vivo 
steady-state level of nucleolin. Heat itself also can effectively reduce protein 
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degradation. It has been shown that heat stabilization of mouse brain tissue at 95°C 
within 1 min after decapitation effectively reduces protein degradation and preserves 
the proteome of the sample better than snap freezing methods, even when protease 
inhibitors are used (238). Therefore, we expect the hot SDS lysis buffer to protect 
proteins much better than the Pierce IP Lysis Buffer. The amount of the 190-kDa 
species relative to the full-length 1A was not decreased by the hot SDS lysis buffer 
(Figure 8 A and C), suggesting that the 190-kDa species is not due to degradation of 
the full-length 1A during sample preparation. Compared with Pierce IP Lysis Buffer, 
hot SDS lysis buffer even increased the relative amount of the 190-kDa species in the 
lysate of cultured mouse cortical neurons (Figure 8C). This may be because the 
190-kDa species is subjected to faster proteolytic degradation than the full-length 
1A, in accordance with the findings that truncated and full-length forms of proteins 
have different rate of degradation (239-241). Sometimes a truncated version of a 
protein undergoes faster proteasomal degradation than the full-length version, most 
likely because it is quickly detected as non-functional (242). However, it is doubtful 
whether this is what happens to the 190-kDa fragment of 1A. Our results and many 
other previous results (see 1.7.2.1) show that the 190-kDa fragment of 1A had the 
most intense band, while the full-length 1A had a lesser intense band. Thus it would 
be surprising if the 190-kDa is simply a non-functional degradation product of 1A. 
Nevertheless, it is possible that the 190-kDa is indeed a non-functional degradation 




It is interesting that 1A is processed into the 190-kDa form only in the brain 
and in cultured neurons, but not in heterologous systems such as Xenopus oocytes and 
HEK 293T cells. One possible explanation for this is that neuron-specific factors, e.g., 
proteases, are necessary for the production of the 190-kDa species. It has been 
reported that endogenous 1S and1C in muscle and brain tissues are present in two 
size forms (one missing part of the C-terminal tail), while those expressed in 
heterologous systems are only present in the full-length form (see 1.6.1.1).  
Moreover, our lab has found that 1C subunits in rat brain and cultured rat 
hippocampal neurons are subjected to mid-channel proteolysis (4, 50), but those 
expressed in Xenopus oocytes and HEK 293T cells are not (50). Calpain has been 
shown to be involved in the mid-channel proteolysis of rat brain 1C (4), and also in 
the proteolysis of the C-terminal tail of skeletal muscle 1S (135) and brain 1C 
(136). Calpain is present in Xenopus oocytes and HEK 293 cells. In Xenopus oocytes, 
calpain has been found to play an important role in osmostress-induced apoptosis 
(243). In HEK 293 cells, calpain has also been shown to be an important participant in 
apoptosis (244). It would be interesting to investigate whether activation or 
overexpression of calpain in Xenopus oocytes and HEK 293 cells can cause 
proteolysis of the 1 subunits of L- and P/Q-type calcium channels. Alternatively, we 
could try to knockdown calpastatin, an endogenous calpain inhibitor present in 
Xenopus oocytes (245) and HEK 293 cells (246). However, a negative result does not 
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mean that calpain does not participate in the proteolysis of these channels, because the 
heterologous expression systems may lack other indispensible factors that are 
expressed in neurons. Alternatively, the 190-kDa species of 1A may not be a product 
of proteolysis at all, but a product of a pre-translational process, which is present in 
neurons but not the heterologous systems. 
Another interesting phenomenon is that in the mouse brain, the full-length 1A 
is almost undetectable and the 190-kDa form is predominant, while in cultured mouse 
cortical neurons the levels of the full-length form and the 190-kDa form are 
comparable. Neurons in the brain and neurons in culture are exposed to drastically 
differently environments. Neurons in the brain are surrounded by a large number of 
glial cells. Astrocytes, comprising about half of the volume of the adult mammalian 
brain, are the most predominant glial cell type (247). Astrocytes not only serve 
supportive and trophic functions for the neurons, but also display excitability and 
communicate with neurons (247). Astrocytes regulate the extracellular environment of 
neurons, offer metabolic support to neurons, and release growth factors such as nerve 
growth factor (NGF), brain-derived neurotrophic factor (BDNF) and fibroblast growth 
factor 2 (FGF-2) (248). 
 It is not surprising that neurons in the culture environment, where no astrocytes 
play these supportive roles, display physiological differences from neurons in the 
brain. A typical example of this is that neurons in the brain can live as long as the 
organism lives (249), while cultured neurons usually survive for no more than a few 
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weeks (250). It is possible that under the trophic and metabolic support of glial cells, 
the mechanism for the production of the 190-kDa species is more engaged in neurons 
in the brain than in neurons in culture. It would be interesting to look at the relative 
amount of the 190-kDa species in neuron-astrocyte co-culture and see whether 
astrocytes influence the production of the 190-kDa species. 
 
  3.10.2 Identity of the 190-kDa species 
Our results indicate that the 190-kDa form of 1A contains the part of the II-III 
loop equivalent to CNA1 in rat 1A (residues 865-881 in mouse 1A, UniProt 
P97445) and the histidine tract (residues 2162-2171) in the C-terminus, but does not 
contain the N-terminal tail. Thus, we hypothesize that the 190-kDa species is an 
N-terminally truncated 1A, starting somewhere in the II-III loop before residue 865. 
In fact, in order for the fragment to be exactly 190-kDa, it would need to start in S6 of 
repeat II. However, we think that this fragment is likely a product of mid-channel 
proteolysis (see 3.10.4), which is more likely to happen in an intracellular loop. 
Therefore, we think the fragment starts in the II-III loop, making it a few kDa smaller 
than 190-kDa. 
Note that the histidine tract is 197 residues away from the C-terminal end. We do 
not have evidence that these 197 residues are present in the 190-kDa species. If the 
190-kDa species has a truncation right after the histidine tract, it would need to start 
from S1 of repeat II to have the exact molecular weight of 190 kDa. Because 
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mid-channel proteolysis is more likely to happen in an intracellular loop, if the 
190-kDa species is a product of mid-channel proteolysis, it is more likely to start 
somewhere in the I-II loop and end right after the histidine tract. The resulting 
cleavage would make it a few kDa larger than 190-kDa. Moreover, it is also possible 
that the 190-kDa species is simply an N-terminally truncated 1A starting somewhere 
near the end of the I-II loop. This will make its molecular weight at least 213 kDa. 
Actually when the 190-kDa is detected as a doublet band, the molecular weight of the 
upper band is 205-210 kDa (Figure 8A and 9E). Moreover, because the apparent 
molecular weights of both the marker and the samples may be inaccurate, it is 
possible that our “190-kDa” species has a real molecular weight of 213 kDa. 
Taken together, the 190-kDa species may include either repeats III and IV or 
repeats II, III, and IV. We favor the former possibility for the following reasons. If the 
190-kDa fragment is a product of mid-channel proteolysis in the II-III loop, the 
proteolysis should also produce a complementary fragment of 80-kDa. Western blot 
analyses with the antibody against the N-terminus of 1A revealed a band slightly 
above 100-kDa in the lysate of cultured mouse cortical neurons (Figure 8D), as well 
as also in the lysate of mouse cerebellum (data not shown).  
Considering that the apparent molecular weights of the marker and the protein 
samples might be inaccurate, this 100-kDa species might be the complementary 
fragment. In fact, when compared with another protein marker (BioRad #1610373), 
this species is closer to 90 kDa. Moreover, the apoptosis-related proteolytic product of 
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PARP has been reported to be 89-kDa (231-233) (also see UniProt Q921K2), but it 
appears to be 100 kDa in our Western blot analysis, indicating that the apparent 
molecular weight of the 100-kDa marker band is inaccurate. Taken together, our 
N-terminus antibody and II-III loop antibody seem to detect a complementary pair of 
truncated 1A, which may be due to mid-channel proteolysis in the II-III loop. 
On the other hand, if the 190-kDa species is produced by a pre-translational 
process, e.g., alternative slicing, it is also more likely to contain repeats III and IV 
instead of repeats II, III, and IV. Evidence suggests that during evolution, the 
four-domain sodium and calcium channels originated from a single domain ancestral 
channel, which would undergo two rounds of gene duplication (180, 181). In modern 
organisms, expression of the two-domain isoforms still occurs through alternative 
splicing (180, 182), probably as an evolutionarily throwback. Therefore, the 190-kDa 
species may also be a two-domain splice isoform as an evolutionarily throwback, 
although no known splice variants of 1A can account for a fragment-channel as 
small as 190-kDa (see 1.7.2.5). 
As for whether the 190-kDa species contains the last 197 residues distal to the 
histidine tract, although we do not have direct evidence for that, previous studies 
reported that antibodies against epitopes distal to the histidine tract detected species of 
molecular weights around 190-kDa (160-220 kDa) in mouse and human cerebellum 
lysates (11, 12). There is no evidence that the C-terminal tail of 1A is subjected to 
proteolytic cleavage. Evidence shows that C-terminal fragments of L-type calcium 
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channels can be produced through proteolysis (see 1.6.1.1) and cryptic promoters (see 
1.7.1). C-terminal fragments of 1A, however, have only been shown to be produced 
by an internal ribosome entry site (IRES) (see 1.7.2.3). Therefore, we surmise that the 
190-kDa species that we found contains the complete C-terminal tail. 
More experiments would be needed to confirm the identity of the 190-kDa form 
of 1A. Immunoblot analyses with antibodies against the I-II loop and the C-terminus 
would be able to address the questions raised above. Moreover, it would be interesting 
to analyze the 190-kDa species using N-terminal sequencing (5, 51) or mass 
spectrometry (130) to not only confirm what parts of the channel it contains but also 
identify its N-terminal sequence. This will give us a clue to the possible origin of the 
190-kDa species. For example, a methionine residue on the N-terminus would suggest 
that the 190-kDa species might be the product of an independent translational event 
due to alternative splicing, IRES, or a cryptic promoter. A different residue on the 
N-terminus would indicate that the 190-kDa species has undergone proteolytic 
processing, but the other three possibilities cannot be ruled out because a truncated 
1A produced by alternative splicing, IRES, or a cryptic promoter might further 
undergo proteolytic processing. 
The 190-kDa species in mouse brain tissue is almost always detected as a doublet 
band (Figure 5, 8A, 9A and 9C), while that in cultured mouse cortical neurons is 
sometimes detected as a doublet band and sometimes almost as a single band (Figure 
6A and 9E) but with a smear to the lower molecular weight side (Figure 8C and 11C). 
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The apparent molecular weights of the two bands in the doublet band are 
approximately 175 kDa and 210 kDa, respectively, in both mouse cerebellar tissue 
(Figure 8A) and cultured mouse cortical neurons (Figure 6A). When it is detected 
almost as a single band, it shows an apparent molecular weight of ~190 kDa (Figure 
11C). Our protein samples were all denatured with the presence of 50-100 mM of 
dithiothreitol (DTT), which is much more concentrated than in most previously 
reported immunoblot analyses of the P/Q-type channel (8, 9, 12). Therefore, it is 
unlikely that the doublet band is caused by insufficient reduction of disulfide bonds. 
The doublet band is probably due to one or more of the following reasons: different 
post-translational modifications, proteolysis at different sites, and alternative splicing 
(251). 
As discussed in 1.5.1.2, CaV2.1 can be regulated by PKA- and PKC-mediated 
phosphorylation. PKC has been shown to modulate CaV2 through phosphorylation of 
the I-II loop and the synprint site in the II-III loop (1). Phosphorylation decreases the 
mobility of proteins in SDS-PAGE (252, 253). The doublet band of 1A may 
correspond to a phosphorylated and a non-phosphorylated form, or a more 
phosphorylated and a less phosphorylated form of truncated 1A. Analysis of the 
mouse 1A peptide sequence (UniProt P97445) using NetPhos 3.1 (254, 255) predicts 
a number of phosphorylation sites distal to repeat II, including 15 PKA sites (2 in the 
II-III loop, 7 in the C-terminal tail), 29 PKC sites (11 in the II-III loop, 11 in the 
C-terminal tail) and 1 CaMKII site (in the C-terminal tail). Phosphorylation of any of 
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these sites may increase the apparent molecular weight of fragment-channel. In theory, 
each phosphate group adds 80 Da to the molecular weight (256). In reality however, 
the degree of shift in mobility is hard to predict. It has been reported that one 
phosphate group could cause a 2-kDa shift (252). The molecular weight difference 
between the two bands in out 1A doublet band is about 35 kDa. It is possible that 
this molecular weight difference is caused by phosphorylation of some of the putative 
phosphorylation sites. Note that the lysate of cultured mouse cortical neurons 
prepared using hot SDS lysis buffer shows almost only a single 1A band (Figure 8C), 
while that prepared using Pierce IP Lysis Buffer shows a doublet band (Figure 6A). A 
possible reason for this phenomenon is that after cells were lysed using Pierce IP 
Lysis Buffer, some of the 190-kDa fragment-channels were dephosphorylated by 
phosphatases, producing the lower molecular weight band. On the other hand, in the 
hot SDS lysis buffer, phosphatases were denatured immediately and almost all the 
190-kDa fragment-channels were kept in their phosphorylated form. 
Phos-tag polyacrylamide gels (NARD Institute Ltd.) can be used to explore the 
phosphorylation status of the doublet band. Phos-tag is a metal complex that binds 
specifically phosphates (257). In SDS-PAGE with Phos-tag-conjugated 
polyacrylamide, the mobilities of phosphorylated proteins are significantly slowed 
down compared with the corresponding dephosphorylated proteins (253, 257). If the 
doublet band of 1A is due to phosphorylation, on a Phos-tag polyacrylamide gel the 
mobility of one or both of the two bands should be slowed down, and the distance 
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between the two bands should be increased, compared with that on a regular 
polyacrylamide gel. Moreover, we can add phosphatases into the lysis buffer to 
increase dephosphorylation (257) or phosphatase inhibitors to suppress 
dephosphorylation (253). If the doublet band is due to dephosphorylation of some of 
the 190-kDa fragment-channels, phosphatases should decrease the abundance of the 
upper band and increase that of the lower band, while phosphatase inhibitors should 
do the opposite. Sites of phosphorylation can be identified using N-terminal 
sequencing (51) or mass spectrometry (258). 
Another common type of post-translational modification that may account for the 
doublet band is glycosylation. Scott et al. reported that a 95-kDa C-terminally 
truncated form of rabbit 1A is glycosylated (5). This 95-kDa fragment contains the 
N-terminus, repeats I and II and part of the II-III loop (5), and is possibly the fragment 
complementary to our 190-kDa fragment produced by mid-channel proteolysis. Scott 
et al. identified two potential glycosylation sites in rabbit 1A, N283 (in the S5-S6 
loop of repeat I) and N1665 (in the S3-S4 loop of domain IV); with the former being 
present in the 95-kDa fragment (5). The two sites are conserved in mouse 1A as 
N285 and N1607, respectively (UniProt P27884 and P97445). Analysis of mouse 1A 
peptide sequence (P97445) by NetNGlyc 1.0 (255) identified 13 potential N-linked 
glycosylation sites, among which only N285 may really be glycosylated because it is 
extracellular. Interestingly, N1607 is not identified as a potential glycosylation site by 
NetNGlyc 1.0. However, another glycosylation site prediction tool, GlycoEP (259), 
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recognized N1607 as a potential glycosylation site. N1607 may be glycosylated, 
causing an increase in the molecular weight and resulting in the upper band in the 
doublet band. To investigate glycosylation of the 190-kDa species, peptide 
N-glycosidase and/or endoglycosidase F can be used to treat the protein samples (5, 
260, 261). If the upper band in the doublet band is due to glycosylation, treatment 
with the enzymes should cleave off the oligosaccharides, causing a decrease in the 
abundance of the upper band and an increase in that of the lower band. 
Ubiquitination can also alter the mobility of a protein in SDS-PAGE. 
Ubiquitination usually results in ladder-like protein bands or smears with increased 
molecular weight (84, 114). Our 190-kDa species, however, has a strong and clear 
upper band. A smear sometimes is present on the lower molecular weight side, instead 
of the higher molecular weight side (Figure 8C and 11C). Therefore, the doublet band 
is unlikely to result from ubiquitination. Because of time constraints, we did not do 
experiments to investigate the post-translational modifications of the 190-kDa species. 
As discussed above, it is possible that the 190-kDa species is due to a truncation 
in the I-II loop, although it is more likely due to a truncation in the II-III loop. It is 
also possible that the doublet band corresponds to two different truncated forms of 
1A, the upper band (205-210 kDa) with the truncation site in the I-II loop, and the 
lower band (175 kDa) with the truncation site in the II-III loop. However, we think 
this is unlikely, since sometimes the fragment-channel is detected almost as a single 
band, with an intermediate molecular weight of 190-200 kDa. 
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Another possible reason that makes the 190-kDa species a doublet band is 
alternative spicing. Several loci of alternative splicing have been found in and distal to 
the II-III loop of 1A. Among these loci, two can cause relatively big changes in 
molecular weight. The exon 43/44 alternative splicing and the exon 47 alternative 
splicing can shift the molecular weight for 6 kDa and 16 kDa, respectively (218). 
Immunoblot analyses using antibodies against the regions encoded by these exons can 
be used to explore which splice variants the two bands in the double band belong to. 
Moreover, PCR using a transcript-scanning strategy (218, 262, 263) can be used to 
systematically screen the cDNA of mouse 1A for alternative splicing. 
It has been reported that HLA-H, (a member of the major histocompatibility 
complex class I family), expressed in HEK 293 cells is detected as a doublet band in 
Western blot analyses, and the two bands are enriched in different fractions of the cell 
lysate (264). The upper 49-kDa band is mainly associated with the plasma membrane, 
while the lower 46-kDa band is mainly present in the Golgi complex, suggesting 
incomplete post-translational processing or modification of the 46-kDa species (264). 
It would be interesting to use density gradient centrifugation to isolate different 
organelles and study the subcellular distribution of the two bands in the 1A doublet 
band so as to better understand the functions and fates of the two bands. 
 
  3.10.3 Is the 190-kDa species on the plasma membrane? 
It is important to know whether the 190-kDa fragment of 1A is expressed on 
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the plasma membrane. Presence of the fragment-channel on the plasma membrane 
would suggest that the fragment-channel contributes to and/or regulates channel 
activities, whereas absence of the fragment-channel on the surface would suggest the 
possibility that the fragment-channel is merely a degradation product of unneeded 
channels. Unfortunately, because the biotinylation reagent sulfo-NHS-SS-biotin was 
found to increase either the expression level or detectability of the 190-kDa species 
(see 3.7), it is inconclusive whether the 190-kDa species is expressed on the plasma 
membrane. 
Possible influence of biotinylation on protein expression has also concerned 
other groups. Volz et al. (1995) analyzed the half-lives of biotinylated and 
non-biotinylated surface transferrin receptor (TfR) and dipeptidylpeptidase IV 
(DPPIV) using pulse-chase experiments, and did not find any influence of 
biotinylation on the metabolic stability of these two proteins (265). To our knowledge, 
there has been no report of biotinylation influencing protein levels. However, it cannot 
be excluded that biotinylation may influence the protein level of the 190-kDa 1A 
fragment. In our experiments, surface biotinylation substantially increased the 
immunoreactivity of the 190-kDa 1A fragment, but not -actin, in the subsequent 
Western blot analyses (Figure 10). The reproducibility of this result and the different 
responses of 1A and -actin indicate that the influence of biotinylation on the 
immunoreactivity of the 190-kDa 1A fragment is not an incident or artifact. 
The only difference between the biotinylation group and the mock biotinylation 
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group is that sulfo-NHS-SS-biotin was added into the biotinylation group, but not the 
mock biotinylation group. Sulfo-NHS-SS-biotin may increase the immunoreactivity 
of the 190-kDa species in two possible ways. It may increase the protein level of the 
190-kDa species, or it may increase the affinity of the 190-kDa species to the II-III 
loop antibody. Because of time constraints, we did not investigate the reason for the 
increase in the immunoreactivity. A simple experiment that can test the two 
possibilities is to replace the II-III loop antibody with an antibody against another 
region of 1A, e.g., the C-terminal tail. The N-terminus antibody should not be used 
since the 190-kDa species does not contain the N-terminus. If the new antibody also 
detects an increase in the immunoreactivity of the 190-kDa species in response to 
biotinylation, we can infer that sulfo-NHS-SS-biotin probably increases the protein 
level of the 190-kDa species, since it is unlikely that biotinylation of the protein can 
increase the affinity of two different epitopes to their antibodies. 
To explore the reason sulfo-NHS-SS-biotin increases the protein level of the 
190-kDa species, pulse-chase analyses can be used to measure the protein synthesis 
and decay rates (266) of the 190-kDa species. A rise in the protein synthesis rate may 
be due to an increase in the rate of translation or an increase in the mRNA level. The 
mRNA level can be measured by methods such as Northern blotting and real-time 
PCR. The mRNA level is determined by the synthesis and decay rates of the mRNA. 
The mRNA synthesis rate can be measured using transcription run-on analysis, in 
which newly synthesized mRNAs are labeled with radioactive nucleotides and then 
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the relative transcription rate of the mRNA of interest is measured by hybridization of 
the mRNA to a sequence-specific probe (267). The mRNA decay rate can be 
measured by inhibiting transcription using thiolutin or actinomycin D, and then 
measuring the amount of the mRNA remaining at different time points (268). 
As will be presented in Chapter 5, hPQB2, an engineered truncated two-domain 
form of human 1A equivalent to the putative truncated mouse 1A corresponding to 
the 190-kDa species, showed a hint of expression on the plasma membrane in 
Xenopus oocytes. However, this experiment did not yield completely conclusive 
results. This suggests the possibility that the 190-kDa species might also be expressed 
on the plasma membrane of neurons in the brain and in culture. However, we cannot 
draw a definitive conclusion because the experiment in Xenopus oocytes may not 
effectively reflect what happens in the neurons. Firstly, the engineered 
fragment-channel, hPQB2, is unlikely an exact equivalent of the 190-kDa, because we 
do not know the exact truncation site and had to estimate its position. Secondly, 
Xenopus oocytes and mouse neurons have substantial physiological differences. For 
instance, in the mouse brain, the major form of 1A is the 190-kDa species and the 
full-length channel is only minor, whereas in Xenopus oocytes, mouse 1A is only 
expressed into the full-length channel (Figure 7C). Moreover, it has been reported that 
the ER retention machinery in Xenopus oocytes is weak for misfolded mammalian 
proteins (212). Therefore, it is possible that the “leaky” ER retention machinery in 
Xenopus oocytes allows hPQB2 to traffic to the plasma membrane, while in the 
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mouse brain the 190-kDa fragment is recognized as a misfolded protein and retained 
in the ER. 
Alternative methods are needed to study the expression of the 190-kDa species 
on the cell surface. One possible method is to isolate plasma membranes using 
sucrose gradient centrifugation, which has been shown to be able to effectively enrich 
plasma membranes of HEK 293 cells (264) and Xenopus oocytes (269). A caveat of 
this method is that the purified sample, albeit enriched in plasma membrane proteins, 
will also contain intracellular proteins from organelles such as the Golgi complex 
(264), mitochondria , and lysosomes (269). Our biotinylation experiments showed that 
most (or all) of the 190-kDa species is intracellular (Figure 10). Therefore, the plasma 
membrane samples purified by sucrose gradient centrifugation will probably contain a 
much smaller amount of the 190-kDa species than the samples enriched for 
intracellular membranes. This will make the result ambiguous as to whether the 
190-kDa is present on the plasma membrane, because the sample enriched for plasma 
membranes will also contain intracellular membranes. 
Another possible method involves radioiodination of surface proteins. Surface 
proteins of live cells are first radioiodinated (270, 271). Next, the cells are lysed and 
the protein of interest is purified using immunoprecipitation, with the antibody either 
directly coupled to Sepharose beads or bound to protein A-Sepharose (271). Then the 
protein sample is analyzed using SDS-PAGE followed by autoradiography (271). In 
our case, the II-III loop antibody can be used to purify the 190-kDa species. 
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Eventually if the 190-kDa species can be detected by autoradiography, we can infer 
that it is expressed on the cell surface. 
The third possible method makes use of peptide toxins that specifically bind to 
1A on its extracellular surface. -agatoxin IVA is a peptide toxin that inhibits the 
P/Q-type channel by altering channel gating (272). The glutamate residue at the end 
of S3 of repeat IV is crucial for the inhibition by the toxin (273), thus the binding site 
of -agatoxin IVA in1A is thought to be in the S3-S4 loop of repeat IV. Another 
peptide toxin, -conotoxin MVIIC, inhibits the P/Q- and N-type channels as a pore 
blocker (274). The precise binding sites of -conotoxin MVIIC has not been clearly 
identified (274). It has been suggested that -conotoxin GVIA, -conotoxin MVIIC 
and -agatoxin-IIIA bind to a similar site in 1B, and-conotoxin MVIIC and 
-agatoxin-IIIA bind to a similar site in 1A (275). In 1B, each of the four repeats 
contributes to the binding of -conotoxin GVIA, especially repeat III, in which the 
extracellular loop between S5 and the “pore loop” is critical for the binding of the 
toxin (276). Therefore, -conotoxin MVIIC probably binds to similar sites in 1A. 
To study surface expression of the 190-kDa species, live cells would be 
incubated with radioiodinated -agatoxin IVA or -conotoxin MVIIC (176). Next, the 
inhibitor and the channel are cross-linked using membrane impermeable cross-linkers 
such as BS3 (277) (for more cross-linkers, see https://www.thermofisher.com/). Then 
the cells would be lysed and the lysate analyzed using SDS-PAGE and 
autoradiography. If the 190-kDa species can be detected by autoradiography, we can 
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infer that it is expressed on the cell surface. 
We can also try other biotinylation reagents, which may not have the effect of 
increasing 1A protein level as sulfo-NHS-SS-biotin does. Amino-oxy-biotin and 
biocytin hydrazide, which specifically biotinylate glycoproteins, are good candidates 
because they have been previously shown to lead to higher purity of plasma 
membrane proteins than sulfo-NHS-SS-biotin (278). Additionally, electrophysiology 
(see 3.10.4) and fluorescent imaging (see Chapter 4) may also offer indirect evidence 
for the presence of the 190-kDa fragment-channel on the plasma membrane. 
 
  3.10.4 Origin of the 190-kDa species 
The Catterall group reported that an anti-CNA3 (peptide sequence 
SEPQQREHAPPREHV in the II-III loop of 1A) antibody recognizes a major band 
of 190 kDa and two minor bands of 220 kDa and 160 kDa, respectively, in the rat 
brain (8). This result has some resemblance to our findings: the 220-kDa band 
corresponds to the full-length channel, and the 190-kDa and 160-kDa bands resemble 
the 190-kDa doublet band that we found. However, their double immunoprecipitation 
experiments revealed that the 220-kDa band and the 190-kDa band contain both the 
N-terminus and the C-terminus of 1A, indicating that these two bands result from 
alternative splicing (8). Our results, however, suggest that the 190-kDa doublet band 
contains the C-terminus but not the N-terminus. This result is compatible with several 
possible origins of the 190-kDa species: mid-channel proteolysis, alternative splicing, 
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IRES, and cryptic promoters. The difference between our result and the result of the 
Catterall group is probably due to the different species used. 
As presented in section 3.9, the two best candidates for potential splice donors in 
exon 1 are both upstream of the start codon. This means that the splice variants 
produced by these two potential splice donors would not contain any part of the 
N-terminal tail. While the possibility that 190-kDa fragment of 1A is produced by 
alternative splicing cannot be excluded, such possibility is very small according to the 
analysis of consensus value (CV) scores presented in 3.9. 
Preliminary results show that an increase in intracellular Ca2+ concentration 
increases the amount of the 190-kDa species (Figure 11C) as well as the relative 
amount of the 110-kDa species recognized by the N-terminus antibody, the putative 
complementary fragment to the 190-kDa species (Figure 11D). Similar results have 
been observed for CaV1.2 (4) and NaV1.2 (158). Increased intracellular Ca
2+ 
concentration promotes the mid-channel proteolysis in the II-III loop of CaV1.2 (4). In 
NaV1.2, mid-channel proteolysis happens in both the I-II loop and II-III loop, and 
both can be promoted by increased intracellular Ca2+ concentration (158). Calpain 
was shown to partially participate in the mid-channel proteolysis of CaV1.2 (4) and 
required for the mid-channel proteolysis of NaV1.2 (158). Therefore, it would not be 
surprising if calpain-mediated mid-channel proteolysis also happens to CaV2.1 and 
can be promoted by increased intracellular Ca2+ concentration. However, it is also 
possible that the 190-kDa of 1A is not produced by proteolysis, but by alternative 
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splicing, IRES, or a cryptic promoter that can be regulated by intracellular Ca2+. More 
experiments are necessary to explore the origin of the 190-kDa species. 
Electrophysiological recordings can be used to investigate whether the 1A is 
subjected to mid-channel proteolysis. Mid-channel proteolysis can either upregulate 
or downregulate channel activity, depending on the type of channel. Mid-channel 
proteolysis of CaV1.2 reduces current amplitude (4). In contrast, proteolysis of the 
voltage-gated sodium channel  subunit prevents normal inactivation and thus leads 
to persistent influx of Na+ (160-163). To examine the acute effect of mid-channel 
proteolysis on the functional properties of CaV2.1, tobacco etch virus protease (TEVp) 
cleavage sites (with the sequence ENLYFQG) were inserted into the I-II loop and 
II-III loop of 1A (4). Inside-out macropatch recordings from Xenopus oocytes 
showed that a 2-min treatment with purified TEVp did not abolish CaV2.1 currents. 
However, it caused an irreversible left shift of the activation curve (4), in accordance 
with an increase in the coupling between voltage sensing and channel opening. 
Two-electrode voltage clamp (TEVC) recordings in Xenopus oocytes show that 
two-domain truncated forms of 1A do not conducted currents when expressed 
individually or coexpressed (see 5.2). These results suggest that after mid-channel 
proteolysis, the fragment-channels can remain associated, at least temporarily, to keep 
functioning as a channel with altered electrophysiological properties (also see 
discussion in 5.5). 
The experiments on engineered CaV2.1 with TEVp sites reveal the putative 
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changes in the electrophysiological properties of the channel after mid-channel 
proteolysis. Next we can study the changes in electrophysiological properties of 
endogenous CaV2.1 after treatments that presumably promote mid-channel proteolysis 
(e.g., KCl and Bay K8644 treatment). If the changes following the treatments are 
similar to the changes that TEVp causes on the engineered channels, we can infer that 
the 190-kDa fragment is likely due to mid-channel proteolysis. One caveat of this 
experiment is that if the treatment (e.g., KCl and Bay K8644 treatment) causes a 
decrease in CaV2.1 currents, it is hard to tell whether it is caused by a change in the 
electrophysiological properties of the channel or internalization of the channels. In 
this case, single-channel recordings on cell-attached patches may be a better choice. 
In single-channel recordings, a complete loss of currents would most likely be due to 
internalization, while changes in the current amplitude or open probability indicate 
other alterations in the channel. Single-channel recordings on cell-attached patches 
also avoid the decrease in channel activity due to rundown, which happens in 
inside-out patch recordings and, to a lesser extent, in whole-cell recordings (279). 
We can also explore indirect evidence for mid-channel proteolysis by trying to 
induce mid-channel proteolysis of 1A in Xenopus oocytes and HEK 293 cells. As 
discussed in 3.10.1, mid-channel channel may be induced by activation or 
overexpression of calpain, or knockdown of calpastatin, in Xenopus oocytes and HEK 
293. Another method for investigating mid-channel proteolysis is fluorescent imaging, 
which will be discussed in Chapter 4. 
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Additionally, the N-terminal truncation site of the 190-kDa species could be 
identified using N-terminal sequencing (5, 51) or mass spectrometry (130). The 
N-terminal sequence of the truncated channel may help us identify the possible 
protease(s) that causes the mid-channel proteolysis, or reveal whether the truncated 
channel is the product of an independent translational event due to alternative splicing, 
IRES or a cryptic promoter. 
Considering the possibility that the 190-kDa species may be produced by a short 
transcript due to alternative splicing or a cryptic promoter, it would be useful to screen 
for short splice variants of 1A that may produce the 190-kDa species. Efforts have 
been made to find splice variants of 1A, and several splice variants have been 
discovered (23, 218, 224), but none can account for a truncated form as short as 
190-kDa. The methods used in these studies, however, have limitations and would not 
be able identify the transcript that produces the 190-kDa species. Bourinet et al. 
identified two splice variants of 1A by screening a cDNA library of rat brain using a 
probe corresponding to domain I of previously cloned neuronal 1 subunits (23). This 
method would not be able to identify the putative transcript for the 190-kDa species, 
which does not contain domain I. Soong et al. systematically scanned the whole 
cDNA of human 1A using PCR primers, and each pair of primers spans 1-4 exons 
(218). This method would not be able to ascertain the putative transcript for the 
190-kDa species either, because the putative transcript is missing more than 10 exons 
(see 3.9) and none of their primer pairs spans so many exons. Rajapaksha et al. used 
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nested PCR with primers targeting the sequence of rat CaV2.1 II-III loop to identify 
splice variants that differs in the sequence of the II-III loop (224). Because these 
primers do not span all the missing exons in the putative transcript for the 190-kDa 
species, the putative transcript would not be identified either. Because we would like 
to identify a transcript for an N-terminally truncated protein and find out the origin of 
that transcript, it is important to obtain the sequence of 5’ end of the transcript. 
Therefore, 5’ RACE-PCR (280) would be an effective method. The putative transcript 
for the 190-kDa species would be missing at least exons 2-16 (see 3.9). A transcript 
with part of exon 1 would be a splice variant, while one completely without exon 1 






































The finding that the 190-kDa fragment of mouse 1A contains the C-terminal 
tail but not the N-terminal tail (see 3.6) implies the possibility that this fragment is a 
product of mid-channel proteolysis. Unfortunately, the surface biotinylation 
experiment could not answer the question whether the 190-kDa fragment exist on the 
plasma membrane (see 3.7). Therefore, we tried to address this question using 
immunofluorescence. 
In a previous study of the mid-channel proteolysis of the L-type calcium channel, 
“LGH3”, an 1C subunit tagged with EGFP on the N-terminus and HA on an 
extracellular loop of repeat III, was expressed in cultured rat hippocampal neurons. 
LGH3 was then labeled with an anti-HA antibody and Alexa594 under 
non-permeabilizing conditions and the neurons were visualized by confocal 
microscopy (4). The result revealed that LGH3 went onto the plasma membrane, and 
in some locations red (HA) did not colocalize with green (EGFP). These red-only 
clusters are consistent with the hypothesis that 1C can be proteolytically cleaved in 
the II-III loop, and further suggests that the cleavage products can dissociate from one 
another on the plasma membrane. Moreover, confocal microscopy with two additional 
EGFP/HA-tagged 1C subunits, LGH1 and LGH2 (HA-tagged extracellularly on 
repeat I and II, respectively), suggests that there might be also a cleavage site in the 
I-II loop. 
If the 190-kDa fragment of 1A exists on the plasma membrane, then very likely 
153 
 
it can dissociate from the complementary 80-kDa fragment, and immunofluorescence 
with EGFP/HA-tagged 1A will reveal the separation of fragment channels on the 
plasma membrane. 
 
4.2 Fixed-cell imaging in cultured neurons under non-permeabilizing conditions 
Four constructs of EGFP/HA-tagged human 1A were made. The four constructs 
are all tagged with EGFP on the N-terminus, and are tagged with HA extracellularly 
on different repeats. Thus they are named hPQGH1, hPQGH2, hPQGH3, and 
hPQGH4, respectively (Figure 14 A-D). Two-electrode voltage clamp recordings in 
Xenopus oocytes shows that all four constructs are able to be expressed on the plasma 
membrane and produce currents (Figure 14E). 
hPQGH3 were expressed in cultured rat hippocampal neurons and visualized by 
fixed-cell imaging as described in Materials and Methods. Briefly, cultured rat 
hippocampal neurons were transfected with hPQGH3 and 3. 36-48 h after 
transfection, neurons were fixed and subjected to immunocytochemistry under 
non-permeabilizing conditions with an anti-HA primary antibody (BioLegend 901502) 
and an Alexa594-conjugated secondary antibody (Life Technologies A-11005). What 
we expected to see was a red “ring” around each neuron that has green fluorescence, 
i.e., a membrane associated pattern of Alexa594, labeling the HA tag of hPQGH3 
expressed on the plasma membrane. However, the staining was highly nonspecific 
(Figure 15A). The fluorescence of Alexa594 appeared in neurons with and without 
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green fluorescence. Moreover, although the cells were stained under 
non-permeabilizing conditions, they seemed to be permeabilized. The fluorescence of 
Alexa594 can be seen in the cytoplasm and sometimes even the nuclei of the neurons. 
To troubleshoot, different conditions were tried in immunocytochemistry (Table 2) but 
could not eliminate the nonspecific staining and unwanted permeabilization. In an 
attempt to increase the expression level of hPQGH3 or improve the folding of 
hPQGH3, 2 was cotransfected with hPQGH3 and 3 in one group of neurons, and 
another group of neurons was kept at 30°C instead of 37°C after transfection before 
fixation. Neither of the conditions improved the staining, although keeping the 
neurons at 30°C did seem to increase the intensity of the green fluorescence (data not 
shown). hPQGH4 was also tried but the same problems arose. LGH3, previously 
shown to display distinct membrane-associated pattern of staining (4), was used as a 
positive control. The staining of LGH3 is much more specific and it showed a hint of 









































Figure 14. Four EGFP/HA-tagged human 1A constructs. Green square represents the EGFP 
on the N-terminus of the channel. Red dot represents the extracellular HA tag. (A-D) Membrane 
topology of hPQGH1, hPQGH2, hPQGH3 and hPQGH4, respectively. (E) Currents conducted by 
the wild-type human P/Q channel (hPQ) and the four tagged P/Q channels, measured by TEVC in 








































































Figure 15. Fixed-cell imaging in cultured rat hippocampal neurons under 
non-permeabilizing conditions. (A) Neurons transfected with hPQGH3 labeled with an anti-HA 
primary antibody and an Alexa594-conjugated secondary antibody. (B) Neurons transfected with 
LGH3 labeled with the same antibodies. Note that the Alexa594 signal is more associated with the 




Table 2. Different conditions tried for fixed-cell imaging with cultured neurons under 
non-permeabilizing conditions. 
Fixation conditions 2% paraformaldehyde solution 
4% paraformaldehyde solution 
Quenching after fixation Quenching with 0.1 M glycine solution 
No quenching 
Blocking conditions 0.5% fish gelatin and 2% goat serum in PBS 
10% goat serum in PBS 
Wash between primary and secondary 
incubations 
Wash with PBS 
Wash with PBS with 300 mM extra NaCl 
Auxiliary subunits 3 
3 + 2 
Culture temperature 37°C 
















4.3 Fixed-cell imaging in HEK 293T cells 
The experiments in 4.2 could not lead to a conclusion whether hPQGH3 can be 
expressed on the plasma membrane, since the red signal in the cytoplasm might have 
concealed the tiny amount of signal from the plasma membrane. Thus HEK 293T 
cells were tried for immunocytochemistry with hPQGH3 and other tagged 1A 
constructs. Although we know that mouse 1A is not expressed into the 190-kDa 
fragment in HEK 293T cells (Figure 7A), immunocytochemistry with HEK 293T 
might give us a clue whether the tagged 1A constructs can go to the plasma 
membrane and be recognized by the antibody. 
LGH3, hPQGH1-4, and hPQGH4x2 (a tagged human 1A with one more 
extracellular HA tag in repeat IV than hPQGH4), were transfected into different 
groups of HEK 293T cells along with 3 and 2. hPQGN, a human 1A subunit 
tagged with EGFP on the N-terminus without HA tags, was also cotransfected with 3 
and 2 as a negative control. Immunocytochemistry was done as described in 
Materials and Methods, with the same primary and secondary antibodies as in 4.2. All 
the tagged channel constructs were expressed, as indicated by the green fluorescence 
in some of the cells of each group. LGH3 showed distinct membrane-associated 
pattern of staining (Figure 16A). However, none of the tagged 1A constructs showed 
such pattern (Figure 16B). The EGFP/HA-tagged 1A constructs had very low 
fluorescence of Alexa594 in general, just like hPQGN. The high background staining 
and unwanted permeabilization seen in cultured neurons were not seen in HEK 293T 
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cells. These results indicate that the tagged P/Q channels expressed in HEK 293T cells 
either cannot adequately traffic to the plasma membrane or cannot be stained on the 






















Figure 16. Fixed-cell imaging in HEK 293T cells under non-permeabilizing conditions. (A) 
HEK 293T cells transfected with LGH3 labeled with an anti-HA primary antibody and an 
Alexa594-conjugated secondary antibody. Note the plasma membrane-associated staining pattern. 
(B) HEK 293T cells transfected with hPQGH3 showed poor labeling of the HA tag. hPQGH1, 





















4.4 Live-cell antibody feeding in cultured neurons 
The lack of staining of the tagged P/Q channels in HEK 293T cells cannot rule 
out the possibility that these tagged channels can go to the plasma membrane and be 
stained on the plasma membrane in culture neurons. However, the high background 
staining and unwanted permeabilization hinders further experiments in culture 
neurons with fixed-cell imaging. Thus the live-cell antibody feeding method was 
implemented to visualize tagged P/Q channels. 
Two groups of cultured rat hippocampal neurons were transfected with hPQGH3 
and hPQGH4, respectively, along with 3. The positive control group was transfected 
with 3 and L-SEP2-HA6, an 1C subunit tagged with a super-ecliptic pHluorin (SEP) 
extracellularly on repeat II and two HA tags extracellularly on repeat III. 36-48 h after 
transfection, live-cell antibody feeding was done as described in Materials and 
Methods. Briefly, live neurons were incubated with the anti-HA primary antibody 
before being washed, fixed and stained with the Alexa594-conjugated secondary 
antibody under non-permeabilizing conditions. All the tagged channels were able to 
be expressed in some neurons, as indicated by the green fluorescence. L-SEP2-HA6 
showed a distinct membrane-associated pattern of staining on the neurons with green 
fluorescence (Figure 17A). hPQGH3 and hPQGH4, however, had no staining at all 






















Figure 17. Live-cell antibody feeding in cultured rat hippocampal neurons. (A) Neurons 
transfected with L-SEP2-HA6 labeled with an anti-HA primary antibody and an 
Alexa594-conjugated secondary antibody. Note the plasma membrane-associated staining pattern 
and the absence of staining in non-transfected neurons. (B) Neurons transfected with hPQGH3 
stained with the same antibodies. Note that the HA tag cannot be detected. hPQGH4 showed a 
similar result. 
4.5 Fixed-cell imaging in cultured neurons under permeabilizing conditions 
Neither fixed-cell imaging nor live-cell antibody feeding enabled us to visualize 
the tagged 1A subunits on the plasma membrane of culture rat hippocampal neurons. 
Do the tagged 1A subunits not traffic to the plasma membrane, or are they not able 
to be stained by the anti-HA antibody because of steric hindrance? To address these 
questions, two groups of cultured rat hippocampal neurons were transfected with 
LGH3 and hPQGH3, respectively, and subjected to immunocytochemistry under 
permeabilizing conditions with the same antibodies as mentioned above. This time, 
the patterns of staining in LGH3 and hPQGH3 are very similar. Although there is 













consistently show stronger staining in the cytoplasm than the neurons without green 
fluorescence (Figure 18). This indicates that hPQGH3, like LGH3, can be stained by 
















Figure 18. Fixed-cell imaging in cultured rat hippocampal neurons under permeabilizing 
conditions. (A) Neurons transfected with LGH3 labeled with an anti-HA primary antibody and an 
Alexa594-conjugated secondary antibody. (B) Neurons transfected with hPQGH3 stained with the 
same antibodies. Note that transfected neurons (neurons with EGFP signal) have stronger 
Alexa594 signal than non-transfected neurons do. 
4.6 Discussion 
The imaging experiments with tagged 1A were performed to address two 
questions: 1) whether the 190-kDa fragment is expressed on the plasma membrane of 
neurons, and 2) whether the 190-kDa species dissociate from the complementary 
80-kDa fragment on the plasma membrane. Unfortunately, the tagged 1A constructs 
did not work well in the imaging experiments. 
In our fixed-cell imaging experiments under non-permeabilizing conditions and 













constructs consistently showed specific labeling on the plasma membrane (Figure 15B, 
16A and 17A), while those transfected with tagged 1A constructs did not show a 
membrane-associated pattern of staining (Figure 15A, 16B and 17B). This difference 
between tagged 1C and tagged 1A has been reported in previous studies.   
Watschinger et al. engineered a human 1A construct tagged with EGFP on the 
N-terminus and two consecutive HA tags in the extracellular loop adjacent to S5 in 
repeat IV, (only 2 residues away from where we inserted the HA tag in hPQGH4). 
They applied to live-cell antibody feeding experiments in culture mouse hippocampal 
neurons using a protocol similar to ours, and no staining of the channel by anti-HA 
antibodies was observed (281). In contrast, an extracellularly HA-tagged 1C could 
be stained with the same protocol (282). Another group reported that the 
above-mentioned tagged 1A construct “was not well exposed” on the surface of 
Neuro2A cells. However, an extracellularly HA-tagged 1B construct (with two 
consecutive HA tags in S3-S4 loop of repeat II) (283) could be stained by an anti-HA 
antibody in a membrane-associated manner in fixed Neuro2A cells under 
non-permeabilizing conditions (190). 
Our fixed-cell imaging experiments under permeabilizing conditions clearly 
indicates expression of both the tagged 1C and tagged 1A constructs in cultured rat 
hippocampal neurons (Figure 18). If the tagged 1A constructs are expressed, why 
can they not be stained on the plasma membrane like tagged 1C and 1B constructs? 
There are two possible reasons: 1) the tagged 1A does not traffic to the plasma 
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membrane, and 2) the HA tags in the tagged 1A constructs cannot be stained under 
the conditions used. Expression of tagged 1A on the plasma membrane can be 
confirmed using whole-cell patch recordings. The Tsien group reported that HEK 293 
cells transfected with human 1A (with 1C and 2) displayed robust whole-cell 
Ba2+ currents (~370 pA/pF), while those transfected with a nonfunctional mutant 1A 
displayed no detectable whole-cell Ba2+ currents (211). The Tsien group also reported 
that cultured 1A-knockout mouse hippocampal neurons transfected with human 1A 
displayed robust whole-cell Ba2+ currents (~110 pA/pF), of which more than half was 
conducted by P/Q-type channels (211, 284). They also showed that in cultured 
wild-type mouse hippocampal neurons, heterologous expression of human 1A 
doubled the whole-cell Ba2+ currents to ~150 pA/pF, of which about half was 
conducted by P/Q-type channels. However, in control neurons, which were 
transfected with EGFP, only ~1/5 of the currents were conducted by P/Q-type 
channels (211). These results indicate that heterologously expressed 1A subunits in 
HEK 293 cells and cultured mouse hippocampal neurons traffic to the plasma 
membrane and form functional channels. Note that in cultured mouse hippocampal 
neurons, the functional expression of human P/Q-type channels on the plasma 
membrane does not required extra auxiliary subunits (211, 284). The P/Q-type 
channel plays an essential role in synaptic transmission (1, 17), and it has been 
reported that the expression level of the P/Q-type channel is higher in the dendrites 
than in the somata of cerebellar Purkinje cells (42, 43). Thus it is reasonable to 
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assume that some, if not all, of the heterologously expressed P/Q channels are 
expressed on the plasma membrane of axon terminals and dendrites. Then can any 
heterologously expressed P/Q channels traffic to the surface of the somata? 
Watschinger et al. reported that the extracellularly HA-tagged human 1A could 
be labeled by anti-HA antibodies in cultured mouse hippocampal neurons after 
fixation under non-permeabilizing conditions. Yet, intracellular proteins such as 
synapsin and microtubule-associated protein 2 (MAP2) could also be stained by 
corresponding antibodies under the same conditions (281). These results suggest that 
the neurons were actually permeabilized, probably by paraformaldehyde during 
fixation, and the labeled 1A subunits might be intracellular instead of on the surface. 
The Tsien group reported that a human 1A construct with an extracellularly HA tag 
could be labeled by anti-HA antibodies in HEK 293 cells (coexpressing 1C and 2) 
under non-permeabilizing conditions after fixation, and the labeling displayed a 
membrane-associated pattern (225). A control experiment showed that the 
intracellular protein calmodulin (CaM) could not be stained by an anti-CaM antibody 
under the same condition (225). These results offer convincing evidence that 
heterologously expressed tagged human 1A can be expressed and stained on the 
surface of HEK 293 cells. Interestingly, our hPQGH2 construct, which has an 
extracellular HA tag in the exact same position as the HA tag in the construct used by 
the Tsien group, could not be stained in HEK 293T cells under non-permeabilizing 
conditions after fixation. The discrepancy is probably due to methodological 
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differences such as the different  subunits used (1C vs. 3) and the different 
methods of primary antibody incubation (4°C overnight vs. room temperature for 1 h). 
There is no doubt that heterologously expressed 1A constructs can be expressed 
in the cytoplasm of the somata of cultured hippocampal neurons from both mouse 
(281) and rat (Figure 18). Additionally, there is no doubt that heterologously 
expressed 1A constructs can form functional channels on the plasma membrane of 
the neurons (211, 284). However, whole-cell patch recordings cannot reveal in which 
parts of the neuron the channels are expressed on the plasma membrane. Nevertheless, 
because whole-cell patch clamp poorly controls voltage in the dendritic tree of 
neurons (285, 286), the whole-cell Ba2+ currents recorded in cultured mouse 
hippocampal neurons heterologously expressing human 1A (211, 284) are unlikely 
to come from merely the dendrites and axon terminals of the neurons. Moreover, 
single-channel P/Q-type currents were recorded on cell-attached patches on the soma 
of acutely isolated rat hippocampal CA1 pyramidal cells. However, P/Q-type currents 
were rarely observed on 9 of 68 patches, compared with L-type currents which were 
observed on 267 of 502 patches (287). Therefore it is reasonable to surmise that 1A 
constructs heterologously expressed in cultured hippocampal neurons can traffic to 
the plasma membrane of the somata. However, to our knowledge, there has been no 
report of successful labeling of endogenous or heterologous 1A in neurons under 
true non-permeabilizing conditions. 
Considering that the lack of labeling of the tagged 1A constructs on the plasma 
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membrane might be due to inadequate surface expression of the tagged channels, we 
have tried several strategies to increase surface expression of the tagged 1A 
constructs. Although it has been reported that heterologous expression of human 1A 
on the surface of cultured hippocampal neurons does not require extra auxiliary 
subunits (211, 284), we tried cotransfecting 2 along with hPQGH3 and 3, which 
did not improve the labeling of surface hPQGH3 (see 4.2). We also tried substituting 
2a for 3 in fixed-cell imaging experiments in HEK 293T cells under 
non-permeabilizing conditions, and obtained no improvement of the labeling of 
hPQGH3 (data not shown). It has been shown that temperature influences the folding 
efficiency of GFP (288-290) and even the functions of GFP fusion proteins (289). At 
37°C, GFP has poor folding efficiency in mammalian cells (288, 289) and E. coli 
(290), and a GFP-fused transcription factor gives no transactivation (289). At 15-30°C, 
however, the folding efficiency of GFP (288-290) and the function of the GFP-fused 
transcription factor (289) are significantly improved. Although EGFP has been shown 
to fold efficiently at both 37°C and 28°C (290), our results show that incubating 
transfected neurons at 30°C enhances the green fluorescence of hPQGH3 (data not 
shown), suggesting that a low temperature improves the folding efficiency of the 
EGFP tag in hPQGH3. Labeling of hPQGH3 under non-permeabilizing conditions, 
however, is not improved by the low temperature (data not shown). Low temperature 
of 15-20°C has been shown to have a dual effect of improving the folding efficiency 
of GFP and arresting vesicular protein transport at the trans-Golgi network in HeLa 
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cells (288). Restoring the temperature to 37°C after low temperature treatment ensures 
both efficient folding and secretion of a GFP-fused secretory protein (288). Incubation 
at 30°C might inhibit trafficking of hPQGH3 to the plasma membrane, and restoring 
the temperature to 37°C might be necessary to obtain robust surface expression of 
hPQGH3. 
Moreover, single-channel recordings on cell-attached patches revealed that on 
the plasma membrane of the somata of acutely dissociated mouse cerebellar Purkinje 
cells, P/Q-type channels are robustly expressed (recorded on 21 of 24 patches) and the 
P/Q-type current comprises ~85% of the whole-cell Ba2+ current (291). In contrast, on 
the soma of acutely isolated rat hippocampal CA1 pyramidal cells, single-channel 
P/Q-type currents were rarely observed (on 9 of 68 patches), compared to L-type 
currents (observed on 267 of 502 patches) (287). Because of the relatively high 
surface expression of P/Q-type channels in cerebellar Purkinje cells, substituting 
cerebellar Purkinje cells for hippocampal neurons in the imaging experiments may 
improve the labeling of tagged 1A on the surface. However, poor surface expression 
may not be the reason or the only explanation for the lack of labeling of tagged 1A 
on the surface. The lack of labeling may be due to poor exposure of the HA tag to the 
extracellular space or steric hindrance of antibody binding. It is surprising that of 
several tagged 1A constructs with the HA tags on different positions that our lab 
(Figures15,17) and other groups (281) tried, none displayed a distinct 
membrane-associated pattern of staining in hippocampal neurons under true 
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non-permeabilizing conditions. Moreover, hPQGH1-4 and hPQGH4x2 all failed to be 
labeled in HEK 293T cells under non-permeabilizing conditions, although it has been 
reported that a construct similar to hPQGH2 displayed a distinct membrane-associated 
pattern of staining in HEK 293 cells under non-permeabilizing conditions (225). 
These results suggests that if the lack of labeling is due to steric hindrance, the steric 
hindrance is not localized to a certain extracellular loop, but is present in the whole 
extracellular portion of the 1A subunit. 
Taken together, imaging experiments that our group and others performed with 
HA-tagged 1A have raised a lot of questions about surface P/Q-type channels. More 
studies are needed to answer these questions. Compared with immunocytochemistry, 
electrophysiology is a more direct method to detect ion channels on the plasma 
membrane. Therefore, it would be best to first use single-channel, inside-out or 
outside-out patch recordings to confirm that our tagged 1A constructs can be 
expressed on the surface of cultured neurons, and in which parts of the neuron the 
channels are expressed on the surface. Once the expression of the tagged 1A 
constructs on the plasma membrane is confirmed, we can further explore how to make 
the channels stainable from the extracellular side. Other tags, such as 
polyhistidine-tags and bungarotoxin-binding site, can be tried and may overcome the 
steric hindrance. Using antibodies directly against extracellular loops of 1A is also 
an alternative. In addition, structural studies of 1A may shed light on the 



























The experiments in Chapter 3 indicate that the 190-kDa fragment of mouse 1A 
contains part of the II-III loop, repeat III, III-IV loop, repeat IV and all or part of the 
C-terminal tail, including the histidine tract, and is missing all or part of the 
N-terminal tail. Thus, it is probable that the 190-kDa fragment is a product of 
mid-channel proteolysis, whose cleavage site is in the II-III loop. This mid-channel 
proteolysis would also produce a product of 80-kDa, N-terminal to the cleavage site. 
Western blot analysis with the II-III loop antibody revealed that most of the 1A 
subunits in the mouse brain are truncated forms instead of the full-length form (Figure 
5). Why do the cells produce these “fragment channels”? Do these fragment channels 
conduct currents? Do they interact with full-length channels? Do they alter the 
electrophysiological properties of full-length channels? 
 
5.2 Functional properties of fragment-channels produced by cleavage in the 
II-III loop of 1A 
Two constructs of truncated human 1A were made as if they were the products 
of a proteolytic cut in the II-III loop (Figure 19A). The cleavage site was chosen to be 
between N719 and A720. The two fragments are named B1 and B2, and have 
molecular weights of 81 kDa and 201 kDa, respectively. An equivalent cleavage site 
in mouse 1A would produce two fragments of 81 kDa and 187 kDa, respectively, 
corresponding to our finding in the Western blot experiments described in Chapter 3. 
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cRNAs of B1 and B2, either individually or together, were injected into oocytes of 
Xenopus laevis along with the cRNAs of the 3 and 2 subunits. Full-length human 
1A was used as a positive control. Current-voltage (I-V) relationship was determined 
using two-electrode voltage clamp (TEVC) as described in Materials and Methods. 
Full length human 1A produced currents with an average peak value of about -8 A, 
while B1 and B2 did not produce currents when they are expressed individually or 
coexpressed (Figure 19B). 
Next, the influences of the B1 and B2 fragments on full-length 1A were tested. 
Full-length human 1A was expressed alone or coexpressed with B1 or B2, along 
with the auxiliary subunits, in Xenopus oocytes. I-V relationship and voltage 
dependence of steady-state inactivation were determined using TEVC. The result 
shows that B1 reduces the average peak current of the full-length channel for about 
50%, while B2 does not have a significant effect on the peak current amplitude of the 
full-length channel (Figure 19C). Neither B1 nor B2 had an obvious effect on the 
shape of the I-V curve or the steady-state inactivation curve of the full-length channel 









































Figure 19. Functional properties of fragment-channels hPQB1 and hPQB2. (A) Schematic 
structures of hPQB1 and hPQB2. Red segment denotes the synprint site. (B) hPQB1 and hPQB2 
do not conduct currents when expressed individually or together. (C) hPQB1 significantly reduces 
currents of full-length P/Q channel, while hPQB2 does not have a significant effect on the current 
amplitude of full-length P/Q channel. (D) Neither hPQB1 nor hPQB2 alters the I-V relationship of 
steady-state inactivation of full-length P/Q channel. (E) Neither hPQB1 nor hPQB2 alters the 
voltage-dependence of steady-state inactivation of full-length P/Q channel. All experiments were 
done using bath solution containing 4 mM of Ba2+, except the experiment in (B), which was done 
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5.3 Functional properties of fragment-channels produced by cleavage in the I-II 
loop and the III-IV loops of 1A 
It is possible that the I-II loop and III-IV loop of the mouse 1A may also be 
subject to proteolytic cleavage. The 1 subunits of the L-type calcium channel and the 
voltage-gated sodium channel have both been shown to have more than one cleavage 
site (4, 158). The 140-kDa band detected by the N-terminus antibody in cultured 
mouse cortical neurons (Figure 6B) might be the N-terminal product of a proteolytic 
cut in the III-IV loop, whose theoretical molecular weight is ~170 kDa. Thus, we 
would also like to know the functional properties of the proteolytic products of these 
cleavage sites. Therefore, two more sets of 1A fragments were made (Figure 20 A 
and B). Fragments A1 and A2 correspond to a proteolytic cut in the I-II loop, while 
fragments C1 and C2 correspond to a proteolytic cut in the III-IV loop. These 
fragments were also expressed in the Xenopus oocytes and characterized using TEVC. 
None of these four fragment channels produced currents by themselves. When 
coexpressed, however, A1 and A2 did produce currents comparable to those 
conducted by full-length channels (Figure 20C). The I-V curve of the currents 
conducted by A1 and A2 is also very similar to that of the full-length channel (Figure 
20D). When coexpressed with the full-length channel, none of the four fragments had 
a significant effect on the current amplitude of the full-length channel, although the 
average current conducted by full-length channels with A2 is significantly larger than 
with A1 (Figure 1 E and F). None of the fragments changed the I-V relationship or the 
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Figure 20. Functional properties of fragment-channels produced by cleavage in the I-II loop 
and the III-IV loops of 1A. (A) Schematic structures of hPQA1 and hPQA2. Red segment 
denotes the -interaction domain (AID). (B) Schematic structures of hPQC1 and hPQC2. (C) 
hPQA1 and hPQA2, when coexpressed, conduct currents comparable to those conducted by 
full-length P/Q channel. (D) I-V relationship of the channel formed by hPQA1 and hPQA2 is 
similar to that of the full-length P/Q channel. (E-J) None of the four fragment-channels 
significantly alters the current amplitude (E and F), I-V relationship (G and H) or 
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5.4 Expression of fragment-channels 
Previous results from our lab shows that all three complementary pairs of L-type 
fragment channels are functional (4). Among the three complementary pairs of 
P/Q-type fragment channels, however, only one pair produced currents. We would like 
to know why the other two pairs cannot produce currents. Is it because the proteins of 
the fragment channels cannot be synthesized? Can the reason be that the fragment 
channels do not go to the plasma membrane? Is it because the complementary pair of 
fragment channels cannot form a functional channel? 
To answer these questions, tagged P/Q fragment channels were expressed in 
Xenopus oocytes and analyzed using Western blot, as described in Materials and 
Methods. In brief, the N-terminal fragments, (A1, B1, and C1), were tagged with 
FLAG, and the C-terminal fragments, (A2, B2, and C2), were tagged with HA. 
cRNAs of each complementary pair of tagged 1A subunits were coinjected into 
Xenopus oocytes, along with 3 and 2. Because A1 and A2 produced currents when 
coinjected, we know that they can be expressed and form functional channels on the 
plasma membrane, and thus A1 and A2 were used as a positive control. Uninjected 
oocytes were used as a negative control. Five days after injection, cell surface protein 
was isolated using surface biotinylation and protein samples were prepared for 
Western blot, as described in Materials and Methods. Briefly, the oocytes were 
subjected to either surface biotinylation or mock biotinylation, in which no 
sulfo-NHS-SS-biotin was added. The membrane fraction was isolated using 
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ultracentrifugation, and NeutrAvidin Agarose was used to pull down the biotinylated 
proteins. Both the flow-through and the eluate from the NeutrAvidin Agarose were 
analyzed using Western blot with anti-FLAG and anti-HA antibodies. 
In the first experiment, FLAG-B1 and HA-B2 were analyzed, with FLAG-A1 
and HA-A2 as positive controls. FLAG-A1 and HA-A2 were both detected in the 
flow-through, as expected (Figure 21 A and C). Additionally, FLAG-B1 and HA-B2 
were also detected in the flow-through (Figure 21 A and C). These results suggest that 
both fragments were expressed. In the eluates, we expected to see FLAG-A1 and 
HA-A2 detected in the biotinylated group, but not in the mock-treated group. 
However, the two fragments were detected in both the biotinylated group and the 
mock-treated group (Figure 21 B and D). Therefore, the fragments can 
non-specifically bind to the NeutrAvidin Agarose.  
Nevertheless, more HA-A2 was detected in the eluate of the biotinylated group 
than in the eluate of the mock-treated group. This indicates that the HA-A2 on the 
plasma membrane was able to be biotinylated. Unfortunately, the bands of FLAG-A1 
in the biotinylated group and the mock-treated group have almost the same intensity, 
which is probably since the non-specific binding of FLAG-A1 to the NeutrAvidin 
Agarose was so strong that it concealed the effect of biotinylation. HA-B2 was also 
detected in both the biotinylated group and the mock-treated group (Figure 21D). Like 
HA-A2, more HA-B2 was detected in the eluate of the biotinylated group than in the 
eluate of the mock-treated group, which suggests that HA-B2 can go to the surface. 
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Very little FLAG-B1 were detected in the eluates (Figure 21B), indicating that B1 
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Figure 21. Expression of fragment-channels in the cytoplasm and on the plasma membrane 
of Xenopus oocytes. (A-D) Western blot analysis of oocytes expressing FLAG-B1 and HA-B2, 
with oocytes expressing FLAG-A1 and HA-A2 as positive controls and uninjected oocytes as 
negative controls. All four fragment-channels were detected in the flow-through (A and C). 
Similar amounts of FLAG-A1 were detected in the eluates of both the biotinylated and 
mock-treated groups (B). FLAG-B1 is not detected in the eluates (B). More HA-A2 and HA-B2 
were detected in the eluate of the biotinylated group than in the eluate of the mock-treated group 
(D). (E-H) Western blot analysis of oocytes expressing FLAG-C1 and HA-C2, with oocytes 
expressing FLAG-A1 and HA-A2 as positive control and uninjected oocytes as negative control. 
All fragment-channels were detected in the flow-through, except FLAG-C1 (E and G). More 
FLAG-A1, HA-A2 and HA-C2 were detected in the eluate of the biotinylated group than in the 
eluate of the mock-treated group (F and H). (I) In the whole-cell lysate, FLAG-C1 could not be 
detected either, while FLAG-A1 could be detected. Because in some samples multiple bands were 
detected, bands of interested were indicated by red arrows. Small pictures show the bands in the 
red squares in the pictures above with a shorter exposure time. Theoretical molecular weights of 
the fragment-channels: FLAG-A1, 51 kDa; HA-A2, 234 kDa; FLAG-B1, 82 kDa; HA-B2, 203 
kDa; FLAG-C1, 173 kDa; HA-C2, 112 kDa. 
 
In the second experiment, FLAG-C1 and HA-C2 were analyzed, with FLAG-A1 
and HA-A2 as positive control. Again, FLAG-A1 and HA-A2 were both detected in 
the flow-through and the eluates of both the biotinylated group and the mock-treated 
group (Figure 21 E-H). This time, both FLAG-A1 and HA-A2 have a stronger band in 
the biotinylated group than in the mock-treated group, indicating that surface 
FLAG-A1 and HA-A2 could be biotinylated. The biotinylated FLAG-A1 and HA-A2 
could be pulled down by the NeutrAvidin Agarose, although there is also non-specific 
binding of FLAG-A1 and HA-A2 to the NeutrAvidin Agarose. HA-C2 was also 
detected in both the flow-through and the eluates (Figure 21 G and H), and more 
HA-C2 was detected in the eluate of the biotinylated group than in the mock-treated 
group, indicating that HA-C2 was expressed and transported to the plasma membrane. 
Surprisingly, FLAG-C1 was not detected in the flow-through or in the eluates (Figure 
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21 E and F). Was FLAG-C1 not expressed? Note that in this experiment, only the 
membrane fraction of the oocytes was isolated and analyzed using Western blot. 
Could the FLAG-C1 be only in the cytosol? In another experiment, we tested the 
whole-cell lysate instead of the membrane fraction, and found that FLAG-C1 cannot 
be detected either (Figure 21I). 
In summary, the above biochemical experiments show that all the 1A fragments 
can be expressed except C1, which can explain the lack of currents when C1 and C2 
are coexpressed. Because of non-specific binding of non-biotinylated 1A fragments 
to the NeutrAvidin Agarose, surface expression of the fragment channels is 
ambiguous. Nevertheless, C2 and B2 did show a hint of surface expression, while B1 
seemed to lack surface expression. This finding can explain the lack of currents when 
B1 and B2 are coexpressed. 
 
5.5 Discussion 
  5.5.1 Why is C1 not expressed? 
By injecting oocytes with cRNAs, we obtained protein expression of all of the 
six engineered truncated 1A subunits except C1 (Figure 21). The absence of C1 
protein might be due to several reasons. Firstly, the cRNA might be unstable in 
oocytes and was degraded, which can be confirmed by Northern blot analysis. Most 
eukaryotic mRNAs require a 7-methyl guanosine (m7G) cap structure at the 5’ end 
and a poly (A) tail at the 3’ end to be stable and efficiently translated. RNA Cap 
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Structure Analog m7G(5')ppp(5')G (New England Biolabs S1404S) is always included 
in our in vitro RNA synthesis system, and the DNA templates for RNA synthesis 
always include a poly (A) stretch downstream of the open reading frame. Thus the 
lack of a cap structure or a poly (A) tail is unlikely to be the reason for any RNA 
instability. However, because C1 is a truncated protein and its cRNA contains a 
premature stop codon, RNA degradation may result from nonsense-mediated mRNA 
decay (NMD) (292). NMD is a quality control process that degrades mRNAs 
containing premature stop codons, thereby repressing the production of truncated and 
potentially harmful proteins (292).  
Secondly, the cRNA of C1 may not be able to be translated. There are two main 
methods of improving translation of cRNA in Xenopus oocytes (293). One is to 
remove the RNA secondary structures in the regions flanking the coding sequence. 
Another method is to use a vector containing the 5’ and 3’ untranslated regions (UTRs) 
of the Xenopus -globulin gene, such as the pSP64T vector (Addgene 15030) (293).  
Thirdly, C1 may be recognized as an unfolded or misfolded protein by the 
endoplasmic reticulum (ER) and induce the unfolded protein response (UPR) or 
endoplasmic reticulum-associated degradation (ERAD) (94). UPR results in 
translation arrest and mRNA destabilization (214, 215). A certain amount of unfolded 
or misfolded protein is required for UPR to take place, and UPR blocks the translation 
of a broad range of proteins (214). Because the C1 protein was completely absent 
while the C2 protein in the same oocytes was robustly expressed (Figure 21 E and G), 
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UPR is unlikely to be the reason for the lack of expression of C1. Misfolded proteins 
can also be retained in the ER and degraded by the proteasome, through a mechanism 
called endoplasmic reticulum-associated degradation (ERAD) (94). This mechanism 
has been shown in HEK 293 cells to be the way in which degradation of the 
EA2-causing truncated 1A, R1281X occurs (178). A simple way to test the presence 
of ERAD is to apply proteasome inhibitors and see whether C1 protein can be 
detected. 
Interestingly, the other two engineered C-terminally truncated 1A, A1 and B1, 
were both able to be expressed. Why C1 is the only fragment-channel that was unable 
to be expressed is unknown. What is more interesting is that C1 resembles two 
EA2-causing truncation mutants with premature stop codons in the III-IV loop, 
R1549X (206) and Q1564X (207) (see GenBank AF004884). However, a lack of 
protein expression, or haploinsufficiency can hardly explain the pathogenesis of these 
truncation mutants (210). Actually R1549X has been studied and was shown to be 
able to be expressed in COS-7 cells (202) and HEK 293T cells 141 (199). R1549X 
was also shown to have a dominant negative effect on full-length CaV2.1 in Xenopus 
oocytes (203) and HEK 293T cells (199). C1, however, not only lacked protein 
expression, but also failed to influence the currents of full-length CaV2.1 (Figure 20 F, 
H and J). Additionally, the truncation sites of C1 and R1549X are only 24 amino 
residues apart. Why do two truncation mutants so similar to each other display such 
different properties? It is crucial to study C1, R1549X and Q1564X in parallel, 
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confirm their different properties, and explore the causes of their different properties. 
 
  5.5.2 A1 and A2 form a functional channel 
The complementary fragment-channels, A1 and A2, when coexpressed, conduct 
Ba2+ currents as strong as those conducted by full-length CaV2.1, indicating that the 
complementary pair of fragment-channels can associate with each other and form a 
functional channel. The phenomenon that complementary fragment-channels form a 
function channel is common among VGCCs. The two-domain forms of 1B, 
CaV2.2-Dom I-II and CaV2.2-Dom III-IV, when expressed individually along with 
auxiliary subunits 1b and 2-1 in COS-7 cells, do not conduct currents, but when 
coexpressed, they form functional channels that conduct low-density whole-cell 
currents with properties similar to full-length CaV2.2 (187). Six engineered truncated 
1C subunits corresponding to the six engineered truncated 1A subunits were 
studied in Xenopus oocytes (4). None of the fragment-channels conducts currents by 
itself, but each complementary pair of fragment-channels conducts whole-cell 
currents of lower density than the full-length channel (4). Interestingly, the currents 
conducted by each complementary pair of truncated L-type channels display a 
positive shift in the I-V relationship and the voltage dependence of steady-state 
inactivation (4). In contrast, the currents conducted by coexpressed A1 and A2, have 
an I-V curve similar to that of the full-length channel (Figure 20D) (steady-state 
inactivation was not tested), and the currents conducted by the complementary pair of 
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truncated N-type channels showed a slight positive shift in the I-V curve but no shift 
in the voltage-dependence of steady-state inactivation (187). These results have 
revealed that mid-channel proteolysis may influence the coupling between voltage 
sensing and gating of different channels in different manners. 
It is not surprising that two complementary fragments of a protein can assemble 
into a complex with a similar function to the full-length protein. Such phenomena 
have been observed elsewhere too. The mechanism of the inactivation of the 
Drosophila melanogaster rapidly inactivating potassium channel, shaker (ShB), could 
be well explained by the ball and chain model originally proposed for voltage-gated 
sodium channels (294). The first 20 amino acid residues in the N-terminus of ShB 
channel form the channel-blocking ball, which is connected to the rest of the channel 
by a chain of 60 or more amino acid residues (295). A mutant ShB channel without 
amino acid residues 6-46, ShB6-46, does not inactivate with a rapid time course 
(295, 296). Interestingly, application of a peptide corresponding to the 
channel-blocking ball to the cytoplasmic side of ShB6-46 restores the rapid 
inactivation (295). Later studies revealed that the ball occludes the channel through a 
long-range electrostatic interaction, which increases the rate of diffusion of the 
peptide to the binding site (297). The genes encoding four-domain ion channels, such 
as CaV and NaV channels, might have evolved by two rounds of gene duplication of a 
gene encoding an ancestral single-domain voltage-gated potassium (KV) channel, 
which contains six transmembrane helices (TMs) like each domain (repeat) of a CaV 
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or NaV channel (180, 181). Although a CaV or NaV 1 subunit and a KV 1 subunit 
have different numbers of domains, the structures of the three types of channels are 
similar. While a CaV or NaV channel contains a single 1 subunit organized into a 
pseudo-tetrameric structure (30, 298, 299), a KV channel contains four identical 1 
subunits organized into a homotetrameric structure (300). The tetramerization of KV 
1 subunits relies on the specific interaction between the 1 subunits. The T1 domain 
formed by the N-termini of the four 1 subunits contains characteristic residues in the 
subunit interface, which are crucial for subfamily-specific tetramerization of the KV 
1 subunits (301). Before the high-resolution crystal structure of CaV1.1 was solved 
(30), structural interpretation of CaV or NaV channels had mainly been based on the 
crystal structures of homotetrameric channels formed by four single-domain 1 
subunits. Therefore it is not surprising that a complementary pair of truncated CaV1 or 
CaV2 channels can associate to form a functional channel, just like the four 
single-domain KV 1 subunits can. 
 
  5.5.3 Why do B1 and B2 not conduct currents when coexpressed? 
It is strange that no current was detected in Xenopus oocytes coexpressing B1 
and B2 (Figure 19B), while equivalent pairs of truncated CaV1.2 and CaV2.2 could 
form functional channels that conduct currents (4, 187). A simple explanation for this 
finding is that B1 did not traffic to the plasma membrane, as shown in the results of 
the surface biotinylation experiments (Figure 21B). However, P1219X (see Table 1), a 
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truncated 1A resembling B1, has been shown to be able to traffic to the plasma 
membrane when expressed in mouse skeletal muscle myotubes (152) or tsA-201 cells 
(6), although it could not conduct currents (152). It has also been shown that P1219X 
has a suppressive effect on full-length CaV2.1 currents, probably by competing with 
the full-length 1A for the  subunits (6). B1 also suppresses full-length CaV2.1 
currents (Figure 19C). Its lack of expression on the plasma membrane is an interesting 
difference from P1219X.  
Western blot analysis shows that the expression level of B1 protein in the 
cytoplasm is relatively low among all the fragment-channels expressed in Xenopus 
oocytes (Figure 21A). Thus it is possible that B1 was expressed on the plasma 
membrane, but the amount of B1 on the plasma membrane was too low to be detected. 
We can try to increase the expression level of B1 by adjusting the amount of cRNA 
injected. Substituting an anti-reverse cap analog (ARCA, 3’-O-Me-m7G(5')ppp(5')G, 
New England Biolabs S1411) for the standard cap analog (m7G(5')ppp(5')G, New 
England Biolabs S1404S) also can increase the expression level. The standard cap 
analog can be incorporated into cRNA in two alternative orientations, resulting in only 
50% of capped cRNA that is translatable. In contrast, ARCA is incorporated into 
cRNA exclusively in the correct orientation, resulting in twice the amount of 
translatable cRNA. 
If increasing the expression level cannot give rise to detectable surface 
expression of B1, it would be interesting to study whether surface expression of B1 
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can be induced by fusing B1 with a membrane-targeting sequence and whether this 
can facilitate the formation of functional channels with B2. It has been reported that 
CD4 fused to a short fragment of CaV1 subunit can facilitate the transport of the 
fragment to the plasma membrane of mammalian cells (84, 193). CD4 is a 
glycoprotein expressed on the surface of T lymphocytes and other immune cells, and 
is a single-pass transmembrane protein with an extracellular N-terminus and an 
intracellular C-terminus (302). It has been reported that a fusion protein containing the 
proto-oncogene protein Wnt-1 whose C-terminus is fused to CD4 can be transported 
to the plasma membrane as a transmembrane protein in Xenopus embryos (303). 
Fusing CD4 to the N-terminus of our B1 fragment-channel may promote the 
expression of B1 on the plasma membrane and subsequently facilitate the association 
of B1 and B2 to form functional channels. Moreover, a C-terminal CAAX motif 
promotes prenylation and palmitoylation of the C-terminus of the protein, thereby 
allowing the protein to associate with intercellular membrane and subsequently the 
plasma membrane in both mammalian cells (304, 305) and Xenopus oocytes (306). 
Adding a CAAX motif to the C-terminus of non-membrane proteins, such as GFP and 
the N-terminal tail of CaV2.2, effectively induces the association of the proteins with 
the plasma membrane (189, 190). Therefore, adding a CAAX motif to the C-terminus 
of B1 may also promote the expression of B1 on the plasma membrane and 
subsequently facilitate the association of B1 and B2 to form functional channels. A 
palmitoylation sequence (MTLESIMACCL) also has also been shown to target a 
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protein to the plasma membrane (116), and thus can also be tried. 
If promoting the surface expression of B1 cannot induce the formation of 
functional channels, we can infer that B1 and B2 either cannot form a complex or 
form a complex without channel function. The formation of the B1-B2 complex can 
be tested by coimmunoprecipitation (co-IP). If B1 and B2 cannot form a complex, it 
would be interesting to study whether adding specific sequences to B1 and B2 can 
induce the association of B1 and B2 and subsequently lead to the formation of a 
functional channel. Coiled coils are a common structure responsible for protein 
complex formation. For example, trimerization of a coiled-coil domain in the 
C-terminus of TRPP2 is crucial for the formation of the TRPP2 trimer and the 
TRPP2/PKD1 complex, which contains 3 TRPP2 and 1 PKD1 (307). We can fuse the 
C-terminus of B1 and the N-terminus of B2 respectively to the two strands of a coiled 
coil, which can be either from a natural protein, such as the transcriptional activator 
GCN4 (308), or designed de novo (309). Coexpression of these two fusion proteins 
may lead to association of B1 and B2 and formation of a functional channel. 
Our lab has previously examined the acute effect of mid-channel proteolysis on 
the functional properties of CaV2.1 by inserting tobacco etch virus protease (TEVp) 
cleavage sites (with the sequence ENLYFQG) into the I-II loop and II-III loop of 1A. 
We then measured the changes in currents upon TEVp treatment using macropatch 
recordings on inside-out patches from Xenopus oocytes (4). The result showed that a 
2-min treatment with purified TEVp did not abolish CaV2.1 currents, but caused an 
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irreversible left shift of the activation curve (4). These findings were in accordance 
with an increase in the coupling between voltage sensing and channel opening. In 
contrast, when the complementary fragment-channels B1 and B2 were coexpressed in 
Xenopus oocytes, no currents were detected (Figure 19B). These two results are 
compatible with each other. In the first case, the full-length 1A was already on the 
plasma membrane before it was cleaved, and thus the resultant fragment-channels will 
likely stay on the plasma membrane for some time, although the further fate of the 
fragment-channels is yet to be studied. In the second case, the two fragment-channels 
were expressed separately and would need to associate with each other properly and 
traffic to the plasma membrane to form a functional channel. Failure in any of these 
steps would lead to an absence of functional channels on the plasma membrane. 
 
  5.5.4 Possible mechanisms underlying the dominant negative effect of B1 
Of all the engineered P/Q-type fragment-channels (except C1 which was not 
expressed), only B1 significantly altered full-length CaV2.1 currents. B1 decreases the 
current amplitude of full-length CaV2.1 without altering the I-V relationship or 
voltage dependence of steady-state inactivation. This result differs from those 
obtained with L-type and N-type fragment-channels. Six L-type fragment-channels 
were engineered, similarly to the six P/Q-type fragment-channels (4). Of the six 
engineered L-type fragment-channels, B1 (1C) and B2 (1C) are the only ones that 
does not show any significant effect on full-length CaV1.2 currents, and C2 (1C) is 
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the only one that suppresses full-length CaV1.2 currents (4). All the other L-type 
fragment-channels only influence the I-V relationship or voltage dependence of 
steady-state inactivation of full-length CaV1.2 currents (4). In the case of N-type 
fragment-channels, CaV2.2-Dom I-II, CaV2.2-Dom III-IV(187), CaV2.2-Dom I (188), 
CaV2.2 without the N-terminal tail and even the N-terminal tail itself (189) all have a 
suppressive effect on full-length CaV2.2 currents without affecting the I-V or 
steady-state inactivation curves. 
The suppressive (dominant negative) effect of B1 on full-length CaV2.1 currents 
may be due to the following reasons: 1) B1 decreases full-length CaV2.1 mRNA level; 
2) B1 decreases full-length CaV2.1 protein level; 3) B1 suppresses the trafficking of 
full-length CaV2.1 to the plasma membrane; 4) B1 alters the single-channel properties 
of full-length CaV2.1. The dominant negative effects of several truncated forms of 
CaV2.1 and CaV2.2 have been studied and three different mechanisms have been 
suggested to underlie the dominant negative effects (see 1.7.2.4). Firstly, some 
fragment-channels (e.g., CaV2.2-Dom I and CaV2.1-P1217fs) suppress the synthesis of 
the cognate full-length channel by associating with the full-length channel and 
initiates the unfolded protein response (UPR). This subsequently leads to translation 
arrest and mRNA destabilization of the full-length channel and other proteins. UPR 
leads to a decrease in both the mRNA and protein levels of the full-length channel. 
Secondly, some fragment-channels (e.g., the EA2-causing truncated 1A R1281X) 
promote the degradation of full-length channel protein though a “destructive 
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interaction mechanism” (DIM) involving ER-associated degradation (ERAD). This 
mechanism leads to a decrease in the protein level of the full-length channel. Thirdly, 
some other fragment-channels (e.g., 1A truncation mutants 402X and P1219X) 
compete with the full-length channel for  subunits. This mechanism suppresses the 
trafficking of the full-length channel to the plasma membrane and may also alter the 
single-channel properties of the full-length channel. 
The fragment-channel B1 (A720X) is truncated near the beginning of the II-III 
loop, remotely resembling a previously studied P/Q-type fragment-channel, P1219X 
(6, 152) (equivalent to R1213X in AF004884), which is truncated near the end of the 
II-III loop. Evidence suggests that P1219X exerts its dominant negative effect by 
competing with full-length 1A for  subunits (6). It is possible that B1 also 
suppresses full-length CaV2.1 currents through this mechanism. However, A1, which 
also contains the -interaction domain (AID) and thus can presumably bind to  
subunits, does not have a dominant negative effect (Figure 20E). Therefore, we 
surmise that competition with full-length 1A for  subunits is unlikely the 
mechanism underlying the dominant negative effect of B1. 
It has been shown that two-domain truncated forms of 1A and 1B not only 
suppress the cognate full-length channels, but also cross-suppress the currents of other 
members of the CaV2 family (188). These findings indicate that the dominant negative 
effects of two-domain truncated forms of 1A and 1B may share the same 
mechanism. Of the truncated forms of 1A and 1B studied, none has a biologically 
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significant effect on the activation and inactivation parameters of the corresponding 
full-length channel (Table 1) (187-189). Moreover, CaV2.2-Dom I-II, despite 
suppressing full-length CaV2.2 currents, does not alter the single-channel properties of 
full-length CaV2.2 (187). Therefore, it is unlikely that B1 suppresses full-length 
CaV2.1 currents by binding to the full-length channel and altering the single-channel 
properties. 
Studies from the Dolphin group suggest that the mechanism underlying the 
dominant negative effects of CaV2.1-P1217fs, CaV2.2-Dom I and CaV2.2-Dom I-II is 
the unfolded protein response (UPR). This response involves the endoplasmic 
reticulum resident RNA-dependent protein kinase (PERK) and results in translation 
arrest and mRNA destabilization of full-length CaV2 and other proteins (187, 188). 
They also provided evidence that the mechanism does not rely on the sequestration of 
 subunits or the ubiquitin-proteasome pathway (187, 188). 
However, other studies revealed that EA2 truncation mutants Q681fs and 
R1281X exert their dominant negative effects through a “destructive interaction 
mechanism” (DIM) involving ER-associated degradation (ERAD), which relies on 
ubiquitin-proteasome pathway (178, 199, 203). Q681fs and R1281X both remotely 
resemble P1217fs studied by the Dolphin group (Figure 2). Their different 
mechanisms of dominant negative effects may be due to the slight differences in their 
truncation sites, but may also be due to methodological differences between different 
studies. Our fragment-channel B1, which remotely resembles all the above three 
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mutants, may exert its dominant negative effect through UPR and/or DIM. Further 
studies will be needed to reveal the mechanism for the dominant negative effect of 
B1. 
The following experiments can be performed to explore the mechanisms 
underlying the dominant negative effect of B1. Co-immunoprecipitation can be used 
to find out whether B1 interacts with  subunits or full-length 1A. If B1 suppresses 
full-length 1A currents by sequestration of  subunits, B1 should be found to interact 
with  subunits. Additionally, mutations in the -interaction domain (AID) of B1 that 
abolish the interaction with  subunits (6) should also abolish the dominant negative 
effect. Interaction of B1 with full-length 1A would be compatible with all the other 
possible mechanisms. In this case, single-channel recordings should be performed to 
see whether B1 alters the single-channel properties of 1A. 
 Moreover, imaging or cell-surface biotinylation assay should be performed to 
examine whether B1 reduces surface expression of full-length 1A. The influence of 
B1 on the protein and mRNA levels of full-length 1A should also be examined. 
Eventually, the involvement of the ubiquitin-proteasome pathway and endoplasmic 
reticulum resident RNA-dependent protein kinase (PERK) will be the most important 
indicators of DIM and UPR, respectively. The expected results for each mechanism 





Table 3 Possible mechanisms underlying the dominant negative effect of B1 and the expected 
phenomena 
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Interaction with  Yes Maybe Maybe Maybe 
Interaction with 
full-length 1A 
Maybe Yes Yes Yes 
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No effect No effect No effect Reduces the 
dominant 
negative effect 
Effect of dominant 
negative PERK 
(188) 




UPR: unfolded protein response 
DIM: destructive interaction mechanism 
AID: -interaction domain (AID) 
PERK: endoplasmic reticulum resident RNA-dependent protein kinase 
 
  5.5.5 Additional concerns 
Our cell-surface biotinylation assays provided some preliminary results about the 
surface expression of the fragment-channels. However, the results are not convincing 
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enough because of the binding of non-biotinylated fragment-channels to the 
NeutrAvidin agarose. To confirm the surface expression of the fragment-channels, the 
cell-surface biotinylation assay needs to be optimized in order to remove the 
nonspecific binding. Before being mixed with the NeutrAvidin agarose, the membrane 
preparation can be processed using one or a combination of the following methods to 
improve the purity of plasma membrane proteins: 1) wash with a hypertonic sucrose 
buffer, 2) wash with 100 mM Na2CO3, and 3) pre-clear with control agarose (278). 0.5% 
(w/v) SDS can be included in the lysis buffer (278) to decrease the binding of 
non-biotinylated proteins to the NeutrAvidin agarose. Harsher washes may also be 
needed. A wash buffer containing 450 mM of NaCl was used in our experiments (see 
Materials and Methods). Increasing the NaCl concentration to 0.5-5 M and including 
0.5% (w/v) SDS and 100 mM Na2CO3 in the wash buffer (278) may help eliminate 
non-biotinylated proteins from the NeutrAvidin agarose. 
Interestingly, in the immunoblot analysis of Xenopus oocytes coexpressing 
FLAG-A1 and HA-A2, the anti-FLAG antibody not only detected a 50-kDa band 
corresponding to FLAG-A1, but also detected a band of ~260 kDa (Figure 21 A and 
B), which is approximately the same molecular weight as full-length 1A (282 kDa). 
A possible explanation is that the 260-kDa band is the complex formed by FLAG-A1 
and HA-A2, which was not broken apart by SDS and DTT. Alternatively, the 260-kDa 
band might just be aggregated FLAG-A1. Moreover, the apparent molecular weight of 
HA-A2 is ~280-kDa, which is higher than it theoretical molecular weight (233 kDa) 
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and closer to the molecular weight of full-length 1A (Figure 21 C and D). Note that 
the expression level of HA-A2 is relatively low.  
Therefore, a possible reason we do not see HA-A2 of its theoretical molecular 
weight is that HA-A2 is saturated with FLAG-A1 and the 280-kDa band recognized 
by the anti-HA antibody is the complex containing both FLAG-A1 and HA-A2. 
However, it is also possible that the 280-kDa band is HA-A2 only and its high 
apparent molecular weight is due to anomalous migration. A similar phenomenon can 
be observed in Xenopus oocytes coexpressing FLAG-B1 and HA-B2. HA-B2 has an 
apparent molecular weight of 270 kDa, which is more than the theoretical molecular 
weight of HA-B2 (202 kDa) and closer to the molecular weight of full-length 1A 
(Figure 21 C and D). FLAG-B1, however, did not show any band of similar molecular 
weight to full-length 1A (Figure 21A). 
All the protein samples from Xenopus oocytes were incubated with 2% SDS at 
37°C in the presence of high concentration (50-90 mM) of DTT, in order to 
thoroughly dissociate protein complexes and denature the proteins. However, it cannot 
be excluded that some protein complexes might be extremely stable and resistant to 
denaturation. Superoxide dismutase (SOD) is one of the most denaturation-resistant 
proteins (310). SOD from Suvolobus acidocaldarius retains almost all its activity after 
24 h incubation at 95°C, and is also extremely resistant to 6 M guanidinium 
hydrochloride or 0.1% SDS at 20°C (310). Bovine SOD retains much of its activity in 
the presence of 10 M urea or 4% SDS (311). Bovine SOD is a homodimer whose two 
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subunits are associated by non-covalent interactions (312). The SOD homodimer is 
highly resistant to dissociation and does not dissociate even in 8 M urea for 72 h at 
25°C (313). Nevertheless, bovine SOD homodimer can be dissociated by incubation 
at 37°C for 2 h in 1% SDS and 1% -mercaptoethanol (314, 315). The 
-mercaptoethanol is necessary for the dissociation (314), even though no intersubunit 
disulfide bond has been found. There is not enough evidence to conclude whether our 
method of sample preparation can disrupt an intersubunit interaction as strong as that 
in SOD. It is possible that our denaturation conditions were not harsh enough to 
dissociate the complementary pair of fragment-channels. 
If the complementary fragment-channels can indeed be shown to form stable 
complexes highly resistant to dissociation, this will provide great insight into the 
functional properties of fragment-channels. To address this issue, we should express 
the fragment-channels individually in separate groups of Xenopus oocytes and analyze 
them using immunoblot blot. If the high molecular weight species are absent and all 
the fragment-channels display their theoretical molecular weights, this indicates that 
the high molecular weight species are complexes formed by the complementary 
fragment-channels. If the high molecular weight species appear as in the oocytes 
coexpressing the complementary fragment-channels, we can infer that the high 
molecular weight species is due to aggregation (in the case of A1) or anomalous 



























6.1 Functional importance of the 190-kDa truncated 1A 
A 190-kDa fragment of 1A was found in mouse brain tissue and cultured mouse 
cortical neurons, but not in heterologous systems expressing full-length 1A. In the 
brain, the 190-kDa truncated channel is the predominant form of 1A, while in 
cultured cortical neurons the amount of the 190-kDa truncated channel is comparable 
to that of the full-length channel. The 190-kDa truncated channel contains part of the 
II-III loop, repeat III, repeat IV and the C-terminal tail. Evidence suggests that the 
190-kDa truncated channel is not due to degradation of the full-length channel during 
sample preparation. Our immunoblot experiments also revealed a 110-kDa short form 
of 1A, which is presumably the truncated channel complementary to the 190-kDa 
truncated channel. 
It is interesting that the brain produces much more truncated P/Q-type calcium 
channels than full-length ones. We would like to know whether the 190-kDa truncated 
channel has functional importance or is only a product of routine protein degradation 
in the cells. Because ion channels carry out their functions mainly on the plasma 
membrane, expression of the 190-kDa truncated channel on the plasma membrane 
would suggest functional importance. It is even possible that most of the functional 
P/Q-type channels on the plasma membrane are formed by complementary pairs of 
truncated channels, instead of full-length channels. We tried two methods to explore 
the expression of the truncated channel on the plasma membrane, but the results were 
inconclusive. The cell surface biotinylation experiment with mouse forebrain slices 
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could not reveal whether the 190-kDa truncated channel is on the plasma membrane, 
because the biotinylation reagent increases the immunoreactivity of the truncated 
channel. The immunocytochemistry experiments show that extracellularly HA-tagged 
1A expressed in cultured rat hippocampal neurons or HEK 293T cells cannot be 
effectively labeled under non-permeabilizing conditions. In contrast, extracellularly 
HA-tagged 1C could be robustly labeled on the plasma membrane under the same 
conditions. The lack of labeling of HA-tagged 1A might be due to either inadequate 
surface expression or poor exposure of the HA tags. Therefore the 
immunocytochemistry experiments cannot give us a clue about the surface expression 
of the truncated channel either. 
To continue exploring the expression of the 190-kDa truncated channel on the 
plasma membrane, we can try the following methods: 1) using another antibody, such 
as an antibody against the C-terminal tail of 1A, in the cell surface biotinylation 
experiment, 2) using other biotinylation reagents such as amino-oxy-biotin and 
biocytin hydrazide, 3) isolating cell surface protein using radioiodination, and 4) 
isolating cell surface 1A using peptide toxins that specifically bind to 1A on its 
extracellular surface. To trouble-shoot the immunocytochemistry experiment, 
single-channel, inside-out or outside-out patch recordings should be used to evaluate 
cell-surface expression of the HA-tagged 1A constructs on the soma. If the 
constructs display low cell-surface expression on the soma, the following methods 
could be tried to boost cell-surface expression: 1) culturing transfected cells first at 
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30°C to improve protein folding and then at 37°C to promote trafficking to the plasma 
membrane, and 2) substituting cerebellar Purkinje cells for hippocampal neurons. If 
the HA-tagged 1A constructs display adequate cell-surface expression on the soma, 
this means poor exposure of the HA tags is the reason for the lack of labeling. In this 
case we should try the following methods: 1) inserting long flanking sequences beside 
the HA tag to improve the exposure of the tag, 2) using other types of tags such as 
FLAG-tag, His-tag and Myc-tag, and 3) directly staining the channel using an 
antibody against an extracellular loop. 
The engineered fragment-channel B1, presumably resembling the truncated 
channel complementary to the 190-kDa truncated channel, suppresses full-length P/Q 
channel currents. The fragment-channel B2, equivalent to the 190-kDa truncated 
channel, does not significantly affect full-length P/Q channel currents. B1 and B2 
cannot form a functional channel when coexpressed in Xenopus oocytes. However, 
these results cannot rule out the possibility that the 190-kDa truncated channel has 
important functions. The 190-kDa truncated channel may regulate other types of 
VGCCs. TEVC recordings should be performed to test the influence of the B2 
fragment-channel on L- and N-type channels.  
Another possible function of the 190-kDa truncated channel is to regulate the 
suppressive effect of its complementary fragment-channel on the full-length channel. 
Several other truncated forms of 1A, including EA2 mutants and non-disease-related 
truncated forms, have been reported to have a dominant negative effect (see Table 1). 
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The dominant negative effect is believed to be an important mechanism for the 
pathogenesis of EA2. It is possible that the 190-kDa truncated channel downregulates 
the suppressive effect of its complementary fragment on the full-length channel, 
thereby preventing it from causing EA2 or a similar disorder. To test this hypothesis, 
we need to use TEVC to measure the dominant negative effect of the B1 
fragment-channel in the presence and absence of B2. The interaction between B1 and 
B2 should be examined using co-IP.  
 
6.2 Origin of the 190-kDa truncated 1A 
Our preliminary data show that the relative abundance of the 190-kDa truncated 
channel and the putative complementary fragment-channel are upregulated by 
increased intracellular [Ca2+]. These findings are reminiscent of the mid-channel 
proteolysis of 1C found by our group (4), and therefore suggest that the 190-kDa 
truncated channel may also be produced by mid-channel proteolysis. Like the 
mid-channel proteolysis of 1C, mid-channel proteolysis of 1A may also serve as a 
negative feedback regulatory mechanism, which downregulates channel activity when 
intracellular [Ca2+] increases.  
To further explore the possibility of mid-channel proteolysis, we can insert a 
TEVp site in the putative cleavage site in the II-III loop of 1A, and then perform 
single-channel recordings to find out how the electrophysiological properties of the 
channel changes upon proteolysis. Next we use single-channel recordings to measure 
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the changes in electrophysiological properties of endogenous CaV2.1 following 
intracellular [Ca2+] increase. If the changes following intracellular [Ca2+] increase are 
similar to the changes that TEVp causes on the engineered channels, we can infer that 
the 190-kDa fragment is likely due to mid-channel proteolysis.  
N-terminal sequencing or mass spectrometry should be performed to confirm the 
identities of the 190-kDa truncated channel and the complementary fragment of 110 
kDa. Considering the possibility that the 190-kDa truncated channel may be produced 
by a short transcript due to alternative splicing or a cryptic promoter, 5’ RACE-PCR 
should be used to screen for short splice variants of 1A that may produce the 
190-kDa species. The putative transcript for the 190-kDa species would be missing at 
least exons 2-16 (see 3.9). A transcript with part of exon 1 would be a splice variant, 
while one completely without exon 1 would be a product of a cryptic promoter. 3’ 
RACE-PCR can be used to screen for splice variants of 1A that may produce the 
110-kDa species. 
My research has expanded our knowledge of VGCCs. The pore-forming 
subunit of a VGCC is usually described as a protein with a single peptide chain 
containing four transmembrane domains. However, my research shows that most of 
the P/Q-type channel 1A subunits in the brain are truncated. These truncated 
channels may play various physiological roles both on the plasma membrane and 
intracellularly. My research also added complexity to our understanding of the 
pathogenesis of EA2. My results suggest that the presence of an EA2 truncation 
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mutant 1A and the absence of a complementary truncated 1A may both be 
contributing factors to EA2. Future studies on the P/Q-type fragment-channels may 
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